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Norovirus, a member of the family Caliciviridae is a non-enveloped, icosahedral and 
single-stranded RNA virus with a genome size of approximately 7.5 kilobase (kb). Based on 
the amino acid sequence comparison of its constituting structural protein virus protein (VP) 
1, the genus norovirus is divided into 7 genogroups (G) with GI, II and IV being primarily 
responsible for infecting humans. During the last two decades, the genogroup II member 
genotype 4 (GII.4) strain has been responsible for the majority of food-borne outbreaks 
worldwide [1]. Recently, however, norovirus GII.17 variant has been emerging and even has 
become predominant in some regions of Asia [2]. In this thesis I aimed to increase our insight 
into norovirus-provoked pathology. 
Currently norovirus is increasingly recognized as the main cause of epidemic 
nonbacterial gastroenteritis worldwide, especially so since rotavirus vaccines have largely 
reduced the disease burden associated with infection with the latter virus [3]. Despite being 
associated with substantial (or even large) economic impact, in addition to considerable 
mortality, norovirus has been given comparatively less attention when compared to other 
infectious pathogens. Due to high genetic diversity observed in different noroviruses and the 
fact that patients that have been sequentially infected with different strains fail to develop 
cross-protection among distinct genotypes, the development of efficacious norovirus 
vaccines is still a major challenge [4]. Until now, no licensed antiviral drugs with respect to 
norovirus are available and clinical management is mainly limited to supportive care with 
oral or intravenous (IV) rehydration and electrolyte supplementation being the mainstay of 
treatment [5]. The lack of a robust cell culture model or a convenient small animal model has 
further hampered the development of strategies aimed at prevention and control of 
norovirus infection. Limited case reports have demonstrated that ribavirin and nitazoxanide 
hold promise for combating norovirus-provoked gastroenteritis, yet their therapeutic value 
and mechanism-of-action need to be further explored. 
Discovery of norovirus 
In 1929, Zahorsky et al first described an epidemic of apparently nonbacterial 
gastroenteritis and proposed the descriptive name ‘winter vomiting disease’, as this entity 
was characterized by clinical presentation of acute onset of nausea and vomiting 
predominantly during winter months [6]. In October 1968, an acute gastroenteritis affected 
50% (116 of 232) of the students and teachers in an elementary school in Norwalk, Ohio and 
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was clinically accompanied by characteristic nausea, vomiting and abdominal pain [7]. Later 
in 1972, Kapikian et al first observed a 27-nm particle with cubic symmetry by immune 
electro microscopy (IEM) in stool samples derived from the Norwalk outbreak [8]. These 
particles were then suggested to be the etiological cause of Norwalk gastroenteritis and are 
now considered the initial discovery of norovirus. But until now, many aspects of norovirus 
pathobiology remain obscure at best. 
Clinical features of norovirus infection 
Human norovirus (HuNV) is notorious for being the main cause of gastroenteritis 
outbreaks worldwide. As a food-borne illness, norovirus infection is predominantly 
transmitted by the fecal-oral route and through person-to-person contact. Inhalation of 
infectious aerosols is another possible mode of transmission [9]. Following exposure and 
after an incubation time of 15 to 36 hours, an acute diarrhea develops which is accompanied 
by vomiting, abdominal cramps, watery stools and fever. Patients normally resolve the 
disease within 2 to 3 days, but sometimes patients can persistently and asymptomatically 
shed virus for up to approximately 8 weeks [10]. Furthermore, chronic and protracted 
norovirus infection is sometimes also observed especially among young children, the elderly 
and immunocompromised individuals. Norovirus caused 47 to 96% of acute pediatric 
gastroenteritis outbreaks and 5 to 36% of sporadic cases [11]. Manish et al estimated that 
each year norovirus resulted in 64,000 hospital admissions and 900,000 polyclinical visits in 
children from developed countries, and up to 200,000 fatalities of children younger than 5 
years old in developing countries [12]. The course of norovirus-mediated disease in older 
adults is characterized by prolonged duration and fatal outcomes [13]. In my systematic 
review (Chapter 2), I have demonstrated that norovirus infection may persist for weeks to 
months in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) 
recipients, and sometimes is accompanied by severe complications that required hospital 
admission. 
Features of norovirus biology 
Norovirus demonstrates largely antigenic and genetic diversity. Based on the amino 
acid sequence of the major capsid protein VP1, norovirus is currently divided into 7 
genogroups (G), whereas each genogroup is further subdivided into several genotypes 
(numbers after G). Genogroup I, II and IV primarily infect humans, and genogroup V is 
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associated with murine diarrhea [14]. The HuNV genome contains three open reading frames 
(ORFs), of which ORF1 encodes a nonstructural protein, while ORF2 and ORF3 encode the 
major and minor capsid protein VP1 and VP2, respectively. The 5’ end of norovirus RNA is 
covalently bound to a virus-encoded protein referred to as VPg, whilst the 3’ end is 
polyadenylated. Gaining understanding of the full life cycle of HuNV had remained largely 
elusive due to the inability to perform in vitro culture of HuNV [15]. Evidence from surrogate 
models of other animal caliciviruses and murine norovirus (MNV) suggests that a norovirus 
VPg-bound intact RNA initiates a ‘pioneer round’ of RNA translation once it enters into a 
permissive cell line. This leads to the production of the ORF1 polyprotein, which is 
subsequently co- and post-translationally processed into 6 nonstructural (NS) proteins, 
namely p48, NTPase, p22, VPg, Pro and Pol. The remaining viral RNAs form a double-
stranded replicative form (RF), which further produces positive-sense genomic and 
subgenomic RNAs in a VPg-dependent manner [16]. The synthesized genomic and 
subgenomic RNAs are covalently linked to VPg protein at 5’ end. The translated structural 
proteins VP1 and VP2 as well as genomic RNAs are further assembled, encapsulated and 
released from host cells [15]. However, it is fair to say that further validation and detailing of 
this proposed life cycle remains necessary. 
Models to study HuNV 
Although a virus particle was identified as the main cause of gastroenteritis, all 
attempts to generate and detect the etiological agent using tissue culture techniques and 
novel organ culture techniques were unsuccessful hitherto [17]. In 2004, Duizer et al 
described the attempt to cultivate HuNV in vitro using 16 human carcinoma derived cell 
lines and 11 non-human hosts derived cell lines. Cell culture systems that mimicked the 
gastrointestinal tract (GI tract) were also included. However, all such attempts proved to be 
unsuccessful [18]. In another study, efforts were further made to study the susceptibility of 
cell cultures of animal origin to HuNV infection. A total of 19 cell cultures from 11 different 
animal species were inoculated with HuNV-containing fecal samples. Cytopathic effect (CPE) 
and reverse transcription PCR (RT-PCR) assays were used to detect norovirus replication. The 
results showed no evidence of any morphological changes or an increase in norovirus RNA 
[19]. In 2006, Chang et al revolutionized the field by pioneering the stable expression of a 
HuNV RNA replicon in the Huh7 cell line. Even though this replicon model fails to fully 
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recapitulate the full life cycle of HuNV, it is a superior alternative to the experimental models 
used earlier for the screening of antivirals for their potential action on HuNV replication [20]. 
By using this model, a set of substances with anti-norovirus activities was identified and this 
set included interferons (IFNs), ribavirin, mycophenolic acid (MPA), calcineurin inhibitors and 
2’-C-methylcytidine (2CMC) [21-23]. Some further advances were recently made. In 2014, the 
currently dominant HuNV strain GII.4-Sydney was employed for successful infection of the 
BJAB human B cell line as evident from a resulting significant increase in viral genomic copy 
numbers. Importantly, this infection was substantially facilitated by free histo-blood group 
antigen (HBGA) or by HBGA-expressing enteric bacteria, which probably served as a cofactor 
for binding and attachment of HuNV to B cells [24]. Later in 2016, the novel human intestinal 
enteroids (HIEs) derived from intestinal crypts were reported to support HuNV replication. 
HIEs contained multiple intestinal epithelial cell types and recapitulated most aspects of the 
human intestinal epithelium, and thus constituted a good culture system to study host-
pathogen interactions. In this system, bile was required for strain-dependent HuNV 
replication, in contrast to the previous report that enteric bacteria was essential for HuNV 
cultivation in B cells [25].  Hence, further research is needed to fully understand how 
norovirus can exploit gastrointestinal physiology for successful replication. 
Further efforts were also made to develop a robust animal model. In 2006, 
gnotobiotic (Gn) pigs were evaluated as a potential model to study HuNV pathogenesis and 
to determine the target cells for HuNV replication. The inoculated Gn pigs developed mild 
diarrhea and were found to be positive for HuNV genome RNA in rectal swab fluids and 
intestinal contents. Meanwhile, enterocytes from duodenal and jejunal origin were 
confirmed to specifically support HuNV replication [26]. A panel of drugs including simvastatin 
[27, 28] and interferon alpha (IFNα) [28] effectively inhibited HuNV replication using this model. 
Later in 2008, the same group reported that Gn calves developed diarrhea and intestinal 
lesions upon inoculation with HuNV strain GII.4-HS66. The inoculated calves secreted virus 
particles in the feces and produced virus-directed antibodies as well as cytokines indicative 
of ongoing infection and immune reaction [29]. In 2010, chimpanzees i.v. inoculated with 
HuNV demonstrated no clinical symptoms of gastroenteritis, but shed virus particles in feces. 
Concurrent with viral shedding in the stools, HuNV RNA became detectable in intestinal and 
liver biopsies. Analysis of  the HuNV-evoked immune response revealed that the 
chimpanzees developed short-term immunity against HuNV and virus like particles (VLPs), 
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and displayed protective immunity even after extended exposure [30]. These models have 
played important roles on fostering our understanding of the pathogenesis of and the  
immunity against HuNV. Meanwhile, they are useful tools to assess the efficacy of potential 
interventions aimed at preventing and treating HuNV infection. 
Murine norovirus (MNV), a model system to study norovirus biology 
and pathogenesis 
Noroviruses are not restricted to infecting humans. Noroviruses in cattle, swine and 
mice have also been identified. Among them, MNV is the only norovirus that is permissive 
for replication in both cell culture and a small animal model. Thus, MNV is useful for studying 
norovirus biology and associated pathology. The first MNV was described in 2003. It was 
observed that immunocompromised mice deficient in signal transducer and activator of 
transcription 1 (STAT1) and recombination-activating gene 2 (RAG2) (RAG/STAT1-/- mice) 
sporadically succumbed to an infectious nonbacterial agent. Representational difference 
analysis (RDA) revealed that the pathogen contained an RNA genome homologous to the 
regions of many calicivirus genomes. It was proposed to name the agent as murine norovirus 
1 (MNV1) and place it into a new norovirus genogroup. Further studies demonstrated that 
MNV1 replicated more efficiently in mice lacking STAT1 than wild type mice, indicating the 
essential role of innate immunity on combating MNV infections [31].  
To further investigate the cellular tropism of MNV, MNV1-infectd STAT1-/- mice 
underwent immunohistochemistry aimed at confirming the presence of MNV1 protein. 
MNV1-specific staining was observed in the Kupffer cells residing in the liver, and in the red 
pulp as well as the marginal zone in the spleen. As expected, bone marrow-derived 
macrophages (Mφ) and dendritic cells (DCs) were permissive for MNV1 replication in vitro. 
Further screening in Mφ cell lines demonstrated that the murine cell line RAW 264.7 
supported MNV1 replication yielding visible CPE after infection [32].  
Further clonal selection performed both in vivo and in vitro generated two MNV 
strains MNV1.CW1 and MNV1.CW3. The former resembled the parental MNV1 with 
attenuated infectivity in STAT1-/- mice; while the latter demonstrated more significant 
virulence but a similar growth rate in vitro [33]. Clones MNV1.CW1 and MNV1.CW3 only 
caused sporadic diarrhea and were rapidly cleared by wild-type mice. A new MNV strain 
MNV1.CR6 can persistently infect wild-type mice and was detected in feces even at day 35 
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after inoculation. Based on those findings, MNV is thought to be a good model system to 
study the biology and pathogenesis of norovirus.  
Host immune response and action of the interferon pathway therein 
toward norovirus 
The knowledge of how a host responds to norovirus infection has mainly been gained 
from studies performed in volunteers, due to the lack of a convenient small animal model 
that sufficiently and effectively supports the natural growth of HuNV. Challenging volunteers 
with Norwalk agent-containing fecal filtrate provoked antibodies to the Norwalk agent, 
indicating a potentially important role of acquired immunity on protecting us against the 
Norwalk gastroenteritis [34]. Consistently, norovirus-associated travelers’ diarrhea was 
associated with higher levels of interleukin (IL)-2 and interferon gamma (IFNγ), suggesting 
that a Th1 immune response was predominant in gut immunity combating norovirus 
infection [35]. Further studies also explored the therapeutic potential of exogenous IFNs 
against HuNV replication by using the HuNV replicon and Gn pig model [21, 28]. In the present 
study, I shall show that HuNV replication was highly sensitive to treatment with type I, II and 
III IFNs. My mechanistic investigations further identified interferon regulatory factor-1 (IRF-
1), retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 
(MDA5) as the ultimate factors that were responsible for the potency of IFNs against 
norovirus [36]. 
Further understanding comes from studies aimed at identifying the predominant 
factors limiting MNV infection. RNA sequencing of MNV-infected murine macrophages 
revealed that MNV infection triggered a cellular immune response that involved nuclear 
factor kappa B (NF-κB), STAT1 and STAT3-based pathways as well as interferon regulatory 
factor 3 (IRF3) activation [37]. These observations correlated well with the fact that IFNs 
exerted in vitro and in vivo efficacy with respect to controlling MNV infection. Type I and II 
IFNs inhibited the in vitro translation of MNV proteins [38]. In vivo studies indicated that IFN-
αβ limited the systemic spreading of the acute strain MNV1.CW3-provoked infection in 
immunocompetent mice [39], whereas interferon lambda (IFNλ) treatment can effectively 
and completely cure persistent MNV infection irrespective of the presence of adaptive 
immunity. Two weeks of IFNλ treatment reduced virus titers to an undetectable level in the 
murine mesenteric lymph nodes (MLN) and colon after infection with the persistent MNV 
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strain MNV1.CR6 [40]. These findings are important. They suggest that exogenous IFNs can be 
promising antiviral options during norovirus infection and that their effects can become 
useful for designing drug discovery strategies. 
Scope of this thesis  
Even though norovirus gastroenteritis (NVGE) is normally self-limiting among 
immunocompetent individuals, it causes severe complications and fatal outcomes in 
immunocompromised patients. Hence novel and specific antiviral treatments are urgently 
needed. In this thesis, I aimed to adequately assess the burden of norovirus infection in 
hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients, and to 
further explore the potency and mechanism-of-action of several chemicals in this specific 
setting. I firstly systematically reviewed the prevalence and clinical presentation of NVGE in 
transplant recipients, and secondly assessed potential treatment strategies for those 
patients. I next mainly focused on the antiviral potential and the mechanisms of 
immunosuppressants, exogenous IFNs and nitazoxanide on norovirus biology and related 
results to clinical experience in NVGE. 
Outline of this thesis 
As the immune system needs to be highly suppressed in order to prevent rejection, 
transplant recipients are at high risk of viral infections. Accordingly, diarrhea is a common 
complication after transplantation. The putative risk factors underlying diarrhea involve 
regimen-associated toxicity, infections and intestinal graft-versus-host disease (GVHD). 
Unfortunately norovirus was not routinely detected in those diarrheal patients. This may be 
due to clinical underestimation of the potential problem as well as insufficiency in studies 
about norovirus biology and pathogenesis, and the absence of convenient and cheap 
detection methodology. Presently the situation has improved and the introduction of highly 
sensitive molecular detection techniques now allows easy identification and characterization 
of norovirus as an etiological agent for diarrhea in those patients. In Chapter 2, I 
systematically reviewed norovirus infection in HSCT and SOT recipients, and was able to 
highlight the prevalence, clinical manifestations, diagnosis, risk factors, transmission and 
evolution, and potential treatments. Immunosuppressants are risk factors for norovirus 
infection. On the one hand, the weakened immunity thus fails to provide protection against 
viral invasion. On the other hand, immunosuppressants directly exert multiple effects on 
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viral replication. Thus, this is a complex discussion. In Chapter 3, I provided answers though. 
I profiled a subset of immunosuppressants and identified MPA as a potent antiviral toward 
norovirus replication. Using this medication for immunosuppression in transplant recipients 
should thus provide protection against norovirus infection. 
IFNs provide host with the first line of defense against viral invasion. They signal 
through the Janus kinase/signal transducers and activators of transcription (JAK-STAT) 
pathway and induce hundreds of interferon-stimulated genes (ISGs), which are the ultimate 
antiviral factors. Given the fact that IFNs have been used in the clinic for decades, in Chapter 
4, I characterized the antiviral potential of type I, II and III IFNs and found that HuNV 
possessed high responsiveness to all types of IFNs. I further comprehensively screened a 
subset of important ISGs by using an overexpression approach and identified IRF-1, RIG-I and 
MDA5 as potent antiviral effectors.  
Nitazoxanide, a thiazolide compound has recently been empirically used in several 
norovirus cases with unknown mechanism requiring clarification. In Chapter 5 and 6, I thus 
further investigated the antiviral activities and mechanisms of nitazoxanide and its main 
metabolite tizoxanide against norovirus. The results extended our knowledge about 
mechanism and application of nitazoxanide in the clinic. An integrating discussion of data 
generated is also included in this thesis. In conjunction, I feel my studies greatly facilitate the 
development of novel rational avenues for treating norovirus infection. 
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ABSTRACT 
Norovirus (NoV) is increasingly reported as an important etiological agent for chronic and 
severe diarrheal complications in transplant recipients. However, a consensus regarding the 
exact prevalence, epidemiology, clinical manifestations and potential clinical management of 
NoV gastroenteritis (NVGE) in those patients is still lacking. We systematically reviewed the 
burden associated with NoV infection in the transplantation setting. NoV accounted for 2.9 
to 60% of severe diarrhea in hematopoietic stem cell transplant recipients and 3.2 to 38.4% 
in solid organ transplant recipients. NVGE in transplant patients was usually chronic, 
protracted and sometimes even fatal. Typically, patients required frequent hospital 
admission and co-infection with other enteric pathogens was also commonly observed. Risk 
factors contributing to susceptibility, severity and chronicity of NVGE varied markedly 
between studies. Although several NoV genotypes existed, NoV genotype 2 (GII) was the 
etiological agent in the majority of cases involved with genotype 1 (GI) being a distant 
second. Interestingly, chronically infected transplant recipients displayed accelerated NoV 
evolution and constituted viral reservoirs releasing novel variants. Several studies have 
explored possible treatment strategies toward NVGE and demonstrated that repurposing 
nitazoxanide showed promise, even if it failed to clear NVGE in a substantial number of cases. 
Due to limited size of the studies involved and the absence of clear mechanism-of-action, it 
cannot yet be considered evidence-based treatment and further evaluation was needed.  
The burden of NVGE in the transplantation setting is more severe than was expected. Thus, 
awareness of this problem should be raised. 
Keywords: norovirus; transplantation; evolution; nitazoxanide.  
Chapter 2 
16 | P a g e  
 
INTRODUCTION 
Norovirus (NoV) is a member of the family Caliciviridae. It is a non-enveloped, 
positive-sense single-stranded RNA virus with a genome size of approximately 7.5 kilobase 
(kb). Based on the amino acid sequence of its major capsid protein virus protein (VP) 1, NoV 
is divided into 7 genogroups (G) with G1, 2 and 4 (GI, II and IV) being primarily responsible 
for infecting humans [1]. NoV represents the leading etiological agent for human viral 
gastroenteritis worldwide [2]. 
NoV gastroenteritis (NVGE) usually manifests as self-limiting diarrheal disease of 
short duration in immunocompetent individuals. However, chronic and protracted infections 
have been observed in young children, the elderly and immunocompromised populations [3-
5]. In such cases the disease may persist for weeks or even months, and can cause severe 
weight loss, debilitation and occasionally even death. Recently NoV has been recognized as 
an important entity for prolonged devastating complications in recipients of hematopoietic 
stem cell transplants (HSCT) and solid organ transplants (SOT) [6]. With the advent of the 
widespread use of reverse transcription-polymerase chain reaction (RT-PCR)-based 
detection of NoV, now an accumulating body of studies have reported the prevalence, 
epidemiology and pathogenesis of NoV in this specific setting. Unfortunately the 
development of a NoV vaccine remains challenging partially due to the highly genetic and 
antigenic diversity of human NoV (HuNoV) as well as the unavailability of small animal 
models [7]. At present, no licensed treatment for NVGE is available except for fluid 
replacement and intensive supportive care [8]. However, several clinical studies have 
explored potential therapies and potentiated the off-label use of FDA-approved nitazoxanide 
as a promising option for chronically infected patients. Given the fact that detailed 
knowledge of NoV infection in the transplantation setting is generally segmented and 
inconclusive, we have now conducted a systematic review to comprehensively evaluate the 
prevalence, epidemiology, clinical manifestations and potential treatment options of NVGE 
in HSCT and SOT recipients. 
 
METHODS 
We searched EMBASE, MEDLINE Ovid, Web of science, Scopus, Cochrane Central and 
Google scholar to identify articles published in English until February 27, 2018, in which NoV 
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infection was described among HSCT and SOT recipients. The search strategies for each 
database were designed by an experienced information specialist (WB) and are available in 
Table S1. After removing duplicates, two independent reviewers (WD and MH) reviewed the 
title and abstract of all articles to eliminate the irrelevant references and references that did 
not meet the inclusion criteria. Disagreements were resolved by consensus. To make sure all 
the relevant publications were captured, we cross-referenced all articles from the 
bibliographies of the selected publications by WD and MH. After reviewing each article, 
studies meeting each of the following inclusion criteria were selected: (i) Original research 
articles or reports describing NVGE in transplant recipients; (ii) Studies using detection 
methods to clearly confirm the presence of NoV as an etiological agent for diarrhea; (iii) All 
subjects in the study were HSCT or SOT recipients. Articles were excluded if (i) full-text was 
not available; (ii) subjects were immunocompromised individuals but not transplant 
recipients. The detailed algorithm for excluding and including studies is further documented 
in Fig. 1. 
 
RESULTS 
Description of the included studies 
Based on our search criteria and after removal of duplicates, a total of 365 references 
were found. By reviewing the type, title and abstract of the articles, we excluded 312 
references. This left 52 eligible articles and 4 additional articles were identified by manual 
search from the reference lists. Further assessing the full-text of these 56 articles ultimately 
resulted in the identification of 47 studies which met the inclusion criteria (Fig. 1). 
More in detail, with respect to the subjects we included studies of NoV infection 
among both HSCT and SOT recipients, and results were taken into account irrespective of 
gender, age, ethnicity and nationality of the patients involved. In line with the purpose of 
the current study and based on the contents of selected publications, we categorized topics 
into 5 aspects, including prevalence and clinical characteristics (n = 38), diagnosis (n = 5), risk 
factors (n = 4), transmission and evolution (n = 12), and treatment (n = 10) (Fig. 1). Of note, 
many publications have addressed several of these topics in the same publication. 
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Figure 1 Flow diagram showing literature search and selection results. 
 
NoV infection in HSCT 
HSCT is a potentially effective treatment for both hematologic malignant and non-
malignant disorders. Since hematopoietic stem cells exist not only in the marrow (also called 
a bone marrow transplantation; BMT) but also in periphery, we collectively referred to HSCT 
as inclusive HSCT regardless of the origin of the stem cells.  
Among HSCT recipients with NVGE, NoV prevalence varied widely within each study, 
ranging from 2.9 to 26% (Table 1) [9-14]. Highest prevalence of NoV infection (60%) was 
observed in a study of 10 autologous stem cell transplantation (ASCT) recipients [15]. After an 
incubation period of 12 to 48 hours following virus exposure, most immunocompetent 
patients experience a classic set of symptoms including sudden onset of vomiting, abdominal 
cramps and watery diarrhea [2, 16]. The illness usually resolves within 24 to 72 hours later, 
although asymptomatic shedding of virus in feces persists for up to 3 weeks [2]. In contrast 
HSCT recipients form a high-risk group for severe chronic diarrhea following NoV infection. 
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The duration of symptoms ranged from a median of 8 days to approximately 2 months 
(Table 1; Table S2) [9-11, 14, 15]. Of 12 NoV-positive (NoV+) HSCT recipients, ten patients 
presented diarrhea for a median of three months (range 0.5 to 14) and persistently shed 
high loads of virus for prolonged periods [17] with comparable results observed in two studies 
that documented viral shedding for a median of 150 days (range 60 to 380) [13] and 145 days 
(range 13 to 263) [12] among 13 and 8 NoV+ HSCT recipients. Thus, HSCT recipients are clearly 
compromised in their capacities to mount effective defense against NoV. 
NVGE causes severe and devastating complications in HSCT recipients. A comparison 
of NoV infection (n = 12) and clostridium difficile infection (CDI; n = 42) in hematopoietic cell 
transplantation (HCT) recipients demonstrated that NVGE cases provoked more intensive 
care unit (ICU) admissions (odds ratio, 4.9; 95% confidence interval [CI], 1.1 to 21.6) and 
resulted in higher mortality (odds ratio, 3.2; 95% IC, 0.74 to 13.5) when compared to CDI [10]. 
In a retrospective analysis of 63 NoV+ HSCT recipients, 24 (35%) patients required 
hospitalization with a median length of stay of 5 days (range 2 to 40) [11]. Co-infection with 
other enteric pathogens was frequently observed. Ten out of 63 NoV+ allogeneic HSCT 
recipients were co-infected with other gastrointestinal pathogens including adenovirus (AdV; 
n = 3), CDI (n = 4), cytomegalovirus (CMV; n = 2) and rotavirus (RV; n = 1) [11]; while 6 out of 8 
NoV+ HSCT patients had co-infections including CDI (n = 4) and CMV (n = 2) [12]. Moreover 
norovirus-associated mortality has been observed in several cases [12, 17, 18]. Hence NVGE is 
clearly a substantial problem in this patient group requiring vigilance during clinical 
management.   
Potential role of the reconstructed immune system on NVGE following HSCT 
Hosts exert rapid and broad immune activation when challenged with HuNV and 
subsequently develop antibody responses, but detailed knowledge of norovirus-host 
interactions is still largely lacking [19, 20]. HSCT recipients experience a period during which 
the immune system is rebuilt. Immune response is not well established during this period. 
This increases the susceptibility of hosts to diverse infections. With respect to NVGE in HSCT 
recipients, two aspects need especially adequate clarification, one is the time from 
transplantation to the onset of NVGE, and the other is whether restored T cells contribute to 
the resolution of NVGE.  
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Evidence suggests that NVGE tends to occur in the first few months after HSCT, which 
corresponds to the time period at which patients are the most highly immunosuppressed. In 
a case series the median time from transplantation to diagnosis of NVGE was 25 days (range 
-80 to 63) among 13 NoV+ HSCT recipients, three of which were diagnosed positive prior to 
transplantation [13]. This was comparable with two other studies of 8 NoV+ HSCT recipients (a 
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median of 36.5 days, range 5 to 517) [12] and 10 NoV+ HSCT recipients (a median of 36 days, 
range 3 to 39) [9]. Another study, however, involving 12 adult allogeneic HSCT recipients with 
NVGE recorded a much longer time of diarrhea onset (a median of 10.5 months, range 0.25 
to 96) following transplantation [17]. Presentation can thus be variable and even long after 
HSCT, and one should be aware of the possibility of NVGE in such patients. 
A few publications highlight the potential role of recovering immunity on the 
clearance of NoV infection in HSCT recipients. Among 13 pediatric NoV+ HSCT recipients, the 
median duration of NoV diarrhea (150 days, range 30 to 380) was almost the same as the 
median time of donor T cell recovery (150 days, range 30 to 390), suggesting a close 
association of NoV clearance with immune reconstitution [13]. However, T cell recovery was 
solely defined by the absolute CD3 count instead of the function. Meanwhile the number of 
patients was rather small requiring further investigation in this respect. 
NoV infection in SOT recipients 
The prevalence of NoV as a cause of acute and chronic gastroenteritis in SOT recipients 
ranged from 3.2 to 38.4%, and thus resembled the situation in HSCT recipients (Table 2) [21-
32]. Likewise, the former patient groups also displayed protracted NVGE with duration 
ranging from a median of 12.5 days to 218 days (Table 2) [21, 22, 25-30].  Studies with small 
sample sizes that were insufficient in evaluating NVGE prevalence and clinical outcomes are 
listed in Table S3. Common clinical symptoms reported were diarrhea, nausea, vomiting and 
abdominal pain, whereas severe wasting, profound weight loss and fever were also less 
commonly reported [25, 30, 33]. Reminiscent from the situation in HSCT recipients, SOT 
recipients with NVGE required more hospital admissions with longer duration when 
compared to those with non-NoV diarrhea, showing a specific vulnerability of these patients 
to NoV. Of 25 NoV+ pediatric HSCT and SOT recipients, 55% (13/25) of patients required 
hospitalization for diarrhea with 27% being admitted into ICU. The study also performed a 
matched case-control to compare clinical outcomes of NoV+ diarrhea subjects (n = 22) and 
non-NoV diarrhea subjects (n = 22). It was found that NoV+ patients required more 
hospitalization (55% vs 36%, P = 0.23) and ICU admission (27% vs 0%, P = 0.02), meanwhile 
experienced more weight loss (median 1.6 vs 0.6 kg, P < 0.01) [29]. Furthermore, 58% (40/67) 
of NoV+ SOT patients were hospitalized with duration of on average 9.6 days, which was  
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Table 3 Co-infections were commonly observed in transplant recipients. 
Referenc
e 
Transplant type 
NVGE episodes 
/Co-infection/Rate 
Co-infections 
[11]  Allo-HSCT 63/10/15.8% AdV (n = 3); CDI (n = 4); CMV (n = 2); RV (n = 1) 
[12]  HSCT 8/6/75% CDI (n = 4); CMV (n = 2) 
[33]  SOT 152/28/18% 
CDI (n = 9); AdV (n = 8); CMV (n = 5); RV (n = 3); CMV 
and AdV (n = 1); Campylobacter spp. (n = 1); E. coli (n = 
1) 
[34]  
SOT (n = 20) 
HSCT (n = 3) 
24/8/33.3% 
CDI (n = 5); RV (n = 3) 
[30]  SOT 67/10/14.9% CDI (n = 7); CMV (n = 3) 
[29]  
SOT (n = 9) 
HSCT (n = 25) 
25/5/20% 
RV (n = 2); CDI (n = 1); AdV (n = 1); CDI and AdV (n = 1) 
[25]  KTx (n = 25) 31/>9/>28.7% Pneumonia (n = 6); UTI (n = 3) 
[15]  ASCT 6/5/83% CMV (n = 4); Bacteria (n = 1) 
[27]  Allo-HSCT 19/4/21% 
RV (n = 1); AsV (n = 1); AdV (n = 1); C. jejuni and EnV (n 
= 1) 
AdV, adenovirus; Allo-, allogeneic; AsV, astrovirus; ASCT, allogeneic stem cell transplantation; C. jejuni, 
Campylobacter jejuni; CDI, Clostridium difficile infection; CMV, cytomegalovirus; E.coli, Escherichia coli; EnV, 
enterovirus; HSCT, hematopoietic stem cell transplantation; KTx, kidney transplantation; RV, rotavirus; SOT, 
solid organ transplantation; UTI, urinary tract infection. 
 
much longer than 6.3 days among a matched non-NoV diarrheal group of patients [30]. In 
accordance, 56% (5/9) NoV+ kidney transplantation (KTx) recipients and 77.4% (24/31) NoV+ 
SOT recipients required hospitalization [25, 26]; while 80% (121/152) NoV+ SOT recipients 
required hospitalization with prolonged length of stay of 10 ± 15.2 days [33]. Likewise, 79% 
(15/19) NoV+ intestinal transplantation (ITx) recipients that were admitted into hospital 
required a median length of stay of 41 days (range 0 to 119) [27]. Compounding the situation 
and analysis is that co-infection with other pathogens was commonly observed in SOT 
recipients including CDI, AdV, RV, CMV, enterovirus (EV), bacterial infections and urinary 
tract infections (UTIs) (Table 3). Thus, it is necessary to perform multiple microbiological 
examinations in diarrheal transplant recipients, even if NoV has been detected. 
Diagnosis 
Various diagnostic assays for establishing NoV status have been employed in the 
transplantation setting (Table S4). Initially, the Kaplan criteria were used as a tool for 
detecting possible NVGE outbreaks in healthcare settings, and this approach had an 
estimated sensitivity of 68% and a specificity of 99% [35, 36]. However, these criteria also 
applied to non-NoV diarrhea [18]. With the first bona fide visualization of NoV particles in 
1972, the definitive diagnosis was thus achieved by immune electron microscopy (IEM) [37]. 
This method is, however, cumbersome, insensitive and only applicable when fecal samples 
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have a high viral load (> 106 particles per mL of specimen). Subsequently, enzyme-linked 
immunosorbent assay (ELISA)-based antigen detection assays were developed. Subsequently 
they were routinely used for detection of NVGE outbreaks. Currently a number of ELISA kits 
are commercially available including the RIDASCREEN® Norovirus 3rd Generation kit and the 
RIDA®QUICK Norovirus test [38, 39]. Compared to IEM, these rapid antigen detection tests 
have a higher sensitivity and specificity. Recently immunochromatography (IC) and 
histopathological analysis have also been used in several studies [18, 40]. The former shows 
high specificity and sensitivity, while the latter has only been used for distinguishing NVGE 
from graft-versus-host disease (GVHD). NVGE is histopathologically characterized by villous 
blunting and a slight elevation of apoptotic epithelial cells at the tip of the villi; while 
intestinal GVHD involves a partial loss of surface epithelium and increased numbers of 
apoptotic crypt epithelial cells [18]. The distinction between NVGE and GVHD is essential for 
decision-making regarding appropriate treatment options, as the former requires a decrease 
in or even discontinuation of immunosuppression, whereas the latter requires more harsh 
immunosuppression. Thus, proper diagnosis is of utmost importance in this respect. 
The current ‘golden standard’ for definitive NoV diagnosis is RT-PCR. This technology 
shows clear superiority over other diagnostic methods on sensitivity and specificity with 
respect to NoV detection. Of 54 severe diarrhea events among 49 adult KTx recipients, NoV 
was undetectable using the classical rapid antigen detection tests, whereas 36% of samples 
were positive using a Multiplex PCR assays [31]. Among 12 HSCT recipients, NoV was detected 
only in two patients by electron microscopy (EM), whereas all the patients had a positive 
signal in RT-PCR assays [17]. Hence PCR-based method is now regarded as the methodology of 
choice for prompt and accurate diagnosis of NoV infection. Nevertheless, this technique has 
not yet seen widespread implementation in the transplantation setting, probably because of 
its high costs and the relatively advanced technical capacity required. Thus, as an alternative 
in many clinical settings, one resorts to a commercially available IC kit that is marketed in 
Asia and Europe [2] and provides cheap and easy NoV diagnosis in the transplantation setting, 
even if superior technology is available. 
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Risk factors 
Many risk factors are associated with a significantly higher risk for NoV infection in 
transplant recipients. In a retrospective analysis of 350 HSCT recipients, a second or 
subsequent allogeneic HSCT was associated with increased risk of contracting NVGE [9]. A 
retrospective study of 55 HSCT recipients showed that recipients who received peripheral 
blood-derived stem cells or cord blood-derived stem cells were more likely to contract NVGE 
when compared to those who received bone marrow. Relatively harsh immunosuppression 
regimens containing fludarabine or alemtuzumab were also associated with a significantly 
greater risk for subsequent NoV infection [12]. Several risk factors that are linked to more 
severe and protracted NVGE in transplant recipients are evident as well. In a study of 193 
transplant recipients, wasting, MHC incompatible kidney transplant status and 
plasmapheresis were associated with longer gastroenteritis [25], whereas severe combined 
immunodeficiency (SCID) was linked to increased chronicity of NoV infection in a study 
involving 494 allogeneic HSCT recipients [11]. Hence for these patients additional vigilance 
with respect to NoV infection is called for. 
NoV evolution 
NoV is divided into 7 distinguished genogroups showing substantial intergenogroup 
genetic diversity. Most NoV strains in transplant recipients belonged to GII, albeit presenting 
with highly divergent intragenogroup variants. In addition, GI was also reported. Evidence 
suggests that chronic NoV infection in transplant recipients accelerates the accumulation of 
genetic alterations and viral evolution. Viruses that are subject to mutation can potentially 
evade the immunity of the host, providing a selective advantage of mutated viruses. In 
transplant recipients this problem may be compounded by a relatively low immune selective 
pressure that can only partially clear NoV. Thus, immunosuppressed patients may constitute 
an environment that fosters NoV evolution and serves as potential reservoirs for novel NoV 
variants [41]. Among 3 HSCT patients with chronic GII.4 Sydney_2012 infection, virus strains 
accumulated 19, 18, and 8 nucleotide mutations within 110, 113 and 22 days respectively, 
most of which were non-synonymous [42]. Consistently, gained 46 nucleotide changes in NoV 
were observed over a period of 683-day virus shedding in a KTx recipient, resulting in 25 
amino acid changes with an overall fixation rate of 0.037 amino acids/day. A fixation rate of 
0.049 and 0.012 amino acid changes per day was observed in two other patients [26]. Two 
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GII.7 and one GII.4 NoV strains in 3 chronically infected transplant recipients gained average 
5 to 9 mutations within 100 days, most of which were non-synonymous [43]; while in a NoV+ 
heart transplantation (HTx) recipient, 32 amino acid changes occurred within the ORF2 over 
a 1-year period, 8 of which located in the hypervariable domain (P2) of the capsid protein [44]. 
Interestingly, it is recently reported that within immunocompromised hosts NoV has evolved 
into phylogenetically distinct variants that are genetically different from the circulating 
strains in the general population [45, 46]. Collectively, the immunocompromised hosts may 
serve as a reservoir for the emergence of novel infectious NoV variants potentially posing 
novel threats to the proof of invading herd immunity. 
Transmission, prevention and control of NVGE 
Although food-borne transmission is the primary mode of transmission, NoV can also 
be acquired through the fecal-oral route or by inhalation of infectious aerosols [2, 47, 48]. Most 
NVGE cases in transplant recipients are community-acquired. However, nosocomial 
transmission is likely to play an important role as well. In a bone marrow transplant (BMT) 
unit, a nosocomial outbreak happened and involved 5 transplant recipients and 4 healthcare 
workers [14]. Another reported nosocomial outbreak involved 7 HSCT recipients and 5 staff 
members following the admission of a NoV+ HSCT index patient. In this case the mode of 
transmission was potentially through inhalation of infectious aerosols or the fecal-oral route 
through sharing a lavatory [18]. In a retrospective analysis of 63 NoV+ HSCT recipients, 47% 
(30/63) patients acquired NoV infection during hospitalization, 6 of which got infected 
during an outbreak at the transplant ward [11]. Several reports also documented nosocomial 
outbreaks of NoV infection in transplant recipients, but the potential mode of transmission 
needed further investigation to allow the development of potentially preventive measures 
for such patients [15, 49].  
Prevention of nosocomial outbreaks is largely dependent on the prompt diagnosis of 
individual cases and the subsequent elimination of possible transmission routes. It has been 
proposed that next-generation whole genome sequencing is a good tool to study the 
direction of NoV spread and potential nosocomial transmission mode [50]. Upon recognition 
of a NoV outbreak, it is essential to promptly implement preventive measures and exert 
extra care to contain the situation. Strategies proposed included the transfer of NVGE 
patients to an isolation ward with in suite toilet facilities, the adherence to strict hygiene 
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regulations by the medical and nursing staff, the complete disinfection of patient rooms, and 
evidence for efficacy had been provided [2, 14, 17]. 
Potential treatment strategies toward chronic NVGE 
Chronic NoV infections in transplant recipients often result in serious complications 
including prolonged diarrhea, allograft failure and mortality. However, no licensed therapies 
are currently available. Reduction or switch (e.g. to an everolimus-based regimen) of 
immunosuppression is generally employed in such cases as a first line strategy (Table S5) [17, 
51, 52]. Oral and systemic administration of human immunoglobulins (HIGs) as well as oral 
serum-derived bovine immunoglobulin (OSDBI) have demonstrated efficacies in some 
studies (Table S5) [34, 53-57]. However, especially the use of nitazoxanide, of which proof of 
efficacy was found serendipically, appears very promising (Table S5) [58-60]. 
It is important to state, however, that the effectiveness, mechanism-of-action and 
extent to which those treatments improve the lot of NVGE patients in the setting of 
transplantation remain largely unknown. In a series of 31 transplant recipients with NVGE,  6 
(19.4%), 2 (6.5%) or 1 (3.2%) patients received monotherapy of nitazoxanide, i.v. 
immunoglobulin (IVIg) or a reduction in immunosuppression respectively, whereas some 
patients received a combination of these treatments with nitazoxanide plus reduction of 
immunosuppression (9; 29%) and nitazoxanide plus IVIg plus reduction of 
immunosuppression (8; 25.8%) being the most frequently chosen strategy. All the patients 
ultimately resolved NVGE [25]. A pediatric KTx recipient whose clinical management was 
complicated by NVGE received oral immunoglobulins (IGs) and medication switching from 
tacrolimus to sirolimus. This strategy, however, was not effective with respect to the 
diarrhea. A subsequent fortnight-course of nitazoxanide led to the resolution of diarrhea and 
complete clearance of the NoV infection as assessed by fecal NoV shedding [59]. Furthermore 
a NoV+ HSCT recipient was successfully treated with nitazoxanide, whereas other 
therapeutic options including IVIg and a reduction in immunosuppression were not 
successful [58]. Thus, these is some evidence that nitazoxanide is a good therapeutic option 
when confronted with NVGE in the setting of transplantation but in absence of better 
controlled studies. A stepwise approach to management of NVGE should be considered. 
The development of medication useful for combating NoV is now gaining momentum 
because of the successful cultivation of HuNV in B cells and stem cell-derived human 
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enteroids [61-63]. Ribavirin, a broad-spectrum antiviral drug has been shown to inhibit in vitro 
NoV replication through depletion of cellular GTP pools [64]. In patients with common 
variable immunodeficiency (CVID), oral ribavirin resulted in viral clearance in some but not 
all of the patients [65]. Whether the combination of nitazoxanide with ribavirin will be more 
effective in transplant recipients deserves further investigation.  
 
CONCLUSION 
This systematic review has comprehensively evaluated the burden inflicted by NVGE 
in the setting of transplantation. Collectively, the data obtained suggest that NoV infection 
should be routinely evaluated in transplant recipients with diarrheal complaints, as NVGE 
results in severe and protracted diarrhea characterized by frequent hospitalization and co-
infection, thus requiring special attention. In addition, the highly contagious nature of NoV 
infection requires special measures to protect other patients as well as hospital staff. 
Moreover, transplant recipients are prone to develop novel variants of NoV for which there 
may not be protective immunity in the population. We also explore the candidate therapies 
toward NVGE, which although still preliminary show promise for combating the virus in the 
setting of transplantation. 
Unfortunately, it appeares not feasible to accurately assess the average prevalence of 
NVGE in transplant recipients. In some studies, only subjects that experienced diarrhea or 
were hospitalized for diarrhea were enrolled; while other studies enrolled all the transplant 
recipients irrespective of whether they had diarrhea or not. Furthermore, different types of 
transplantation and immunosuppressive medicine may be associated with differential 
sensitivity to NoV infection. Finally, overall patient number described in the literature was 
fairly small. Nevertheless, it is evident from our analysis that NVGE in the transplantation 
setting is a serious concern because of its problematic management and highly contagious 
nature.  
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ABBREVIATION 
AdV, adenovirus; ASCT, autologous stem cell transplantation; CDI, clostridium difficile 
infection; CMV, cytomegalovirus; CVID, common variable immunodeficiency; EM, electron 
microscopy; G, genogroup; GVHD, graft-versus-host disease; HCT, hematopoietic cell 
transplantation; HSCT, hematopoietic stem cell transplantation; HTx, heart transplantation; 
HuNV, human norovirus; IC, immunochromatography; IEM, immune electron microscopy; 
IGs, immunoglobulins; ITx, intestine transplantation; IVIg, intravenous immunoglobulin; KTx, 
kidney transplantation; LTx, liver transplantation; NoV, norovirus; NVGE, norovirus 
gastroenteritis; RT-PCR, reverse transcription-polymerase chain reaction; RV, rotavirus; SOT, 
solid organ transplantation; SCID, severe combined immunodeficiency; Tx, transplantation. 
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Supplementary Information 
SUPPLEMENTARY TABLES AND FIGURES 
Table S1 Search terms used in our study. 
Embase.com: 250 
('Norovirus'/exp OR 'norovirus infection'/exp OR (Norovir* OR (norwalk* NEAR/3 virus*)):ab,ti) AND 
('transplantation'/exp OR 'graft dysfunction'/exp OR 'recipient'/exp OR (transplant* OR allotransplant* OR 
autotransplant* OR graft* OR allograft* OR autograft* OR recipient*):ab,ti) 
Medline Ovid: 98 
("Norovirus"/ OR (Norovir* OR (norwalk* ADJ3 virus*)).ab,ti,kf.) AND (exo "transplantation"/ OR 
transplantation.xs. OR "Primary Graft Dysfunction"/ OR exp Transplants/ OR "Transplant Recipients"/ OR 
(transplant* OR allotransplant* OR autotransplant* OR graft* OR allograft* OR autograft* OR 
recipient*).ab,ti,kf.) 
Web of science: 170 
TS=(((Norovir* OR (norwalk* NEAR/2 virus*))) AND ((transplant* OR allotransplant* OR autotransplant* OR 
graft* OR allograft* OR autograft* OR recipient*)))  
Scopus: 188 
TITLE-ABS-KEY(((Norovir* OR (norwalk* W/2 virus*))) AND ((transplant* OR allotransplant* OR autotransplant* 
OR graft* OR allograft* OR autograft* OR recipient*)))  
Cochrane CENTRAL: 7 
((Norovir* OR (norwalk* NEAR/3 virus*)):ab,ti) AND ((transplant* OR allotransplant* OR autotransplant* OR 
graft* OR allograft* OR autograft* OR recipient*):ab,ti) 
Google scholar: 100 
Norovirus|"norwalk virus" 
transplantion|allotransplantion|autotransplantion|graft|allograft|autograft|recipients 
 
 
Table S2 Studies reporting NVGE in HSCT recipients with limited information. 
Author, 
publication 
year, 
[Reference] 
Study type 
Study 
period 
Coun
try 
Subject
s with 
NVGE 
Patient
s group 
Duration 
(days) 
Genotype 
Gallimore et al, 
2004, [1]  
Case report 
Jan 2000- 
Jul 2000 
UK 1 P 156 
ARG320/1999/US-
like recombinant 
norovirus (rGII-3) 
Roddie et al,  
2009, [2]  
Retrospectiv
e study 
Nov 2004-
Aug 2007 
UK 12 A 
90 
(median, 
range 15 
to 420) 
GII-4 (n = 9) 
Abbreviation: A, adult; P, pediatric. 
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Ta
b
le
 S
3
 S
tu
d
ie
s 
re
p
o
rt
in
g 
N
V
G
E 
in
 S
O
T 
an
d
 m
u
lt
i-
o
rg
an
 t
ra
n
sp
la
n
t 
re
ci
p
ie
n
ts
 w
it
h
 li
m
it
e
d
 in
fo
rm
at
io
n
. 
A
u
th
o
r,
 
p
u
b
lic
at
io
n
 
ye
ar
, 
[R
ef
e
re
n
ce
] 
St
u
d
y 
ty
p
e
 
St
u
d
y 
p
e
ri
o
d
 
C
o
u
n
tr
y 
Su
b
je
ct
s 
w
it
h
 N
V
G
E 
P
at
ie
n
ts
 
gr
o
u
p
 
Tr
an
sp
la
n
t 
ty
p
e
 
D
u
ra
ti
o
n
 (
d
ay
s)
 
G
e
n
o
ty
p
e
 
W
es
th
o
ff
 
et
 
a
l, 
2
0
0
9
, [
3
] 
 
Ex
ce
p
ti
o
n
al
 c
as
e
 
 
G
er
m
an
y 
2
 
A
 
R
Tx
 
>1
2
0
 
G
II
 
B
o
n
an
i 
et
 
a
l, 
2
0
1
7
, [
4
] 
 
A
 
p
ro
sp
ec
ti
ve
 
p
ar
al
le
l 
co
h
o
rt
 p
ilo
t 
st
u
d
y 
Ju
l 
2
0
1
3
-
M
ar
 2
0
1
5
 
Sw
it
ze
rl
an
d
 
7
 
A
 
R
Tx
 
2
4
5
 
(m
ed
ia
n
, 
ra
n
ge
 1
6
8
 t
o
 3
2
2
) 
G
II
.4
 
C
h
eh
ad
e 
et
 
a
l, 
2
0
1
2
, [
5
] 
 
C
as
e 
re
p
o
rt
 
 
Sw
it
ze
rl
an
d
 
1
 
P
 
K
Tx
 
 
G
II
 
C
h
ag
la
 
et
 
a
l, 
2
0
1
3
, [
6
] 
 
ca
se
 r
ep
o
rt
 
 
C
an
ad
a 
1
 
A
 
R
Tx
-P
Tx
 
 
G
II
.4
 
Sy
d
n
ey
 
2
0
1
2
 
C
h
o
n
g 
et
 
a
l, 
2
0
1
6
, [
7
] 
 
R
et
ro
sp
ec
ti
ve
 
ch
ar
t 
re
vi
ew
 
Ja
n
 
2
0
1
0
-
A
p
r 
2
0
1
4
 
U
SA
 
1
5
2
 
P
 +
 A
 
K
Tx
 (
m
ai
n
ly
) 
6
 (
IQ
R
: 2
-1
1
) 
G
II
 (
9
1
%
) 
G
I (
9
%
) 
Ec
h
en
iq
u
e 
et
 
a
l, 
2
0
1
6
, [
8
] 
 
C
as
e 
re
p
o
rt
 
 
U
SA
 
1
 
 
P
Tx
 
 
G
II
.4
 
Fl
o
re
sc
u
 
et
 
a
l, 
2
0
1
1
, [
9
] 
 
A
 
m
at
ch
ed
 
ca
se
-
co
n
tr
o
l s
tu
d
y 
Ju
l 
2
0
0
6
-
N
o
v 
2
0
0
8
 
U
SA
 
2
3
 
A
 +
 P
 
SO
T 
 
 
Fl
o
re
sc
u
 
et
 
a
l, 
2
0
0
8
, [
1
0
] 
 
C
as
e 
re
p
o
rt
 
 
U
SA
 
2
 
P
 
SB
T 
 
 
G
ai
ra
rd
-D
o
ry
 
et
 
a
l, 
2
0
1
4
, [
1
1
] 
 
A
 
re
tr
o
sp
ec
ti
ve
 
ch
ar
t 
re
vi
ew
 
Ja
n
 
2
0
0
9
-
M
ay
 2
0
1
3
 
Fr
an
ce
 
1
2
 
 
LT
x 
 
 
H
o
ff
m
an
n
 
et
 
al
, 
2
0
1
2
, [
1
2
] 
 
R
es
ea
rc
h
 a
rt
ic
le
 
 
G
er
m
an
y 
3
 
 
B
M
T 
(n
 =
 2
) 
SB
T 
(n
 =
 1
) 
>8
1
 
G
II
.7
 
G
II
.4
 2
0
0
6
b
 
Ju
rg
en
s 
et
 
a
l, 
2
0
1
7
, [
1
3
] 
 
ca
se
 s
er
ie
s 
2
0
1
6
 
U
SA
 
3
 
 
O
H
Tx
 
 
 
K
ar
an
d
ik
ar
 
et
 
a
l, 
2
0
1
6
, [
1
4
] 
 
R
es
ea
rc
h
 a
rt
ic
le
 
Ja
n
 
2
0
1
0
-
M
ay
 2
0
1
2
 
U
SA
 
3
1
 
A
 +
 P
 
H
SC
T 
(n
 
=
 
1
3
);
 S
B
T 
(n
 =
 
1
8
) 
 
M
ai
n
ly
 G
II
.4
 
Le
e 
et
 a
l, 
 
2
0
0
8
, [
1
5
] 
 
C
as
e 
re
p
o
rt
 
 
C
an
ad
a 
1
 
P
 
LT
x-
P
Tx
-S
B
Tx
 
1
1
4
 
G
II
 
M
o
u
n
ta
in
 
st
ra
in
 
K
au
fm
an
 
et
 
a
l, 
2
0
0
3
, [
1
6
] 
 
C
as
e 
re
p
o
rt
 
 
U
SA
 
1
 
P
 
IT
x 
1
2
0
 
G
II
 M
ia
m
i B
ea
ch
 
G
el
fa
n
d
 
et
 
a
l, 
2
0
1
7
, [
1
7
] 
 
C
as
e 
re
p
o
rt
 
 
U
SA
 
1
 
A
 
SO
T 
1
5
0
 
G
I/
G
II
 
Eb
d
ru
p
 e
t 
a
l, 
2
0
1
1
, [
1
8
] 
 
V
ir
o
lo
gy
 q
u
es
ti
o
n
 a
n
d
 
an
sw
er
 s
ch
e
m
e
 
 
D
en
m
ar
k 
1
 
A
 
H
Tx
 
5
3
 
G
II
.4
 (
2
0
0
6
b
) 
B
la
n
co
 e
t 
a
l, 
2
0
1
1
, [
1
9
] 
 
Le
tt
er
 t
o
 t
h
e 
ed
it
o
r 
 
Sw
it
ze
rl
an
d
 
1
 
A
 
H
SC
T-
Lu
n
gT
x 
1
8
0
 
G
II
.4
 
A
b
b
re
vi
at
io
n
: 
A
, 
ad
u
lt
; 
B
M
T,
 b
o
n
e 
m
ar
ro
w
 t
ra
n
sp
la
n
ta
ti
o
n
; 
H
Tx
, 
h
ea
rt
 t
ra
n
sp
la
n
ta
ti
o
n
; 
H
SC
T,
 h
e
m
at
o
p
o
ie
ti
c 
st
e
m
 c
el
l 
tr
an
sp
la
n
ta
ti
o
n
; 
IT
x,
 i
n
te
st
in
al
 
tr
an
sp
la
n
ta
ti
o
n
; 
IQ
R
, 
in
te
rq
u
ar
ti
le
 r
an
ge
; 
K
Tx
, 
ki
d
n
ey
 t
ra
n
sp
la
n
ta
ti
o
n
; 
LT
x,
 l
iv
er
 t
ra
n
sp
la
n
ta
ti
o
n
; 
Lu
n
gT
x,
 l
u
n
g 
tr
an
sp
la
n
ta
ti
o
n
; 
O
H
Tx
, 
o
rt
h
o
to
p
ic
 h
ea
rt
 
tr
an
sp
la
n
ta
ti
o
n
; P
, p
ed
ia
tr
ic
; P
Tx
, p
an
cr
ea
se
 t
ra
n
sp
la
n
ta
ti
o
n
; R
Tx
, r
en
al
 t
ra
n
sp
la
n
ta
ti
o
n
; S
B
T,
 s
m
al
l b
o
w
el
 t
ra
n
sp
la
n
ta
ti
o
n
; S
O
T,
 s
o
lid
 o
rg
an
 t
ra
n
sp
la
n
ta
ti
o
n
. 
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Ta
b
le
 S
4
 L
ab
o
ra
to
ry
 m
e
th
o
d
s 
fo
r 
d
et
e
ct
io
n
 o
f 
n
o
ro
vi
ru
s.
  
D
et
e
ct
i
o
n
 
R
ef
e
re
n
ce
 
D
e
sc
ri
p
ti
o
n
 
R
e
su
lt
s 
C
o
n
cl
u
si
o
n
 
P
C
R
 
M
o
st
 
st
u
d
ie
s 
M
ai
n
ly
 
u
se
d
 
fo
r 
d
et
ec
ti
o
n
 
o
f 
N
o
V
 R
N
A
 in
 s
to
o
ls
. 
Su
p
er
io
r 
se
n
si
ti
vi
ty
 a
n
d
 s
p
ec
if
ic
it
y 
1
. 
G
o
ld
 s
ta
n
d
ar
d
 m
et
h
o
d
 t
o
 d
ia
gn
o
se
 N
V
G
E;
 2
. 
N
o
 w
id
es
p
re
ad
 c
lin
ic
al
 u
se
 d
u
e 
to
 h
ig
h
 c
o
st
 a
n
d
 
co
m
p
lic
at
ed
 t
e
ch
n
iq
u
e 
re
q
u
ir
ed
. 
EM
 
[2
] 
 
N
o
V
 w
as
 d
ia
gn
o
se
d
 b
y 
EM
 a
n
d
 
R
T-
P
C
R
 
am
o
n
g 
1
2
 
H
SC
T 
re
ci
p
ie
n
ts
. 
EM
 
d
et
ec
te
d
 
N
o
V
 
p
ar
ti
cl
es
 
in
 
o
n
ly
 
2
 
o
u
t 
o
f 
9
 
p
at
ie
n
ts
 t
e
st
ed
, 
w
h
er
ea
s 
R
T-
P
C
R
 d
ia
gn
o
se
d
 e
ve
ry
 
in
st
an
ce
 w
it
h
 N
V
G
E 
p
o
si
ti
ve
. 
1
. 
In
se
n
si
ti
ve
; 
2
. 
Ex
p
en
si
ve
 
an
d
 
co
m
p
lic
at
ed
 
te
ch
n
iq
u
e 
re
q
u
ir
ed
. 
IC
 
[2
0
] 
 
3
5
0
 
d
ia
rr
h
ea
l 
H
SC
T 
re
ci
p
ie
n
ts
 
w
er
e 
ex
am
in
ed
 
b
y 
IC
 
u
si
n
g 
a 
co
m
m
er
ci
al
 IC
 k
it
. 
N
o
V
 w
as
 d
et
ec
te
d
 in
 1
0
 o
u
t 
o
f 
3
5
0
 p
at
ie
n
ts
. 
1
. 
Sl
ig
h
tl
y 
le
ss
 
se
n
si
ti
vi
ty
, 
b
u
t 
si
gn
if
ic
an
tl
y 
ch
ea
p
er
 
co
m
p
ar
ed
 
to
 
P
C
R
; 
2
. 
A
 
p
ro
m
is
in
g 
d
ia
gn
o
si
s 
to
o
l i
n
 t
h
e 
tr
an
sp
la
n
ta
ti
o
n
 s
et
ti
n
g.
 
EL
IS
A
 
 
[1
1
] 
 
N
o
V
 w
as
 d
et
ec
te
d
 b
y 
a 
th
ir
d
-
ge
n
e
ra
ti
o
n
 
co
m
m
er
ci
al
 
R
ID
A
SC
R
EE
N
 E
LI
SA
 k
it
 i
n
 1
2 
LT
x 
re
ci
p
ie
n
ts
. 
A
ll 
th
e 
p
at
ie
n
ts
 w
er
e 
d
ia
gn
o
se
d
 p
o
si
ti
ve
. 
1
. 
8
0
%
 s
en
si
ti
vi
ty
 a
n
d
 1
0
0
%
 s
p
ec
if
ic
it
y 
co
m
p
ar
ed
 
to
 P
C
R
. 
2
. 
Pa
ti
e
n
ts
 s
h
o
w
in
g 
u
n
ex
p
la
in
ed
 d
ia
rr
h
ea
 
sh
o
u
ld
 b
e 
re
p
ea
te
d
ly
 t
e
st
ed
 f
o
r 
N
V
G
E 
d
u
e 
to
 t
h
e 
lim
it
ed
 s
en
si
ti
vi
ty
 o
f 
EL
IS
A
 d
ia
gn
o
st
ic
 m
et
h
o
d
. 
H
is
to
lo
gi
ca
l 
an
al
ys
i
s 
[3
] 
 
Tw
o
 
R
Tx
 
re
ci
p
ie
n
ts
 
w
it
h
 
p
er
si
st
en
t 
N
o
V
 
ex
cr
et
io
n
 
fo
r 
m
o
re
 t
h
an
 3
 m
o
n
th
s 
u
n
d
er
w
e
n
t 
h
is
to
lo
gi
ca
l a
n
al
ys
is
. 
D
ee
p
 
d
u
o
d
en
al
 
b
io
p
si
e
s 
d
e
m
o
n
st
ra
te
d
 
a 
p
ar
ti
al
 
vi
llo
u
s 
at
ro
p
h
y 
an
d
 
ch
ro
n
ic
 
in
fl
am
m
at
io
n
 
in
 
th
e 
la
m
in
a 
p
ro
p
ri
a.
 
1
. 
Th
e 
p
at
h
o
lo
gi
ca
l 
an
al
ys
is
 s
h
o
w
ed
 n
o
n
sp
ec
if
ic
 
fi
n
d
in
g 
to
w
ar
d
 
N
V
G
E;
 
2
. 
It
 
is
 
a 
su
p
p
le
m
en
te
d
 
m
et
h
o
d
 t
o
 d
is
ti
n
gu
is
h
 N
V
G
E 
fr
o
m
 G
V
H
D
, 
as
 b
o
th
 
re
ve
al
ed
 a
 d
is
ti
n
ct
 h
is
to
p
at
h
o
lo
gi
c 
p
at
te
rn
. 
[2
1
] 
 
D
u
o
d
en
al
 
b
io
p
si
es
 
w
e
re
 
av
ai
la
b
le
 
fo
r 
h
is
to
lo
gi
ca
l 
an
al
ys
is
 
in
 
3
 
N
o
V
+
 
H
SC
T 
re
ci
p
ie
n
ts
 
d
u
ri
n
g 
G
V
H
D
 
an
d
 
af
te
r 
o
n
se
t 
o
f 
N
o
V
 in
fe
ct
io
n
. 
1
. 
H
is
to
p
at
h
o
lo
gy
 f
in
d
in
gs
 d
em
o
n
st
ra
te
d
 a
 d
is
ti
n
ct
 
h
is
to
p
at
h
o
lo
gi
c 
p
at
te
rn
s 
to
w
ar
d
s 
G
V
H
D
 a
n
d
 N
V
G
E.
 
2
. 
N
V
G
E 
re
ve
al
ed
 
vi
llo
u
s 
b
lu
n
ti
n
g 
an
d
 
w
as
 
ch
ar
ac
te
ri
ze
d
 
b
y 
a 
sl
ig
h
t 
in
cr
ea
se
 
in
 
ap
o
p
to
ti
c 
ep
it
h
el
ia
l 
ce
lls
 p
ro
n
o
u
n
ce
d
 a
t 
th
e 
lu
m
in
al
 s
u
rf
ac
e
 
an
d
 
a 
si
gn
if
ic
an
tl
y 
el
e
va
te
d
 
n
u
m
b
er
s 
o
f 
in
tr
ae
p
it
h
el
ia
l l
ym
p
h
o
cy
te
s 
in
cl
u
d
in
g 
C
D
8
+ 
ce
lls
. 
A
b
b
re
vi
at
io
n
: 
EM
, 
el
ec
tr
o
n
 m
ic
ro
sc
o
p
y;
 E
LI
SA
, 
en
zy
m
e-
lin
ke
d
 i
m
m
u
n
o
so
rb
en
t 
as
sa
y;
 G
V
H
D
, 
gr
af
t-
ve
rs
u
s-
h
o
st
 d
is
ea
se
; 
IC
, 
im
m
u
n
o
ch
ro
m
at
o
gr
ap
h
y;
 N
o
V
, 
n
o
ro
vi
ru
s;
 N
o
V
+
, n
o
ro
vi
ru
s 
p
o
si
ti
ve
; N
V
G
E,
 n
o
ro
vi
ru
s 
ga
st
ro
en
te
ri
ti
s;
 R
T-
P
C
R
, r
e
ve
rs
e 
tr
an
sc
ri
p
ti
o
n
-p
o
ly
m
er
as
e 
ch
ai
n
 r
e
ac
ti
o
n
. 
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Ta
b
le
 S
5
 S
tu
d
ie
s 
o
f 
p
o
te
n
ti
al
 t
re
at
m
en
ts
 f
o
r 
N
V
G
E 
in
 t
ra
n
sp
la
n
t 
re
ci
p
ie
n
ts
. 
Tr
e
at
m
e
n
t 
R
ef
e
re
n
ce
 
D
e
sc
ri
p
ti
o
n
 
O
u
tc
o
m
e 
C
o
n
cl
u
si
o
n
 
IS
 r
ed
u
ct
io
n
 
R
o
d
d
ie
 e
t 
a
l 
[2
] 
 
 
8
 o
u
t 
o
f 
1
2
 N
o
V
+
 H
SC
T 
re
ci
p
ie
n
ts
 r
eq
u
ir
ed
 
w
it
h
d
ra
w
al
 o
r 
re
d
u
ct
io
n
 o
f 
IS
. 
1
. 
A
 s
lig
h
t 
d
ec
re
as
e
 o
f 
fe
ca
l 
vo
lu
m
e
 
an
d
 
fr
eq
u
en
cy
; 
2
. 
So
m
e
 
ca
se
s 
p
re
se
n
te
d
 
p
er
si
st
en
t 
d
ia
rr
h
ea
 
fo
r 
se
ve
ra
l m
o
n
th
s.
 
IS
 
re
d
u
ct
io
n
 
fa
ci
lit
at
ed
 
th
e 
im
p
ro
ve
m
en
t 
o
f 
sy
m
p
to
m
s.
 
H
o
w
ev
er
, 
st
an
d
ar
d
 a
d
ju
st
m
e
n
t 
w
as
 
n
o
t 
es
ta
b
lis
h
ed
. 
IS
 c
h
an
ge
 
En
ge
le
n
 e
t 
a
l 
[2
2
] 
 
 
IS
 w
as
 s
w
it
ch
ed
 t
o
 a
 m
am
m
al
ia
n
 t
ar
ge
t 
o
f 
ra
p
am
yc
in
 (
m
TO
R
) 
in
h
ib
it
o
r 
ev
er
o
lim
u
s 
in
 a
 
h
et
er
o
to
p
ic
 H
Tx
 r
ec
ip
ie
n
t 
w
it
h
 c
o
n
ti
n
o
u
s 
an
d
 
re
cu
rr
en
t 
N
V
G
E.
 
D
ia
rr
h
ea
 
st
o
p
p
ed
 
w
it
h
 
n
e
ga
ti
ve
 
P
C
R
 r
e
su
lt
 f
o
r 
N
o
V
. 
Ev
er
o
lim
u
s 
is
 a
 p
o
te
n
ti
al
 o
p
ti
o
n
 f
o
r 
IS
 
in
 
tr
an
sp
la
n
t 
re
ci
p
ie
n
ts
 
w
it
h
 
ch
ro
n
ic
 N
o
V
 i
n
fe
ct
io
n
, 
b
u
t 
fu
rt
h
er
 
m
ec
h
an
is
ti
c 
st
u
d
y 
is
 n
e
ed
ed
. 
B
la
n
co
 e
t 
a
l 
[1
9
] 
 
IS
 w
as
 s
w
it
ch
ed
 f
ro
m
 F
K
5
0
6
 t
o
 s
ir
o
lim
u
s 
in
 a
 
d
o
u
b
le
 H
SC
T-
LT
x 
re
ci
p
ie
n
t 
w
it
h
 c
h
ro
n
ic
 N
V
G
E
. 
P
C
R
 f
o
r 
N
o
V
 w
as
 n
e
ga
ti
ve
 i
n
 t
h
e 
st
o
o
l a
ft
er
 3
 a
n
d
 h
al
f 
a 
w
e
ek
s.
 
H
IG
 
Fl
o
re
sc
u
 e
t 
a
l 
[9
] 
 
1
. 
A
 m
at
ch
ed
 c
as
e 
co
n
tr
o
l 
st
u
d
y 
o
f 
2
4
 N
o
V
+
 
SO
T 
re
ci
p
ie
n
ts
 (
1
2
 c
as
e
s 
an
d
 1
2
 c
o
n
tr
o
ls
);
 2
. 
Ea
ch
 c
as
e 
re
ce
iv
ed
 2
0
0
 m
g
/k
g 
o
ra
l 
H
IG
 p
lu
s 
st
an
d
ar
d
 
su
p
p
o
rt
iv
e 
th
e
ra
p
y,
 
w
h
er
ea
s 
ea
ch
 
co
n
tr
o
l 
so
le
ly
 
re
ce
iv
ed
 
st
an
d
ar
d
 
su
p
p
o
rt
iv
e 
th
er
ap
y.
 
H
IG
 f
av
o
re
d
 r
es
o
lu
ti
o
n
 o
f 
d
ia
rr
h
ea
 
(P
 
= 
0
.0
7
8
, 
O
R
 
= 
6
5
.3
) 
an
d
 
re
d
u
ct
io
n
 
in
 
st
o
o
l 
o
u
tp
u
t,
 
b
u
t 
sh
o
w
ed
 
n
o
 
e
ff
ec
ts
 
o
n
 
to
ta
l 
re
so
lu
ti
o
n
 t
im
e,
 l
en
gt
h
 o
f 
h
o
sp
it
al
 
st
ay
 a
n
d
 c
o
st
 o
f 
h
o
sp
it
al
iz
at
io
n
. 
H
IG
 t
re
at
m
en
t 
p
o
te
n
ti
al
ly
 f
av
o
u
re
d
 
d
ia
rr
h
ea
 
re
so
lu
ti
o
n
 
an
d
 
th
e 
re
d
u
ct
io
n
 in
 s
to
o
l o
u
tp
u
t,
 b
u
t 
fa
ile
d
 
to
 a
ff
ec
t 
re
so
lu
ti
o
n
 t
im
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ABSTRACT 
Norovirus is a major cause of acute gastroenteritis worldwide and has emerged as an 
important issue of chronic infection in transplantation patients. Since no approved antiviral 
is available, we evaluated the effects of different immunosuppressants and ribavirin on 
norovirus and explored their mechanisms of action by using a human norovirus (HuNV) 
replicon-harboring model and a surrogate murine norovirus (MNV) infectious model. The 
roles of the corresponding drug targets were investigated by gain- or loss-of-function 
approaches. We found that the calcineurin inhibitors cyclosporin A (CsA) and tacrolimus 
(FK506) moderately inhibited HuNV replication. Gene silencing of their cellular targets, 
cyclophilin A, FKBP12, and calcineurin, significantly inhibited HuNV replication. A low 
concentration, therapeutically-speaking, of mycophenolic acid (MPA), an uncompetitive IMP 
dehydrogenase (IMPDH) inhibitor, potently and rapidly inhibited norovirus replication and 
ultimately cleared HuNV replicons without inducible resistance following long-term drug 
exposure. Knockdown of the MPA cellular targets IMPDH1 and IMPDH2 suppressed HuNV 
replication. Consistent with the nucleotide synthesizing function of IMPDH, exogenous 
guanosine counteracted the antinorovirus effects of MPA. Furthermore, the competitive 
IMPDH inhibitor ribavirin efficiently inhibited norovirus and resulted in an additive effect 
when combined with immunosuppressants. The results from this study demonstrate that 
calcineurin phosphatase activity and IMPDH guanine synthase activity are crucial in 
sustaining norovirus infection; thus, they can be therapeutically targeted. Our results 
suggest that MPA shall be preferentially considered immunosuppressive medication for 
transplantation patients at risk of norovirus infection, whereas ribavirin represents as a 
potential antiviral for both immunocompromised and immunocompetent patients with 
norovirus gastroenteritis. 
KEYWORDS: norovirus, mycophenolic acid, calcineurin inhibitors, ribavirin, cell culture 
model, cell culture, noroviruses. 
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INTRODUCTION 
Following widespread implementation of rotavirus vaccination, norovirus infection is 
now becoming the major cause of acute gastroenteritis worldwide [1]. As a single-strand 
positive-RNA virus belonging to the family Caliciviridae, norovirus is classified into 6 distinct 
genogroups (GI to GVI). Genogroup 2, genotype 4 (GII.4) is the most prevalent, accounting 
for 96% of all sporadic infections [2]. Although norovirus infection is often self-limiting in 
adults, every year, it is estimated that noroviruses resulted in up to 200,000 deaths in 
children below 5 years of age, mainly in developing countries [3]. It is recently estimated that 
norovirus causes more than 200,000 deaths across all ages per year worldwide, of which 
more than 90,000 are in children under five [4]. 
Accumulating evidence indicates that transplant recipients are highly susceptible to 
norovirus infection, irrespective of their status as a pediatric or adult patient [5, 6]. Norovirus 
infection has been described in many types of transplant recipients, including those 
receiving orthotopic transplantation of lung [7], kidney [8-10], liver [11], heart [12, 13], renal [14-16], 
intestine [17-19], small bowel [20], or hematopoietic stem cells [21-24]. Norovirus infection in such 
patients often resulted in severe clinical pathology with prolonged illness [21, 25]. Although the 
exact mechanism of norovirus susceptibility in orthotopic transplant recipients remains 
unclear, the use of immunosuppressants for preventing rejection is conceivably an 
important risk factor [5, 26]. It is plausible that an immunosuppressed status weakens host 
immunity defending virus invasion. Therefore, a cautious reduction and withdrawal of 
immunosuppressants has been taken into consideration for managing chronic norovirus 
gastroenteritis in transplant recipients [27]. Intriguingly, immunosuppressants have been 
reported to directly modulate viral infection [28], but the direct effects on norovirus infection 
remain to be investigated. 
Despite its significant impact on public health, no vaccination or specific antiviral 
treatment is available. Ribavirin has broad antiviral activity against many viruses in vitro and 
has been approved for treating chronic hepatitis C virus (HCV) patients for decades. A recent 
study reported that chronic norovirus infection in two patients with common variable 
immunodeficiency (CVID) was successfully treated by oral ribavirin, indicating the use of 
ribavirin as a potential therapy against norovirus infection [29], although the definitive effect 
requires further evaluation. 
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In this study, we profiled the effects of different immunosuppressants on norovirus in 
cell culture models. We reveal that cellular calcineurin and IMPDH enzymes are essential 
factors supporting norovirus replication, which could be targeted by the corresponding 
immunosuppressants, calcineurin inhibitors and mycophenolic acid (MPA), to exert 
antinorovirus effects. Furthermore, we demonstrate that ribavirin, a general antiviral drug of 
a non-immunosuppressive IMPDH inhibitor, has potent antinorovirus effects and exerts an 
additive effect when combined with calcineurin inhibitors or MPA. These results provide an 
important reference for managing immunosuppression and antiviral treatment for 
transplantation patients infected by norovirus or at risk of norovirus infection. 
 
MATERIALS AND METHODS 
Reagents 
The immunosuppressants, including dexamethasone (DEX; Chemical Abstract Service 
[CAS] no. 50-02-2), prednisolone (PRED; CAS no. 50-24-8), rapamycin (RAP; CAS no. 53123-
88-9), leflunomide (LEF; CAS no. 75706-12-6), brequinar (BQR) sodium salt hydrate (Method 
Detection Limit [MDL] no. MFCD21363375), and mycophenolic acid (MPA; CAS no. 24280-
93-1) were purchased from Sigma-Aldrich (St Louis, MO). The calcineurin inhibitors (CNIs) 
cyclosporine (CsA; CAS no. 59865-13-3) and tacrolimus (FK506; CAS no. 104987-11-3) were 
obtained from Bio-Connect (Huizen, The Netherlands) and Abcam (Cambridge, MA), 
respectively. Two nonimmunosuppressive CsA derivatives, 431-32 and 440-02, together with 
a novel calcineurin inhibitor, voclosporin, were provided by the Isotechnika Pharma 
Incorporation (Edmonto, AB, Canada). All the compounds were dissolved in dimethyl 
sulfoxide (DMSO) and stored in aliquots at -20℃ before use.  
Primary antibodies targeting cyclophilin A (CyPA; polyclonal rabbit, 1:1,000 dilution; 
Abcam), cyclophilin B (CyPB; polyclonal rabbit, 1:1,000 dilution; Abcam), IMPDH1 (polyclonal 
rabbit, ab33039, 1:1,000 dilution; Abcam), IMPDH2 (monoclonal rabbit, ab131158, 1:1,000 
dilution; Abcam), FKBP12 (polyclonal rabbit, sc-28814, 1:500 dilution; Santa Cruz), and β-
actin (monoclonal mouse, 1:1,000 dilution; Santa Cruz) were used. Secondary antibodies 
IRDye® 800CW-conjugated goat anti-rabbit and goat anti-mouse IgGs (1:10,000 dilution; Li-
Cor Bioscience, Lincoln, USA) were used, as appropriate. 
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MTT assay 
The cytotoxicities of the compounds on host cells were determined by a 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. In brief, cells were 
seeded into 96-well tissue culture plates containing 0.5% DMSO (control) or increasing 
concentrations of drugs. After the time indicated, 10 mM MTT (Sigma, Zwijndrecht, The 
Netherlands) was added. With another 3 hour of incubation, the medium was removed and 
100 μL of DMSO was added to each well. The plate was incubated at 37℃ for 50 min. The 
absorbance at 490 nm was recorded on the microplate absorbance reader (Bio-Rad, CA, 
USA). 
Cell cultures and virus propagation 
HG23 (Huh7 cells containing a stable subgenomic HuNV replicon), RAW 264.7, and 
human embryonic kidney 293T cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Lonza Verviers, Belgium) supplemented with 10% (vol/vol) heat-inactivated fetal 
calf serum (FCS; Hyclone, Logan, UT, USA). A marker cassette containing the neomycin 
phosphotransferase gene was inserted between nucleotides (nt) 5456 and 6753 of open 
reading frame 2 (ORF2) of HuNV, conferring HG23 resistance to neomycin. Gentamicin (G418; 
Gibco) was added to HG23 culture medium at 1.5 mg/mL for selection before 
experimentation. 
The Murine norovirus 1 (MNV-1) [30] was produced by consecutively inoculating MNV-
1 (kindly provided by Herbert Virgin, IV, Department of Pathology and Immunology, 
Washington University School of Medicine) into RAW 264.7 cells. After 4 consecutive 
passages, the MNV-1 cultures were purified, aliquoted, and stored at -80℃ for all 
subsequent experiments. The MNV-1 stock was quantified three independent times by the 
50% tissue culture infective dose (TCID50). 
TCID50 
MNV-1 was quantified by TCID50 assay. Briefly, 10-fold dilutions of MNV-1 were 
inoculated into RAW cells grown in 96-well tissue culture plate at 1,000 cells/well. The plate 
was incubated at 37℃ for another 5 days, followed by observing the cytopathic effect (CPE) 
of each well under a light scope. The TCID50 was calculated by using the Reed-Muench 
method. 
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Quantitative real-time polymerase chain reaction 
Total RNA was isolated with a Macherey NucleoSpin RNA II Kit (Bioke, Leiden, The 
Netherlands) and measured with a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was 
reverse transcribed from 500 ng of RNA using a cDNA synthesis kit (TaKaRa Bio, Inc.). The 
cDNA of a targeted gene transcript was amplified for 50 cycles and quantified with a SYBR 
Green-based real-time PCR (Applied Biosystems), according to the manufacturer’s 
instructions. All the PCRs were performed in duplicate, and amplification specificity was 
confirmed by melting-curve analysis. Human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and murine GAPDH genes were used as reference genes. The relative expression of 
targeted gene was calculated as 2-∆∆CT, where ∆∆CT = ∆CTsample - ∆CTcontrol (∆CT = CT[targeted gene] - 
CT[GAPDH]). All primer combinations are listed in Table S1. 
Antiviral assay with HuNV replicon model 
Before the experiments, HG23 cells were cultured overnight without G418. The next 
day, HG23 cells were seeded into 48-well tissue culture plates at 5 × 104 cells per well and 
treated with 0.5% DMSO (control) or drugs. After 48 hours of treatment, total RNA was 
extracted from cells, and HuNV replication was determined by qRT-PCR analysis.  
Antiviral assay with MNV-1 
The antiviral assay with MNV-1 was initiated by inoculating MNV-1 into RAW cells at 
a multiplicity of infection (MOI) of 0.1. After 1 hour of infection, cells were washed with 
phosphate-buffered saline (PBS) for 4 times to remove free virus and were subsequently 
treated with 0.5% DMSO (control) or drugs. After 24 hours of treatment, extracellular RNA 
and intracellular RNA were extracted from the cell culture supernatant (100 μL) and cell 
layer, respectively. The relative intracellular MNV-1 RNA level was normalized to murine 
GAPDH and calculated with the 2-∆∆CT method. For absolute quantification of MNV-1 RNA in 
the supernatant, the virus genome copy number was detected using qRT-PCR. In brief, a 
cDNA-containing target sequence positioned between nt 4972 and 5064 in MNV-1 was 
amplified, purified, and 10 times serially diluted. The dilutions were quantified by qRT-PCR 
to generate a standard curve, which was expressed by plotting the log copy numbers against 
the cycle threshold (CT) value (Fig. S1). The viral genome copy numbers in the MNV-1 culture 
were calculated by comparing the CT with that of the standard curve. 
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MNV-1 could induce cytopathic effect (CPE) in RAW cells [30]. The antiviral activity of 
drugs on MNV-1 was further verified by using an MTT-based CPE inhibition assay. Briefly, 
MNV-infected RAW cells were seeded into 96-well tissue culture plates at 10,000 cells/well. 
After 72 hours of treatment with 0.5% DMSO or drugs, more than 95% CPE was observed in 
the control well. Then, an MTT assay was initiated, and the absorbance (optical density [OD]) 
at 490 nm was recorded. CPE inhibition was calculated as [(ODtreated)MNV - ODVC]/[ODcc - ODvc], 
where (ODtreated)MNV represented the OD of virus-infected cells treated with drugs, while ODcc 
and ODvc represented the OD of the cell control and virus control, respectively. 
Clearance and rebound assay 
A clearance and rebound assay was performed according to the procedure described 
by Joana et al., with modifications [31]. In brief, HG23 cells were seeded into 48-well tissue 
culture plates at 2.5 × 104 cells per well and treated with increasing concentration of drugs 
but no G418. After 2 days of treatment, the cells were trypsinized, 2.5 × 104 cells were sub-
cultured into 48-well tissue culture plates containing the same concentration of drugs for 
another 4 days of treatment and 2 × 104 cells were collected for qRT-PCR analysis. After 6 
days of treatment, the same treatment process was performed for the second time. After 10 
days of treatment, 2.5 × 104 cells were subcultured into a 48-well tissue culture plate with 
fresh medium containing G418 (1.5 mg/mL). With another 5 days of culture, the cell layers 
were stained with hematoxylin and eosin, and were visualized with an inverted light 
microscope. For HuNV RNA level quantification, each passage of drug-treated cells was 
compared to 0.5% DMSO-treated control cells with the same passage number. 
In vitro selection of MPA-resistant MNV 
MPA-resistant MNV-1 was selected by culturing MNV-1 for 20 passages under 
antiviral pressure. Briefly, MNV-infected RAW (MOI, 0.1) cells were treated with 0.5% DMSO 
or MPA (0.1 or 0.5 μg/mL). After 24 hours of incubation, the MNV-1 cultures were collected 
by freezing-thawing process and titrated by qRT-PCR for use in the next passage. After 10 
passages, MNV-1 was continuously exposed to the same MPA concentrations for another 10 
passages, and MNV-1 was exposed to increased MPA concentrations for another 10 
passages. When MNV-1 serial passaging with MPA was done, the inhibitory effect of MPA on 
20th-passage MNV-1 was quantified by qRT-PCR. 
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Short-hairpin RNA delivery by lentiviral transduction 
Gene knockdown was performed as described previously [32]. In brief, pLKO.1-based 
vectors containing the RNA interference sequences were obtained from the Biomics Center 
at the Erasmus Medical Center. The lentiviral vectors were generated in HEK293T cells and 
condensed by high-speed centrifugation (if indicated). Transduction was initiated by 
inoculating short-hairpin RNA (shRNA) vectors into HG23 cells. As the vectors also express a 
puromycin resistance gene, following 3 days of transduction, cells were selected with 3 
μg/mL puromycin (Sigma-Aldrich). A validated nonsilencing scrambled vector (shCTR) was 
used as a control. All the shRNA vector sequences are listed in Table S2. For simultaneous 
knockdown, HG23 cells were transduced with a first lentiviral vector. After selection with 
puromycin, HG23 cells were subsequently transduced with a second condensed lentiviral 
vector. The knockdown efficacy and specificity was confirmed by qRT-PCR and Western blot 
analysis. 
Western blotting 
Cell samples were lysed and loaded onto a 10 to 15% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel. After electrophoresis at 120 V for 100 
min, the proteins were electrotransferred to a polyvinylidene difluoride (PVDF) membrane 
(pore size, 0.45 μM; Invitrogen) for 1.5 h, with an electric current of 250 mA. The membrane 
was probed with primary antibody plus secondary antibody and detected with Odyssey 3.0 
infrared imaging system (Li-Cor Biosciences). Beta-actin served as a standardization for 
sample loading. 
Synergy analysis 
To evaluate the interaction of ribavirin and immunosuppressants on norovirus 
replication, MacSynergy 2 (kindly provided by Mark Prichard) [33], a mathematical model 
based on the Bliss Independence theory, was employed to analyze the data from 48 hours of 
combined treatment of ribavirin and immunosuppressants on an HuNV model. In the 
MacSynergy model, the theoretical additive effect with two compounds could be calculated 
using the equation Z = X + Y (1 - X), where X and Y represent the inhibition produced by the 
individual drugs, and Z represents the theoretical effect produced by the combination of two 
drugs. The theoretical additive surface is subtracted from the actual experimental surface. 
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When a combination is additive, the data points of the calculated surface lie in the zero 
plane. A surface that lies >20% above the zero plane indicates a synergistic effect of the 
combination, and a surface >20% below the zero plane indicates antagonism. The 95% 
confidence interval was considered to be statistically significant. 
Statistics 
Data are presented as mean ± standard error of the mean (SEM). Comparisons 
between groups were performed with Mann-Whitney test using GraphPad Prism (GraphPad 
Software Inc., La Jolla, CA, USA). Differences were considered significant at a P value of <0.05. 
The 50% cytotoxic concentration (CC50) and 50% inhibitory concentration (IC50) were 
determined by fitting the data with a variable-slope dose response-inhibition nonlinear 
regression equation using GraphPad Prism (Table S3). 
 
RESULTS 
Not all immunosuppressants directly affected norovirus replication 
A major challenge in antinorovirus drug development is the lack of an infectious 
human isolate that recapitulates the entire life cycle of the virus in a cell culture model. 
Therefore, we used an HuNV subgenomic replicon model that closely mimicked viral 
replication in the absence of the production of infectious particles [34]. In our study, we 
observed that glucocorticoids, including prednisone (see Fig. S2A in the supplementary 
material) and dexamethasone (Fig. S2B), rapamycin (Fig. S2C), brequinar (Fig. S2D), and 
leflunomide (Fig. S2E) showed no effect on HuNV replication, demonstrating that 
modulation of norovirus infection is not a general property of immunosuppressants. 
CsA and its immunosuppressive analogue, voclosporin, inhibited HuNV 
replication through a CyPA-dependent mechanism 
CsA is a calcineurin inhibitor targeting cellular cyclophilins. In the HuNV model, 
treatment with CsA (5 μg/mL) for 48 hours inhibited HuNV replication by 82 ± 3.3% (P < 0.05, 
n = 6; Fig. 1A). To further confirm that this inhibitory effect relates to the compound 
targeting cyclophilins, a series of CsA derivatives were tested. Voclosporin, a novel 
immunosuppressive cyclophilin inhibitor, diminished cellular HuNV RNA levels by 49 ± 10% 
(P < 0.05, n = 6; Fig. 1B) after 48 hours of treatment, even at the low concentration of 1 
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μg/mL, whereas the parental compound CsA at this concentration had no effect on HuNV. 
This observation relates well with the notion that voclosporin is a more potent calcineurin 
inhibitor than CsA [35]. Two nonimmunosuppressive CsA derivatives, 431-32 and 440-02, 
which are chemically similar to CsA, if functionally distinct, had no effect on HuNV 
replication (P > 0.05, n = 4; Fig. 1C), suggesting that the effects of CsA analogues on 
norovirus replication are related to calcineurin inhibition. 
It is necessary to determine whether long-term exposure to these 
immunosuppressants completely eliminated HuNV replicons from host cells. For this 
purpose, a clearance and rebound assay was employed. If the replicons are completely 
cleared, the cells could not survive and proliferate in the presence of G418. If the cells still 
carry replicons, they will proliferate. CsA at 5 μg/mL caused a reduction in HuNV RNA level 
levels by 79 ± 3.8% (P < 0.05, n = 6; Fig. 1D) after 10 days of treatment. Consistently, CsA-
treated cells survived and proliferated in the presence of the selection marker (Fig. 1E), 
demonstrating that although CsA inhibited HuNV replication, it did not completely cause 
elimination of all replicons from cells. Voclosporin at 2.5 μg/mL provoked potent inhibition 
of HuNV replication, as evidenced by a reduction of 91 ± 1.5% (P < 0.05, n = 6; Fig. 1F) in viral 
RNA. Following subsequent challenge with the selection marker, only a small portion of cells 
stayed alive (Fig. 1G), showing that voclosporin treatment cleared most HuNV replicons from 
cultures, but a replicon-containing compartment remained. 
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Figure 1 Antiviral activities of CsA and its derivatives against HuNV replication. CsA (A) and 
its immunosuppressive derivative voclosporin (B) dose-dependently inhibited HuNV replication 
without potent toxicity to host cells after 48 hours of treatment. The level of HuNV RNA was 
quantified by qRT-PCR and was compared to that in cells treated with 0.5% DMSO (control) (n = 3 
independent experiments with 2 replicates each). (C) Its nonimmunosuppressive derivatives 431-32 
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and 440-02 failed to inhibit HuNV replication after 48 hours of treatment, even at the highest 
concentration tested (n = 2 independent experiments with 2 replicates each). (D and F) Clearance 
assay with CsA and voclosporin. HG23 cells were treated with CsA or voclosporin for 1, 2, 6 or 10 
days. At the end of each treatment period, the level of HuNV RNA was determined by qRT-PCR and 
normalized to that of the control cells from the same treatment time (n = 3 independent 
experiments with 2 replicates each). (E and G) Rebound assay with CsA and voclosporin. After 10 
days of treatment, drugs were omitted, and HG23 cells (48-well tissue culture plate with 2.5 × 104 
cells per well) were cultured under the selective pressure of G418 (1.5 mg/mL). With another 5 days 
of culture, the cell layers were stained with hematoxylin and eosin, and visualized by an inverted 
light microscope. Images are representative of three independent experiments with 2 replicates each. 
Data are presented as the means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant). 
 
Cellular cyclophilins, in particular the cyclophilin A (CyPA) and cyclophilin B (CyPB) 
isoforms, are the canonical drug targets of CsA. To study the potential involvement of CyPA 
and CyPB in CsA-caused inhibition of HuNV replication, an RNA interference (RNAi)-mediated 
loss-of-function assay was performed. Upon transduction of lentiviral vectors targeting CyPA 
(shCyPA) or CyPB (shCyPB), specific downregulation of the target genes at the mRNA level 
was observed at both day 6 and day 10 posttransduction, compared to a scrambled control 
(shCTR) (Fig. 2A and B). Downregulation at the protein level was observed only at day 10 (Fig. 
2C). Consistently, following knockdown, no effect on HuNV was observed at day 6, but a 
significant reduction in viral replication by 60 ± 5.7% (P < 0.05, n = 8; Fig. 2D) was observed 
by knockdown of CyPA, but not that of CyPB, at day 10 posttransduction. Notably, 
knockdown of CyPA also resulted in an elevation of CyPB mRNA expression at day 10 
posttransduction and vice versa, suggesting that a compensatory mechanism may exist 
between CyPA and CyPB (Fig. 2A and B). Concomitant with CyPA knockdown, CsA (P < 0.05, n 
= 5; Fig. 2E) and voclosporin (P < 0.05, n = 5; Fig. 2F) lost their capacity to inhibit HuNV after 
48 hours of treatment. Collectively, these results show that CsA and voclosporin inhibited 
HuNV replication through targeting CyPA, not CyPB. 
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Figure 2 CyPA, but not CyPB, is involved in CsA-caused inhibition of HuNV replication. (A 
and B) Knockdown of CyPA and CyPB through lentiviral shRNA vectors. HG23 cells were transduced 
with shRNA vectors against CyPA (shCyPA), CyPB (shCyPB), or control (shCTR). At the indicated time 
points, the level of cyclophilin RNA was measured by qRT-PCR and compared to the control (n = 2 
independent experiments with 2 replicates each). (C) Western blot analysis of CyPA and CyPB in 
HG23 cells transduced with shRNAs. Images are representative of three independent experiments. 
Transduction of CyPA and CyPB shRNAs resulted in a dramatic downregulation of CyPA and CyPB 
expression at day 10 (10 d) but not at day 6 (6 d) posttransduction. (D) qRT-PCR analysis of HuNV 
RNA in HG23 cells transduced with shRNAs. Knockdown of CyPA but not CyPB resulted in a significant 
decrease in viral replication at day 10 but not at day 6 posttransduction (n = 3 independent 
experiments with 2 to 3 replicates each). (E and F) Knockdown of CyPA abrogated the inhibition of 
HuNV replication by CsA and voclosporin. After successful knockdown of mRNA and protein of CyPA, 
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the responsiveness of HuNV to CsA and voclosporin treatment was detected after 48 hours of 
treatment. CsA and voclosporin possessed the anti-norovirus activity against shCTR-treated HG23 
cells but failed to suppress HuNV replication in shCyPA HG23 cells. Data are presented as the means 
± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
 
FK506 moderately inhibited HuNV replication via targeting FKBP12 
FK506 (tacrolimus) is another calcineurin inhibitor. FK506 at 2.5 μg/mL caused a 
reduction in HuNV replication by 77 ± 5.0% (P < 0.05, n = 6) and 70 ± 8.3% (P < 0.05, n = 6) 
after short-term (2 days, Fig. 3A) and long-term (10 days, Fig. 3B) treatment, respectively. Of 
note, FK506 at high concentration of 2.5 μg/mL quickly inhibited HuNV replication being 
evident from effects even after 1 day of treatment. Similar to CsA analogues, FK506 did not 
completely clear HuNV replicons from the cultures (Fig. 3C). 
FK506 suppresses the immune system by binding to FKBP12, resulting in inhibition of 
the phosphatase activity of calcineurin. To understand the role of FKBP12 in FK506-mediated 
inhibition of HuNV, we knocked down the expression of FKBP12. It is demonstrated that 
knockdown of FKBP12 (Western blot analysis in Fig. 3D and reverse transcription-
quantitative PCR [qRT-PCR] analysis in Fig. S3), but not FKBP8 (a control; qRT-PCR analysis in 
Fig. S3) resulted in reduced HuNV replication (Fig. 3E). At the same time, FKBP12 knockdown 
partially abrogated FK506-mediated inhibition of HuNV (P < 0.05, n = 8; Fig. 3F), suggesting 
that FK506 inhibited HuNV replication through a pathway involving FKBP12. Thus, the 
calcineurin pathway appears to be essential for norovirus propagation, and experiments 
were initiated to confirm this notion. 
Calcineurin activation is indispensable for efficient replication of norovirus  
Calcineurin inhibitors are effective against norovirus replication, whereas 
nonimmunosuppressive CsA derivatives are ineffective, suggesting that calcineurin activity is 
required for CsA and FK506-mediated inhibition of norovirus. To confirm this hypothesis, we 
used RNAi to knock down protein phosphatase 3, catalytic subunit, alpha isozyme (PPP3CA) 
to inhibit calcineurin phosphatase activity. After successful knockdown of PPP3CA (Fig. 3G), 
it is shown that HuNV replication was inhibited (Fig. 3H). Thus, calcineurin activation is vital 
for norovirus replication, supporting the idea that CsA and FK506 exerted anti-norovirus 
activity through the inhibition of calcineurin. 
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Figure 3 FK506 moderately inhibited HuNV replication through FKBP12 and calcineurin. (A) 
Concentration-dependent antiviral effects of FK506 on HuNV replication after 48 hours of treatment 
(n = 3 independent experiments with 2 replicates each). (B) Clearance assay with FK506. Long-term 
exposure to FK506 resulted in a moderate reduction of HuNV replication (n = 3 independent 
experiments with 2 replicates each). (C) Rebound assay with FK506. After long-term clearance phase, 
HG23 cells were cultured in the presence of G418 for another 5 days. Reduced cell confluency was 
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observed, indicating that FK506 partially cleared the HuNV replicons from host cells. (D) Western blot 
analysis of FKBP12 knockdown by lentiviral shRNA vectors. Images are representative of three 
independent experiments. (E) qRT-PCR analysis of HuNV RNA level in shCTR, shFKBP8, and shFKBP12 
cells after transduction of lentiviral shRNA vectors for 10 days. FKBP12 but not FKBP8 knockdown 
inhibited HuNV replication (n = 2 independent experiments with 2 replicates each). (F) FKBP12 
knockdown partially blocked FK506-induced inhibition of HuNV after 48 hours of treatment (n = 3 
independent experiments with 2 to 3 replicates each). (G) qRT-PCR analysis of calcineurin knockdown 
at the RNA level. The level of calcineurin subunit PPP3CA RNA was presented as the relative value to 
the shRNA control (n = 2 independent experiments with 2 replicates each). (H) PPP3CA knockdown 
inhibited HuNV replication, as determined by qRT-PCR (n = 2 independent experiments with 2 
replicates each). Data are presented as the means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
 
MPA potently inhibited norovirus replication and completely cleared HuNV 
replicons from host cells 
Examining the effects of MPA on HuNV replication, we observed that treatment with 
only 0.25 μg/mL of MPA, which was even lower than the blood concentration 
(approximately 1 to 10 μg/mL) in transplantation patients [36], potently inhibited HuNV 
replication by 79 ± 2.7% (P < 0.05, n = 6; Fig. 4A) after 48 hours of treatment. Likewise, 
following long-term treatment with 0.5 μg/mL MPA (10 days; Fig. 4B), HuNV replication was 
reduced by 94 ± 1.7% (P < 0.05, n = 6). Correspondingly, in the rebound experiment (Fig. 4C), 
MPA-treated cells completely lost the ability to proliferate and succumbed to the selection 
marker, suggesting that MPA treatment totally cleared replicons from the host cells. In 
apparent support, when we tested other 4 IMPDH inhibitors with differential inhibitory 
efficacies on IMPDH enzymatic activity (Ki values toward IMPDH1 and IMPDH2 are shown in 
the Table S4), all of them exerted significant anti-norovirus activities at a 1 μM concentration 
(P < 0.05, n = 6; Fig. 4D). 
In the face of a lack of a cell culture system for HuNV, we considered MNV a suitable 
surrogate for studying HuNV biology and pathogenesis. Consistent with the results in the 
replicon model, MPA at 0.1 μg/mL reduced MNV-1 cellular viral RNA by 83 ± 8% (P < 0.05, n 
= 6 to 8; Fig. 4E) and virus production in the supernatant (P < 0.05, n = 6; Fig. 4F) after 24 
hours of treatment. The inhibitory effect was also confirmed in a cytopathic effect (CPE) 
inhibition assay, demonstrating that MPA at 0.1 μg/mL protected RAW cells from MNV-1 
induced CPE formation by 57 ± 14% (P < 0.05, n = 8; Fig. 4E). Collectively, our results 
demonstrated that MPA potently inhibited norovirus replication and could even completely 
clear the virus.  
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High barrier to resistance development  
In the HuNV replicon model, MPA completely cleared the viral replicons, which 
obviously prevented the emergence of resistance and thus leaves the question unanswered 
about whether norovirus develops resistance to MPA treatment. To address this issue, MNV-
infected RAW cells were exposed to MPA in different setups for 20 passages. As shown in Fig. 
4G, MNV-1 retained its sensitivity to MPA treatment, even at passage 20, with inhibitory 
efficacy varying from 98.5 ± 0.07% to 99.6 ± 0.07% following treatment with 0.5 μg/mL MPA, 
which was comparable to that in the unchallenged control (99.6 ± 0.05% inhibition). Thus, 
norovirus is not prone to developing resistance to MPA. 
MPA inhibited norovirus replication by simultaneously targeting IMPDH1 and 
IMPDH2 
MPA acts through inhibition of IMPDH. There are two isoforms of IMPDH, IMPDH1 
and IMPDH2, in mammals. MPA has a 5-fold more potent inhibitory effect on IMPDH2 than 
on IMPDH1 [33]. In view of the low concentrations of MPA required to counteract norovirus, 
IMPDH2 appears to be the more likely drug target with respect to its effects on the norovirus 
life cycle. However, knockdown of IMPDH2 had no significant effect on HuNV replication (Fig. 
5C), even though such knockdown profoundly decreased IMPDH2 mRNA and protein levels, 
as assessed by qRT-PCR (Fig. S4) and Western blot (Fig. 5A). Similarly, knockdown of IMPDH1 
decreased IMPDH1 expression at the RNA level (Fig. S4) and protein level (Fig. 5B) but 
caused no significant change in HuNV replication (Fig. 5C). Surprisingly, simultaneous 
knockdown of IMPDH1 and IMPDH2 (qRT-PCR analysis in Fig. S5 and Western blot analysis in 
Fig. 5D) suppressed HuNV replication by 64 ± 5.3% (P < 0.05, n = 4; Fig. 5E), showing the 
interchangeable roles of IMPDH1 and IMPDH2 on norovirus life cycle. 
Guanosine restored norovirus replication in MPA-treated and IMPDH1/2 
knockdown cells 
MPA inhibits de novo guanosine nucleotide biosynthesis by inhibiting IMPDH. To examine 
whether MPA exerts an inhibitory effect on norovirus via guanosine depletion, we 
challenged norovirus cultures either with only MPA or with a combination of MPA and 
guanosine (with guanosine at 1, 10 or 100 μg/mL concentrations). After 24 hours of 
incubation, norovirus replication was determined by qRT-PCR analysis. We observed that the 
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Figure 4 MPA potently inhibited norovirus replication and completely eliminated HuNV 
replicons from host cells without concomitant drug resistance. (A) Treatment with MPA for 48 
hours potently inhibited HuNV replication, as determined by qRT-PCR (n = 3 independent 
experiments with 2 replicates). (B) Clearance assay with MPA (n = 3 independent experiments with 2 
replicates). (C) Rebound assay with MPA. Long-term treatment with 0.5 μg/mL MPA completely 
cleared HuNV replicons from host cells, and no colony formation was observed. (D) Comparison of 
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the antinorovirus effects of MPA and 4 IMPDH inhibitors on HuNV. In the HG23 cells, treatment with 
4 IMPDH inhibitors (the same concentration of 1 μM as MPA) resulted in a reduction in HuNV 
replication (n = 3 independent experiments with 2 replicates). (E) The antinorovirus effects of MPA 
were validated on MNV-1 as quantified by means of an MTT-based CPE reduction assay and qRT-PCR 
(n = 2 independent experiments with 2 to 3 replicates). ND, not detected. (F) Same as panel E for 
detecting the cellular MNV-1 RNA level, the viral RNA copy numbers in the supernatant (secreted 
viruses) were also detected after 24 hours of treatment with MPA. MPA potently inhibited MNV-1 
virus particle production (n = 2 independent experiments with 2 or 3 replicates). (G) The inhibitory 
efficacy of MPA against MNV-1 following 20 passages (20P) exposed to MPA or vehicle control. In the 
selection process, MNV-1 was either directly cultured in the presence of a fixed MPA concentration 
(0.1 or 0.5 μg/mL) or in a lengthy stepwise selection concentration from 0.1 to 0.5 μg/mL or from 0.5 
to 1 μg/mL. After selection, the antinorovirus effects of MPA on the 20th passage of MNV-1 were 
determined by qRT-PCR. Data are presented as the means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 
0.001). 10P, 10 passages. 
 
inhibitory effect of MPA on norovirus replication was sensitive to supplementation with 
guanosine. An 100 μg/mL guanosine concentration completely negated MPA effects in both 
the MNV-1 model (P < 0.05, n = 6 to 8; Fig. 5F) and HuNV replicon model (P < 0.05, n = 5; Fig. 
5G). In apparent agreement, exogenous supplementation of guanosine reversed the 
inhibitory effects of IMPDH1/2 knockdown on HuNV replication (P < 0.05, n = 5; Fig. 5H). 
Thus, norovirus biology requires substantial intracellular guanosine levels, and the inhibitory 
effects of MPA and IMPDH knockdown are mediated by the depletion of this guanosine pool. 
Ribavirin efficiently inhibited norovirus partially through nucleotide depletion 
Ribavirin at 2.5 μg/mL concentration resulted in a reduction of HuNV replication by 
64 ± 6.1% (P < 0.05, n = 6; Fig. 6A) and 61 ± 8.5% (P < 0.05, n = 6; Fig. 6B) after short-term 
and long-term treatment, respectively. Additionally, ribavirin at higher concentrations (5 and 
10 μg/mL) was capable of clearing cells of most replicons following 10 days of consecutive 
culture (Fig. 6C). The antiviral activity of ribavirin was confirmed in the MNV-1 model. 
Ribavirin at concentration of 5 μg/mL effectively decreased MNV-1 cellular RNA (P < 0.05, n 
= 6; Fig. 6D) and extracellular viral particles in the supernatant (P < 0.05, n = 6; Fig. 6E). In the 
CPE inhibition experiment, treatment with ribavirin for 3 days dose-dependently increased 
cell viability and decreased CPE formation by inhibiting MNV-1 replication (P < 0.05, n = 8; 
Fig. 6D), further validating the antiviral activity of ribavirin on MNV-1. To further explore the 
mechanism of ribavirin, we investigated whether the addition of exogenous guanosine 
would revert the antiviral effect of ribavirin. As shown in Fig. S6, a high concentration of 
guanosine partially reverted the antiviral activity of ribavirin for both HuNV and MNV, 
indicating that guanosine depletion contributed to the antiviral activity of ribavirin. 
Chapter 3 
60 | P a g e  
 
 
Figure 5 Simultaneous knockdown of IMPDH1/2 reduced HuNV replication, which was 
reversed by exogenous guanosine. (A and B) Validation of IMPDH downregulation in shCTR cells and 
shIMPDH cells by Western blotting. Images are representative of three independent experiments. (C) 
qRT-PCR analysis of HuNV RNA level in IMPDH knockdown cells. Compared to control cells, 
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knockdown of IMPDH1 or IMPDH2 alone had no significant effect on HuNV replication (n = 2 
independent experiments with 2 replicates each). (D) Validation of IMPDH downregulation after 
simultaneous knockdown of IMPDH1/2 by Western blotting. Images are representative of three 
independent experiments. (E) Simultaneous silence of IMPDH1/2 decreased HuNV replication (n = 2 
independent experiments with 2 replicates). (F and G) Guanosine restored norovirus replication in 
MPA-treated cells. MNV-1 and the HuNV replicon were treated with MPA alone or combined with 
guanosine (1, 10 or 100 μg/mL). After 24 hours of incubation, norovirus replication was quantified by 
qRT-PCR. (H) IMPDH1/2 knockdown cells were cultured with medium or increasing concentrations of 
guanosine. After 24 hours of incubation, the HuNV RNA level was analyzed by qRT-PCR and was 
compared to the shCTR cells (n = 2 independent experiments with 2 replicates). Data are presented 
as the means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
 
 
Figure 6 Ribavirin effectively inhibited norovirus replication. (A) Treatment with ribavirin for 
48 hours dose-dependently decreased HuNV replication, as determined by qRT-PCR (n = 3 
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independent experiments with 2 replicates each). (B) Clearance assay with ribavirin (n = 3 
independent experiments with 2 replicates each ). (C) Rebound assay with ribavirin. (D) The 
antinorovirus activity of ribavirin was also confirmed on MNV-1. Ribavirin treatment decreased MNV-
1-induced CPE and viral RNA replication in RAW 264.7 cells (n = 3 independent experiments with 2 to 
3 replicates). (E) Ribavirin treatment also decreased MNV-1 virus particle production in supernatant 
as quantified by viral RNA copy numbers (n = 3 independent experiments with 2 replicates). Data are 
presented as the means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
 
Combinatory effects of ribavirin and immunosuppressants on norovirus 
replication 
Immunosuppressants are often used in combination in the clinic. First, we evaluated 
the interaction of immunosuppressants on HuNV using MacSynergy 2 combination analysis. 
As shown in Fig. 7A, the combined calcineurin inhibitors, FK506 and CsA, exerted a 
moderately synergistic antiviral effect, with a log volumes of 5.55. The maximal degree of 
combined inhibition between FK506 and CsA was achieved at 1 μg/mL FK506 and 0.4 μg/mL 
CsA, with a synergy volume of 35.06 μM2% above the expected value. The combination of 
MPA with FK506 (Fig. 7B) or CsA (Fig. 7C) achieved a synergy volume of -7.79 μM2% (log 
volume of -0.93) or -14.58 μM2% (log volume of -1.32), respectively, indicating an additive 
effect. These results highlight the dependency of norovirus biology on both calcineurin 
phosphatase activity and the presence of an adequate intracellular guanosine pool. 
Next, we assessed the combinatory antiviral effects of ribavirin and 
immunosuppressants. The combined effects of ribavirin and immunosuppressants, including 
CsA (Fig. 7D), FK506 (Fig. 7E), and MPA (Fig. 7F) were additive, with synergy volumes of 0 
μM2% (log volume of 0), 0 μM2% (log volume of 0) and -4.04 μM2% (log volume of -0.37), 
respectively. 
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Figure 7 The combinatory effects of ribavirin and immunosuppressants on norovirus 
replication. The combinatory effects of two drugs in the 48-hour antiviral assay with HuNV were 
analyzed using the mathematical model MacSynergy. The three-dimensional surface plot represents 
the differences (within 95% confidence interval [95% CI]) between actual experimental effects and 
theoretical additive effects of the combination at various concentrations of the two compounds (n = 
5). The antiviral effects of FK506 in combination with CsA (A) or MPA (B) as well as CsA in 
combination with MPA (C) was analyzed by MacSynergy model. Combinations of ribavirin with CsA 
(D), FK506 (E) or MPA (F) were analyzed by the relative HuNV RNA level compared to the control and 
MacSynergy model. 
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DISCUSSION 
Immunosuppressants are universally used to deliberately induce immunosuppression 
after organ transplantation to prevent allograft rejection. However, this results in increased 
susceptibility to opportunistic infections, and especially norovirus infection has emerged as a 
major concern in this respect. A recent study reported that among 116 
immunocompromised pediatric hematopoietic stem cell and solid organ transplant 
recipients, norovirus infection was associated with prolonged diarrhea and frequent 
intensive care unit (ICU) admission [5]. Although new classes of immunosuppressive 
medications have been introduced to the transplant community during the last decades, T-
lymphocytes remain the key targets of these agents, as this cell type is a major effector in 
graft rejection. T-lymphocytes, however, also play an important role in the adaptive immune 
response following viral infection; thus, reduced resistance to viral infection is an expected 
side effect of graft tolerance-inducing medications. Intriguingly, immunosuppressive 
medications may also directly interfere with the viral life cycle. For various viruses, it is now 
clear that the choice of immunosuppressive medications relates to patient sensitivity to 
infection [38]. Norovirus biology, however, is relatively poorly understood, and its interaction 
with different immunosuppressive regimens remains obscure at best. Here, we have profiled 
the commonly used immunosuppressants on norovirus infection and related the effects to 
their cellular effectors. Thus, our data provide guidance as to the host biochemical 
mechanisms essential for norovirus replication and may guide clinical management of 
transplantation patients at risk for norovirus infection. With respect to the latter, the 
remarkable sensitivity of norovirus to MPA is especially important, particularly in view of the 
absence of norovirus-directed vaccines or antiviral medications. 
Interestingly, our study reveals a hitherto unexpected role for calcineurin 
phosphatase activity in the norovirus life cycle. Calcineurin inhibitors include FK506 and CsA. 
FK506 is currently a widely used immunosuppressive agent for managing transplantation 
patients. CsA binds to cyclophilins, and FK506 binds to FK binding proteins (FKBPs). Both 
events result in a profound inhibition of the phosphatase activity of calcineurin, which in 
turn suppresses T cell proliferation. In general, FK506 is thought to have no effect on viral 
infections [28]. In contrast, CsA has been demonstrated to interact with the biology of a broad 
range of viruses, mainly through inhibiting cyclophilins. Of note, CsA inhibited HCV 
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replication both in vitro and in vivo in an apparently specific manner. HCV RNA replication 
requires the non-structural HCV NS5A protein that serves as a direct ligand for CyPA. CsA 
could disrupt the CyPA-NS5A interaction, further reducing HCV RNA replication [39]. In our 
study, FK506 and CsA exerted a moderate inhibitory effect on norovirus replication through 
FKBP12 and CyPA, respectively. Furthermore, nonimmunosuppressive CsA analogues, which 
do not inhibit calcineurin, failed to suppress norovirus replication, supporting the hypothesis 
that calcineurin activation is required for the norovirus life cycle.  
Calcineurin is a heterodimeric Ca2+- and calmodulin-dependent serine/threonine 
protein phosphatase composed of a 60-kDa catalytic subunit (PPP3CA) and a 19-kDa calcium 
binding regulatory subunit (PPP3R1) [40]. Our results showed that knockdown of PPP3CA 
resulted in a dramatic reduction of HuNV replication, demonstrating that calcineurin is 
required for HuNV replication. Although the exact mechanism as to how calcineurin 
facilitates norovirus replication is unknown, it may resemble its role in the life cycle of the 
polyomavirus BK [41]. The observation that CsA, but not NIM811 (a nonimmunosuppressive 
CsA derivative), inhibited BK virus (BKV) replication by inhibiting CyPA and calcineurin 
activation is highly reminiscent of the results obtained in the present study, but concluding 
that the effects are mechanistically identical requires further validation, especially with 
respect to the role of the nuclear factor of activated T cells (NFAT). 
Mycophenolate mofetil (MMF) has been widely used in kidney, pancreas, liver and 
heart transplantation [42]. MPA, the active form of MMF in vivo, is a potent inhibitor of 
IMPDH, a rate-limiting enzyme in the de novo synthesis of guanosine nucleotides. By 
inhibiting IMPDH, MPA results in the depletion of the intracellular GTP and dGTP pools and 
exerts potent immunosuppressive effects. MPA has been demonstrated to inhibit a variety 
of viruses, ranging from DNA virus, including hepatitis B virus (HBV), to RNA viruses, 
including HCV, dengue virus, yellow fever virus, and Chikungunya virus [28]. Here, we 
demonstrated that MPA potently inhibited both MNV and HuNV replication through 
simultaneously targeting IMPDH1 and IMPDH2. Furthermore, MPA at levels below the 
serum concentrations in patients completely eliminated HuNV replicons from cells after 
long-term treatment. In apparent agreement, 4 IMPDH inhibitors also inhibited HuNV 
replication in our experiments. Apparently, MPA has a high barrier against developing drug 
resistance with respect to its action on norovirus biology. Of note, characterization of the 
potential mutagenesis of the viral genome in response to MPA exposure is interesting for 
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future research. In conjunction, our data provide compelling evidence that MPA should be 
the immunosuppressant of choice in transplantation patients at risk for norovirus infection. 
The optimization of immunosuppression might help the clearance of norovirus 
infection in a proportion of infected organ recipients. However, for the transplant or other 
types of patients who fail to clear the virus, effective antiviral therapy is urgently needed, 
whereas no proven antiviral medications are available. Ribavirin, a general antiviral, has 
been used in the clinic for decades to treat various types of viral infections. A recent study 
reported that ribavirin cleared norovirus and resulted in complete symptomatic and 
histological recovery in two CVID patients, which raises the possibility of ribavirin as a 
potential antiviral therapy for norovirus infection. Several studies have attempted to 
understand the antiviral activity and the mechanism of ribavirin on norovirus. It has been 
reported that addition of guanosine to the ribavirin treatment could moderately reversed 
ribavirin inhibition on HuNV [43], which is consistent with our results. Another two studies 
demonstrated that ribavirin inhibited MNV through increased mutagenesis and quasispecies 
diversity [44, 45]. In our study, ribavirin at concentrations comparable to serum concentrations 
in patients [46] inhibited norovirus replication. Ribavirin, combined with MPA or calcineurin 
inhibitors, additively inhibited norovirus replication, which supports the potential of ribavirin 
as a therapy for norovirus infection in transplant patients. However, it remains to be further 
investigated whether the optimal combination with ribavirin is MPA, CsA or FK506. 
In summary, we profiled the effects of clinically relevant immunosuppressants on 
norovirus replication and observed that norovirus was sensitively dependent on IMPDH 
guanine synthesizing activity but also required calcineurin phosphatase activity. MPA 
represents a potent inhibitor of norovirus replication, with a high barrier toward the 
development of drug resistance. Ribavirin is a promising candidate in treating norovirus 
infection, athough further evaluation, particularly in patients, is needed. 
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Supplementary Information 
SUPPLEMENTARY TABLES AND FIGURES 
Table S1 PCR primer sequences were listed. 
Name Sequences 
Neomycin 
phosphotransferase 
F: 5’-CCGGCTACCTGCCCATTC-3’ 
R: 5’-CCAGATCATCCTGATCGACAA G-3’ 
MNV-1
a
 F: 5’-CACGCCACCGATCTGTTCTG-3’ 
R: 5’-GCGCTGCGCCATCACTC-3’ 
Human GAPDH F: 5’-GTCTCCTCT GACTTCAACAGCG-3’ 
R: 5’-ACCACCCTGTTGCTGTAGTAGCCAA-3’ 
Murine GAPDH F: 5’-TTCCAGTATGACTCCACTCACGG-3’ 
R: 5’-TGAAGACACCAGTAGACTCCACGAC-3’ 
CyPA F: 5’-TAAAGCATACGGGTCCTGG-3’ 
R: 5’-TCGAGTTGTCCACAGTCAG-3’ 
CyPB F: 5’-ATGTAGGCCGGGTGATCTTT-3’ 
R: 5’-TTTATCCCGGCTGTCTGTCT-3’ 
FKBP12 F: 5’- TGCTAGGCAAGCAGGAGGTGAT-3’ 
R: 5’- GTGGCACCATAGGCATAATCTGG-3’ 
FKBP8 F: 5’- ACTCCTACGACCTCGCCATCAA-3’ 
R: 5’- GGTAGTGGTCGAGCTTCAGCTG-3’ 
PPP3CA F: 5’-GCCCTGATGAACCAACAGTTCC-3’ 
R: 5’-GCAGGTGGTTCTTTGAATCGGTC-3’ 
IMPDH1 F: 5’-GCACACTGTGGGCGAT-3’ 
R: 5’-GAGCCACCACCAGTTCA-3’ 
IMPDH2 F: 5’-TCTTCAACTGCGGAGAC-3’ 
R: 5’-CTGTAAGCGCCATTGCT-3’ 
a accession# NC008311 
 
 
Figure S1 Standard curve for quantifying MNV-1 genome copy numbers.  
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Table S2 Sequences of shRNA-mediated vectors were listed. 
Name sequences 
Scrambled vector 5’-CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCAT 
CTTGTTGTTTTT-3’ 
CyPA 5’-CCGGTGGTGACTTCACACGCCATAACTCGAGTTATGGCGTGTGAA 
GTCACCATTTTTG-3’ 
CyPB 5’-CCGGGCCTTAGCTACAGGAGAGAAACTCGAGTTTCTCTCCTGTAG 
CTAAGGCTTTTTG-3’ 
shFKBP8-1 5’-CCGGACGTCGCTGGAGAATGGCACACTCGAGTGTGCCATTCTC 
CAGCGACGTTTTTT-3’ 
shFKBP8-2 5’-CCGGAGTGGACATGACGTTCGAGGACTCGAGTCCTCGAACGTC 
ATGTCCACTTTTTT-3’ 
shFKBP12-1 5’- CCGGAGAGAGCCAAACTGACTATATCTCGAGATATAGTCAGTTTG 
GCTCTCTTTTTT-3’ 
shFKBP12-2 5’-CCGGGCCAAACTGACTATATCTCCACTCGAGTGGAGATATAGTCA 
GTTTGGCTTTTT-3’ 
shFKBP12-3 5’-CCGGGAGAGCCAAACTGACTATATCCTCGAGGATATAGTCAGTTTG 
GCTCTCTTTTT-3’ 
shPPP3CA-1 5’-CCGGCACCACAACATAAGATCACTACTCGAGTAGTGATCTTATGTT 
GTGGTGTTTTT-3’ 
shPPP3CA-2 5’-CCGGGAATAATAACAGAGGGTGCATCTCGAGATGCACCCTCTGTTA 
TTATTCTTTTT-3’ 
shIMPDH1-1 5’-CCGGCCAGGATTCATAGACTTCATACTCGAGTATGAAGTCTATGAA 
TCCTGGTTTTT-3’ 
shIMPDH1-2 5’-CCGGCGGAAGGTCAAGAAGTTTGAACTCGAGTTCAAACTTCTTG 
ACCTTCCGTTTTT-3’ 
shIMPDH1-3 5’-CCGGGTGACGTTGAAAGAGGCAAATCTCGAGATTTGCCTCTTTCA 
ACGTCACTTTTT-3’ 
shIMPDH1-4 5’-CCGGCCTGAAGAAGAACCGAGACTACTCGAGTAGTCTCGGTTCTT 
CTTCAGGTTTTT-3’ 
shIMPDH2-1 5’-CCGGCACCTACAATGACTTTCTCATCTCGAGATGAGAAAGTCATTG 
TAGGTGTTTTT-3’ 
shIMPDH2-2 5’-CCGGGACTGTTTCTTGGAAGAGATACTCGAGTATCTCTTCCAAGAA 
ACAGTCTTTTT-3’ 
 
 
Table S3 In vitro anti-norovirus and cytotoxic activity of compounds. 
 Compounds 
Inhibition of viral RNA 
replication EC50, μg/mL 
Inhibition of cell 
proliferation CC50, 
μg/mL 
Selectivity index 
Human 
norovirus 
model 
Cyclosporin A 
(CsA) 
3.90 14.34 3.67 
Voclosporin  
(VCS) 
0.94 4.74 5.04 
Tacrolimus  
(FK506) 
2.92 3.72 1.27 
Mycophenolic 
acid (MPA) 
0.13 4.11 31.61 
Ribavirin 1.25 14.94 11.95 
Mouse 
norovirus 
model 
Mycophenolic 
acid (MPA) 
0.05 0.80 40 
Ribavirin 0.74 30.87 41 
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Figure S2 Not all immunosuppressants directly affect norovirus replication. Glucocorticoids, 
including PRED (A) and DEX (B) showed no effects on HuNV replication. Likewise, rapamycin (C), an 
mTOR inhibitor produced no significant changes in HuNV replication. Similarly, BQR (D) and LFM (E), 
which are in clinical development for use in transplantation medicine, showed no significant effects 
on HuNV replication. Six replicates were performed (three independent experiments, each with two 
replicates) and data are presented as the means ± SEM. 
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Figure S4 qRT-PCR analysis 
of IMPDH RNA levels in IMPDH1 or 
IMPDH2 knockdown cells. 
Figure S5 qRT-PCR analysis 
of IMPDH RNA levels after 
simultaneous knockdown of 
IMPDH1 and IMPDH2. 
Figure S3 qRT-PCR analysis 
of FKBP8 and FKBP12 RNA levels 
after shRNA-based knockdown. 
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Table S4 The Ki values of 4 IMPHD inhibitors toward IMPDH1 and IMPDH2. Because of 
confidentiality, the structures are not shown. 
# IMPDH I Ki in nM IMPDH II Ki in nM MW 
1315 0.60 13.90 744.53 
1346 859.1 243.9 546.54 
1351 618.40 185.90 549.59 
1356 70.12 65.69 588.67 
 
 
Figure S6 The effects of exogenous guanosine on the antiviral effect of ribavirin toward 
HuNV (A) and MNV (B) model. 
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SUPPLEMENTARY DISCUSSION 
Glucocorticosteroids were widely used during the early years of organ 
transplantation. Nowadays clinicians generally attempt to avoid prescribing steroids in case 
of active infection because of their potential of facilitating the infectious process and the 
concern about long-term complications associated with such treatment regimens [1]. For 
instance, steroids boluses used to treat acute rejection in hepatitis C virus (HCV) infection-
related liver transplantation were often associated with an increase in viral load and the 
severity of HCV recurrence [1, 2]. In cell culture, steroids had no effect on HCV replication [3], 
but can specifically facilitate viral entry by enhancing the expression of the HCV co-receptors 
[4]. In the present study, however, we observed no direct effects of steroids on norovirus 
replication in vitro, although their impact on norovirus infection in patients remained to be 
further addressed. Rapamycin when complexed to FKBP12 to form the FKBP-rapamycin 
complex that directly binded to mTOR complex 1 and thus inhibited the mTOR pathway, 
appeared likewise safe but was associated with anti-norovirus activity per se. This contrasted 
the situation with respective to HCV infection. Rapamycin potently inhibited HCV RNA 
replication, but did not influence the early replication cycle steps associated with its biology 
such as cell entry and viral RNA translation [5]. Diametrically opposing the situation with HCV, 
another study showed that rapamycin facilitated hepatitis E virus (HEV) replication through 
inhibition of PI3K-PKB-mTOR pathway. The latter pathway limited HEV infection and acted as 
a gate-keeper with respect to HEV in human HEV target cells. In our study, rapamycin 
treatment resulted in no change on norovirus replication in cell culture models. Thus, effects 
of mTOR inhibitors on viral life cycle appear highly virus specific, hampering design of 
rational immunosuppressive therapies using this medication. Brequinar and leflunomide, 
two best-known inhibitors of dihydroorotate dehydrogenase (DHOD), interfere with cell 
proliferation by inhibiting pyrimidine nucleotide biosynthesis [6]. Leflunomide has been 
extensively studied and is approved for the treatment of psoriatic arthritis and rheumatoid 
arthritis [7]. Leflunomide has been shown to inhibit HIV-1 replication mainly through 
pyrimidine nucleotide pool depletion [8]. In our study, both leflunomide and brequinar 
showed no effects on HuNV replication and appeared thus not specifically useful for the 
management of patients at risk for norovirus infection. 
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ABSTRACT 
Norovirus represents the main cause of acute nonbacterial gastroenteritis worldwide. In 
immunocompromised patients, it bears high risk of causing chronic infection with significant 
morbidity and mortality. The lack of specific treatment prompts the development of anti-
norovirus agents. In this study, we have investigated the role of interferon (IFN) response 
and evaluated antiviral activities of different IFNs against human norovirus (HuNoV) 
replication using a HuNoV replicon model. We found that HuNoV RNA replication was 
sensitive to all types of IFNs, including IFNα (type I), IFNγ (type II), IFNλ1 and 3 (type III). IFNs 
canonically induce interferon-stimulated genes (ISGs) to exert their antiviral activities. By 
profiling a subset of important human ISGs using an overexpression approach, we have 
identified RTP4 and HPSE as moderate anti-norovirus ISGs, whereas IRF-1, RIG-I (also known 
as DDX58) and MDA5 (also known as IFIH1) were identified as potent anti-norovirus 
effectors. Interestingly, type I and III IFNs coordinately induced IRF-1, RIG-I and MDA5, 
whereas type II IFN predominantly induced IRF-1 to exhibit their anti-norovirus activities. 
Combination of different IFNs revealed that IFNγ worked cooperatively with type I or type III 
IFNs to induce ISGs and subsequently inhibit HuNoV replication. Of note, replication of 
HuNoV did not interfere with antiviral IFN response. In summary, we showed the potent 
anti-norovirus activities of different types of IFNs and identified the key anti-norovirus 
effectors. These findings are important for understanding norovirus-host interactions and 
developing antiviral therapies. 
KEYWORDS: Norovirus; Interferon; IRF-1; RIG-I; MDA5 
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INTRODUCTION 
Norovirus represents the main cause of infectious viral gastroenteritis worldwide 
with significant morbidity and mortality. It is estimated that norovirus infection causes over 
200,000 deaths annually of which more than 90,000 deaths occur in children under five 
years [1]. Although norovirus gastroenteritis is usually self-limiting, it has been recently 
recognized as a risk factor for chronic gastroenteritis in specific populations, particularly 
transplant patients [2, 3]. In transplant settings, norovirus gastroenteritis is characterized by 
severe complications, including protracted illness with malnutrition, organ failure and 
chronic viral shedding [4].  
As an important component of the innate immune system, interferons (IFNs) 
constitute the first line of defense against invading pathogens. Currently, IFNs are classified 
into three major groups including type I, II and III IFNs. Upon viral infections, both type I and 
III IFNs are induced by the stimulation of pattern recognition receptors (PRRs), such as Toll-
like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I) like helicases. Type I IFNs 
consisting of 13 subtypes are expressed by most cell types and secreted into the 
extracellular milieu. Secreted type I IFNs bind to the IFNAR receptors in an auto- or paracrine 
fashion and activate the Janus kinase (JAK)-signal transducer and activator of transcription 
(STAT) signaling pathway, leading to the expression of a broad range of IFN-stimulated genes 
(ISGs), which are ultimate antiviral effectors [5]. Type III IFNs consist of three members 
including IFNλ1, λ2 and λ3 (IL29, IL28A and IL28B, respectively) and also induce a type I IFN-
like response. Unlike type I IFNs which target most of the cell types, type III IFNs primarily 
target epithelial cells [6]. They play an important role in the epithelial antiviral host defense 
and consequently constitute a major barrier for enteric virus infections. Notably, type II IFN 
has solo member (IFNγ) and is involved in resisting a broad range of intracellular 
microorganisms [7].  
First discovered in 1957, IFNα was clinically applied for treating hepatitis C virus (HCV) 
infection in 1986 [8]. It has been the backbone regimen for chronic HCV therapy for decades. 
In addition, PEG-IFNα has also been clinically used for treating chronic hepatitis B virus (HBV) 
infection [9]. Type II IFNγ-1b branded under the name Actimmune was approved in 2000 by 
the Food and Drug Administration (FDA) for the treatment of chronic granulomatous disease 
and severe malignant osteopetrosis [10]. However, IFNγ failed to reduce viral load in human 
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immuno-deficiency virus (HIV) [11] or HCV [12] patients. Type III IFNs displayed comparable 
antiviral efficacy but reduced side effects when compared with IFNα for treating chronic HCV 
in phase III trial [9]. The success of IFNs as antiviral treatment in the clinic has promoted us to 
foresee their anti-norovirus potential, since no specific medication for norovirus 
gastroenteritis is currently available. 
In this study, we have characterized the antiviral activities of type I, II and III IFNs 
against norovirus using a human norovirus (HuNoV) replicon model [13]. Furthermore, we 
have identified the key anti-norovirus effectors that are coordinately activated by different 
types of IFNs. These results have revealed new insights into norovirus-host interactions and 
provided a basis for future therapeutic applications of IFNs against norovirus gastroenteritis. 
 
METHODS 
Cell lines and Reagents 
Human Huh7 hepatocellular carcinoma cells expressing a genotype 1 HuNoV replicon 
(HG23) and human embryonic kidney 293T cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Lonza Verviers, Belgium) supplemented with 10% (vol/vol) heat-
inactivated fetal calf serum (FCS) (Hyclone, Logan, UT, USA), 100 μg/mL of streptomycin, and 
100 IU/mL of penicillin. A neomycin resistant gene was engineered into ORF2, thereby 
conferring resistance of HG23 cells to gentamicin (G418; Gibco) treatment. So G418 was 
added to HG23 culture medium at 1.5 mg/mL for selection before experimentation. 
Human IFN alpha 2a recombinant protein (IFNα) (Thermo-Fisher Scientific, Cat # 
111001) and human IFN beta 1a recombinant protein (IFNβ) (Sigma-Aldrich, Cat # 14151) 
were stocked in phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin 
(BSA) at 1 × 105 units/mL based on international units. Recombinant human IFN gamma 
(IFNγ) (BioLegend, Cat # 570202), human recombinant IL29 protein (IFNλ1) (Abnova, Cat # 
P3635), IL28A (IFNλ2) (Abnova, Cat # P5985) and IL28B (IFNλ3) (Abcam, Cat # ab201872) 
were stocked in PBS containing 0.1 % BSA at 100 μg/mL. To avoid repeated freeze-thaws, the 
compounds were aliquoted and stored at -80℃. During experimentation the compounds 
were stepwise diluted to desired concentration. CP-690550 (CAS 477600-75-2; Santa Cruz 
Biotechnology) was dissolved in DMSO at 1 mg/mL. The cytotoxicity of IFNs against HG23 
cells was determined by MTT assay. 
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HuNoV antiviral assay 
HG23 cells were seeded into 48-well cell culture plates (2.5 × 104 cells per well), 
treated with IFNs alone or in combination and assayed for HuNoV RNA levels after 2 days of 
treatment. To further evaluate the long-term effects of IFNs on HuNoV, a clearance and 
rebound assay was performed (Fig. S1) [14]. During the clearance phase, HG23 cells were 
treated with IFNs for 2, 6 or 10 days. At the end of each treatment period, the levels of 
HuNoV RNA were determined. After clearance phase, IFNs were omitted. HG23 cells were 
plated into 48-well cell culture plate (2.5 × 104 per well) and cultured under the selective 
pressure of G418 (1 mg/mL). With another 5 days of culture, the cell layers were stained 
with hematoxylin and eosin, and visualized by an inverted Zeiss Axiovert 200 microscope 
equipped with Zeiss AxioCam MRm camera (LLC, Thornwood, NY, USA). 
Generation of ISG-expressing lentiviral pseudoparticles and lentiviral 
transduction 
HEK293T cells were used to generate ISG-expressing lentivirus vectors. Twenty-four 
hours before transfection, 2 × 106 cells were plated into T75 flask. Two hours before 
transfection, the cell monolayers were washed with PBS for 3 times and refreshed with FCS-
free DMEM. The plasmids expressing the pTRIP.CMV.IVSb.ISG.ires.TagRFP, HIV-1 gag-pol and 
VSV-G were combined in Opti-MEM at a ratio of 1:0.8:0.2, respectively. For each 
transfection, 150 μg PEI was added to 30 μg of total DNA to a final volume of 1 mL Opti-
MEM. After 20 min of incubation at room temperature, the mixture was added dropwise to 
the cells. Six hours later the cells were gently washed once with PBS and refreshed with 
growth medium. After 48 hours and 72 hours of transfection conditioned medium were 
pooled and filtered through a 0.45-μm pore size filter. Two hours of ultracentrifugation 
(22,000 rpm) was used to concentrate lentiviral particles. The pellet was subsequently re-
suspended and stored at -80℃ with the dilution of 1 × 107 viral RNA copies per mL. 
For transduction assay, HG23 cells were inoculated into 48-well cell culture plate (5 × 
104 cells per well) and transduced with lentiviral pseudoparticles encoding ISGs. After 2 days 
of culture the cells were collected for detection of transduction efficiency by using a 
FACSAriaTM flow cytometer (BD Bioscience) equipped with a 561-nm laser. 
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Statistics 
Data are presented as the mean ± SEM. Comparisons between groups were 
performed with Mann-Whitney test using GraphPad Prism 5.0 (GraphPad Software Inc., La 
Jolla, CA, USA). Differences were considered significant at a P value less than 0.05. 
 
RESULTS 
Type I, II and III IFNs universally and effectively inhibited HuNoV replication 
To determine the antiviral potential of different types of IFNs against HuNoV, we use 
a HuNoV replicon model to monitor HuNoV RNA replication after IFNs treatment. HG23 cells 
were treated with individual IFNs and viral replication was measured after 2 days of 
treatment by qRT-PCR. As shown in Fig. 1A and Table S1, IFNs reduced the levels of HuNoV 
RNA in a dose-dependent manner (EC50 and EC90): IFNα (59.88 and 330.7 IU/mL), IFNβ 
(156.20 and 935.0 IU/mL), IFNγ (8.26 and 11.53 ng/mL), IFNλ1 (0.79 and 1.34 ng/mL), IFNλ2 
(2.69 and 8.64 ng/mL) and IFNλ3 (1.43 and 10.97 ng/mL). The effects of IFNs on host cells 
were monitored by MTT assay. Even at the highest concentration, IFNs showed no major 
effects on the viability of HG23 cells with the exception of IFNλ1. Highest concentration of 
IFNλ1 (100 ng/mL) inhibited HG23 cell proliferation by 21 ± 3.1%. We next examined the 
kinetics of antiviral activities of IFNs over a time course ranging from 2 to 10 days. As shown 
in Fig. 1B, 10 days of treatment with IFNα (1,000 IU/mL), IFNβ (1,000 IU/mL), IFNγ (10 
ng/mL), IFNλ1 (10 ng/mL), IFNλ2 (10 ng/mL) or IFNλ3 (10 ng/mL) decreased HuNoV RNA 
levels by 99.9 ± 0.05%, 87 ± 5.3%, 80 ± 10%, 99.98 ± 0.01%, 47 ± 16% and 99.6 ± 0.01%, 
respectively.  
To further study whether IFNs could completely clear HuNoV replicons from host 
cells after long-term treatment, gel-based RT-PCR assay was performed using RNA extracted 
from 10-day treated HG23 cells. Two primer sets, including neomycin primers (Neo) and 
HuNoV GI-specific diagnostic primers (NVp36/35) were used (Table S2, Fig. S2). We observed 
that the intensity of Neo and NVp36/35 products in HG23 cells was almost undetectable 
after treatment with 1,000 IU/mL of IFNα, 100 ng/mL of IFNγ, 10 ng/mL of IFNλ1 or IFNλ3, 
whereas there was a moderate decrease in HG23 treated with 100 IU/mL of IFNα, 1,000 
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IU/mL of IFNβ or 100 ng/mL of IFNλ2 (Fig. 2A). Consistently, a rebound assay was designed 
to confirm the complete clearance of HuNoV replicons from HG23 cells after IFN treatment. 
 
Figure 1 IFNs robustly inhibited HuNoV replication at concentrations without significant 
cytotoxicity. (A) HG23 cells were treated with different concentrations of IFNs as indicated. After 2 
days of treatment the antiviral activities and cytotoxicity were measured by qRT-PCR and MTT assay, 
respectively. The concentration of type I IFNs is given as international units (IU/mL); while that of 
type II and III IFNs is given as weight per volume (ng/mL). The left y axis displayed the relative HuNoV 
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RNA levels compared with those of the untreated control; while the right y axis showed cell viability 
compared with medium group. (B) In prolonged treatment, HG23 cells were treated with different 
concentrations of IFNs for 2, 6 or 10 days. At the end of each treatment, HuNoV RNA was determined 
by qRT-PCR and normalized to human GAPDH gene. The level of remaining HuNoV RNA in IFN-
treated cells was compared to that in untreated cells at the same time point. Shown are the means ± 
SEM from three independent experiments with duplicates each (Mann-Whitney test; *, P < 0.05; **, 
P < 0.01). 
 
Figure 2 High concentrations of IFNs completely cleared HuNoV replicons. (A) Gel-based RT-PCR 
analysis was performed to determine HuNoV replicon levels in HG23 cells after long-term treatment 
with IFNs. Equal amounts of total cellular RNAs isolated from HG23 samples were first reverse 
transcribed into cDNA and then subjected to RT-PCR analysis by using neomycin primer pair (804 bp) 
and HuNoV GI-specific primer pair (470 bp). Human GAPDH primer set was used as a reference gene. 
A total of 6 samples were detected and indicated by numbers. (B) Rebound assay. IFNs-treated HG23 
cells were cultured with G418 (1 mg/mL). After 5 days of culture the plate was stained and visualized 
under light microscope. Images are representative of three independent experiments. 
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Ten-day IFN-treated HG23 cells were grown in the presence of G418 (1 mg/mL). If HG23 cells 
contained HuNoV replicons, they could survive in G418 selection and even proliferate. 
Treatment with IFNβ (1,000 IU/mL), IFNγ (10 ng/mL) or IFNλ2 (10 ng/mL) resulted in a 
relatively moderate reduction of HuNoV replicon (Fig. 2A). Therefore HG23 cells proliferated 
and formed colonies (Fig. 2B). In contrast, treatment with IFNα (1,000 IU/mL), IFNλ1 (10 
ng/mL) or IFNλ3 (10 ng/mL) resulted in a more pronounced drop in HuNoV RNA levels during 
the long-term treatment. Therefore HG23 cells lost the ability to survive (Fig. 2B), indicating 
that these IFNs were able to completely clear HuNoV replicons from the host cells.  
Profiling important ISGs identifys RTP4 and HPSE as mild antiviral ISGs 
against HuNoV 
ISGs are the ultimate antiviral effectors induced by IFNs. After IFN treatment 
hundreds of ISGs are induced. The induction of a subset of ISGs by different types of IFNs in 
HG23 cells was shown in Fig. S3. To identify the key ISGs that are potentially responsible for 
the anti-norovirus effects of IFNs, we have profiled well-known antiviral ISGs, including IRF-1, 
C6orf150 (also known as MB21D1), HPSE, RIG-I (also known as DDX58), MDA5 (also known 
as IFIH1), IFITM3, DDX60, IFI44L, IFI6, IFITM2, MAP3K14, MOV10, NAMPT (also known as 
PBEF1), OASL, RTP4, TREX1, ADAR, FAM46C, MCOLN2, IRF-2, UNC84B (also known as SUN2), 
IFITM1, LY6E and IRF-7 on HG23 cells. A bicistronic lentiviral vector co-expressing an ISG and 
a red fluorescent protein TagRFP was used to overexpress the ISG (Fig. 3A) [15]. With a pilot 
experiment, we have found that a 48-hour transduction was an optimal time point for 
transgene expression (Fig. S4A). Next, all ISGs were tested for their anti-norovirus activities 
using HG23. After 2 days of transduction expression levels of different ISGs and their relative 
anti-norovirus effectiveness were determined (Table S3, Fig. 3B). Three of these lentiviral 
vectors including IFI44L, IFITM2 and MOV10 failed to mediate high-level transduction in host 
cells, perhaps resulting from ISG-mediated toxicity and poor packaging of the vector genome. 
Most of the successfully expressed ISGs did not have major effects on HuNoV replication; 
whereas RTP4 and HPSE showed moderate antiviral activities and inhibited HuNoV 
replication by 50.5 ± 6.6 % and 42.2 ± 4.3 %, respectively (Table S3, Fig. 3B). The kinetics of 
HPSE and RTP4 expression were further determined after 24, 48 and 72 hours of 
transduction by detecting the ISGs mRNA (Fig. 3C and E) and RFP protein (Fig. S4B and C). 
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After verifying the successful overexpression of HPSE and RTP4, we found that HPSE and 
RTP4 exerted the most potent inhibition of HuNoV replication at 48 hours (Fig. 3D and F).  
 
 
 
 
 
 
IRF-1, RIG-I and MDA5 were potent anti-norovirus effectors 
Among these tested ISGs, IRF-1, RIG-I and MDA5 exerted strong anti-norovirus 
activities (Fig. 3B). We also profiled the antiviral dynamics of these three potent effectors 
after 12, 24 and 48 hours of transduction. The transduction efficiency was monitored by RFP 
expression with flow cytometry analysis (Fig. S5). IRF-1, RIG-I and MDA5 expression was 
determined by qRT-PCR and Western blotting (Fig. 4A, C and E). After 2 days of transduction, 
IRF-1, RIG-I and MDA5 inhibited HuNoV RNA replication by 95 ± 2%, 83 ± 3% and 77 ± 6%, 
respectively (Table S3, Fig. 4B, D and F). 
 
 
Figure 3 Profiling ISGs 
identifies HPSE and RTP4 as 
mild anti-norovirus effectors. 
(A) Schematic of the Gateway-
compatible, bicistronic lentiviral 
vector. (B) Dot plots of HuNoV 
replication levels in the 
presence of overexpressed ISGs 
at 48 hours (n = 4 independent 
experiments with duplicates 
each). The y axis displayed the 
relative HuNoV RNA levels 
normalized to the Fluc control. 
The black line reflected the 
population mean. (C) HG23 cells 
were transduced with HPSE 
overexpression lentiviral vector 
or Fluc vector. After 24, 48 and 
72 hours of transduction, HPSE 
mRNA levels were confirmed by 
qRT-PCR (n = 4 independent experiments with duplicates each). HPSE mRNA expression was 
increased as early as 24 hours and persisted to 72 hours. (D) HuNoV replication was determined by 
qRT-PCR and compared to that in Fluc control samples at the same points (n = 4 independent 
experiments with duplicates each). (E and F) HG23 cells were transduced with RTP4 
overexpression lentiviral vector. The overexpression efficiency and antiviral effectiveness were 
determined by qRT-PCR (n = 4 independent experiments with duplicates each). The abbreviation 
used was: hpt, hours post-transduction. Data are presented as the mean ± SEM (*, P < 0.05; **, P < 
0.01). 
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RTP4, HPSE, IRF-1, RIG-I and MDA-5 were differentially induced by different 
types of IFNs 
Although all three types of IFNs exerted anti-norovirus effects, their potency varied 
considerably (Fig. 1A and B). Therefore, we have investigated whether it was due to the 
different induction levels and patterns of these anti-norovirus effectors stimulated by 
different types of IFNs. We found that type I and III IFNs coordinately and strongly induced 
RTP4, HPSE, IRF-1, RIG-I and MDA5. On the contrary, IFNγ slightly stimulated RIG-I, MDA5 
and RTP4, but robustly and predominantly induced IRF-1 (Fig. 5A, Table S4). These results 
Figure 4 Identification of IRF-1, 
RIG-I and MDA5 that potently 
inhibited HuNV replication. (A, 
C and E) HG23 cells were 
transduced with ISG lentiviral 
vectors. After 12, 24 and 48 
hours of transduction, cells 
were collected for 
determination of ISG mRNA 
and protein expression. (i) qRT-
PCR was employed to quantify 
the expression of ISGs. The 
results were normalized to 
GAPDH and compared to Fluc 
control (n = 4 independent 
experiments with duplicates 
each). (ii) Western blotting was 
used for analysis of ISG 
proteins. IRF-1, RIG-I and 
MDA5 mRNA levels were 
significantly induced as early as 
12 hours and were sustained 
for 48 hours. (B, D and F) To 
quantify HuNoV replication, 
qRT-PCR analysis was 
performed and the results 
were compared to Fluc control 
(n = 4 independent 
experiments with duplicates 
each). The abbreviation used 
was: hpt, hours post-
transduction. Data are 
presented as the mean ± SEM 
(*, P < 0.05; **, P < 0.01; ***, P 
< 0.001). 
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were further confirmed by Western blot (Fig. 5B). These results suggested that different 
types of IFNs exerted variable anti-norovirus effects by inducing distinct subsets of ISGs. 
 
Figure 5 Type I and III IFNs coordinately induced IRF-1, RIG-I and MDA5; whereas type II IFN 
predominantly induced IRF-1 to exert their antiviral activities against HuNoV. HG23 cells were 
treated with high concentrations of IFNs. After 2 days of treatment the expression of ISG mRNA and 
protein was detected by qRT-PCR (A) (n = 3 independent experiments with duplicates each) and 
Western blotting (B), respectively. Data are presented as the mean ± SEM (*, P < 0.05; **, P < 0.01). 
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IFNγ potentiated the anti-norovirus effects of type I and III IFNs by 
cooperative induction of IRF-1, RIG-I and MDA5 
Different types of IFNs bind to their unique receptors and activate a distinct pattern 
of antiviral effectors. We therefore explored the combination of different IFNs to inhibit 
HuNoV replication. As shown in Fig. 6A, the combination of IFNγ with IFNλ1 resulted in a 
pronounced decline of HuNoV RNA replication (83 ± 1.8%) after 2 days of treatment when 
compared with IFNγ (10 ng/mL; 70 ± 4.2%) or IFNλ1 (10 ng/mL; 54 ± 12%) alone. IFNγ 
combined with IFNα were more effective and decreased HuNoV RNA level by 98.2 ± 0.2% 
when compared with IFNγ (10 ng/mL; 74 ± 4%) or IFNα (100 IU/mL; 85 ± 4%) alone. However 
this was not observed in the combination of IFNα with IFNλ1. 
Consistently, the combination of IFNs significantly enhanced the magnitude of IRF-1, 
RIG-I and MDA5 expression when compared with individual IFNs alone (Fig. 6B and C). These 
results suggested that cooperative induction of essential anti-norovirus ISGs by the 
combination of different IFNs augmented their antiviral activities. 
Pharmacological inhibition of JAK completely abolished the anti-norovirus 
effects of type I and III IFNs, but partially attenuated the effects of type II IFN 
The JAK-STAT pathway mediates the induction of ISGs and antiviral effects of IFNs. 
CP-690550 (tofacitinib), a pharmacological inhibitor of JAK has been approved by FDA for the 
treatment of rheumatoid arthritis [16]. Thus, we have investigated the role of CP-690550 on 
IFNs-induced inhibition of HuNoV replication. Of note, a high concentration (1,000 ng/mL) of 
CP-690550 alone had a mild inhibition of HuNoV replication by 30 ± 9% after 2 days of 
treatment (Fig. 7A). Combination of CP-690550 with type I or III IFNs could completely 
restore the HuNoV RNA replication. However, it partially restored HuNoV replication when 
combined with IFNγ. Consistently, CP-690550 effectively blocked ISG expression induced by 
IFNs (Fig. 7B, Fig. S6), demonstrating that CP-690550 counteracted the inhibition of HuNoV 
replication by IFNs through blocking ISG induction.  
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Figure 6 Combinatory effects of different IFNs on HuNoV replication and ISG induction. (A) HG23 
cells were treated with IFNα (0, 10 and 100 IU/mL), IFNγ (0, 1 and 10 ng/mL), IFNλ1 (0, 1 and 10 
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ng/mL) or in combination. After 2 days of treatment, the inhibitory effects of different IFN 
combinations on HuNoV replication were compared to those of the IFN-only treated samples (n = 3 
independent experiments with duplicates each). The expression of anti-norovirus ISGs at mRNA and 
protein levels were detected by qRT-PCR (B) and Western blotting (C), respectively. The qRT-PCR 
results were normalized to GAPDH and displayed as fold change relative to untreated control (n = 3 
independent experiments with duplicates each). The Western blot images were representative of 
three independent experiments. Data are presented as the mean ± SEM (*, P < 0.05; **, P < 0.01). 
 
 
Figure 7 Inhibition of JAK negated the anti-norovirus activities and the induction of ISGs by IFNs. (A) 
HG23 cells were treated with IFNs, JAK inhibitor CP-690550 (1,000 ng/mL) or in combination. After 2 
days of treatment HuNoV replication was quantified by qRT-PCR and compared to medium control (n 
= 3 independent experiments with duplicates each). ISG expression was quantified by qRT-PCR and 
compared to medium control (B; n = 3 independent experiments with duplicates each). Data are 
presented as the mean ± SEM (*, P < 0.05; **, P < 0.01). 
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DISCUSSION 
Although the burden of norovirus gastroenteritis has been well-recognized [1, 4], no 
specific anti-norovirus treatment is currently available except for supportive care and 
supplementation of fluids. Ribavirin is effective in inhibiting both HuNoV and murine 
norovirus (MNV) RNA replication in vitro [17]. However, in vivo study has revealed that only a 
subset of patients responded to ribavirin treatment [18]. Nitazoxanide, a broad-spectrum 
antimicrobial agent, has been reported to be a safe therapeutic option in managing 
norovirus gastroenteritis in immunocompetent adults [19] and transplantation patients [20, 21]. 
However, a case report has described that nitazoxanide was ineffective for treatment of 
chronic norovirus gastroenteritis in patient with X-Linked Agammaglobulinemia [22]. Thus, 
the investigation of anti-norovirus effects of IFNs in this study bears important clinical 
implications. 
The lack of suitable tissue culture or a convenient small animal model is a great 
barrier for understanding the true nature of HuNoV pathogenesis and developing specific 
antivirals. Cultivation of HuNoV has been attempted in 27 cell lines, including eight human 
gastrointestinal epithelia cells, but was unsuccessful [23]. HuNoV was recently found to infect 
B cells in vitro requiring the presence of histo-blood group antigen (HBGA)-expression 
enteric bacteria [24]. In addition, multiple HuNoV strains have been successfully cultivated in 
stem cell-derived, nontransformed human intestinal enteroids [25]. However, both B cells and 
intestinal enteroids have not been widely used yet, probably due to technical challenges and 
limitations. In our study, we employed a widely used HuNoV replicon model and revealed 
that IFNα and type III IFNs (IFNλ1 and IFNλ3) exerted rapid and potent antiviral activities 
against HuNoV replication. Moreover, IFNγ also robustly inhibited HuNoV RNA replication. 
As type III IFNs are expressed in a tissue-dependent fashion and primarily act on epithelial 
cells in vivo [26], IFNλ holds considerable therapeutic potential in restricting norovirus 
gastroenteritis. 
Though highly sensitive to IFN treatment, HuNoV is still less sensitive to IFNs when 
compared with HCV. Treatment with 1 IU/mL of IFNα resulted in robust inhibition of HCV 
replication in the Huh7-based subgenomic replicon containing a luciferase reporter and 
almost completely suppressed HCV replication after 72 h of treatment. Consistently, in the 
full-length HCV model, IFNα (10-1,000 IU/mL) dose-dependently inhibited viral replication 
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[27], which was almost 10 times more sensitive than that in our HuNoV study. The same 
phenomenon was observed in respect to type II and III IFNs on HCV and HuNoV. However, 
our study demonstrated that IFNs at clinically achievable concentrations exerted a strong 
inhibition of HuNoV replication. Meanwhile combination of IFNα with ribavirin showed 
additive effects on the inhibition of HuNoV replication [17], indicating that IFN monotherapy 
or combination therapy with ribavirin had the potential for treating norovirus gastroenteritis. 
It has been previously reported that IFNα/β and IFNγ potently inhibited HuNoV 
replication in the replicon-bearing cells in vitro [13, 17]. By transfecting stool-derived HuNoV 
RNA into mammalian cells, HuNoV RNA replication and virus particle production were 
sensitive to type I and III IFNs treatment [28]. Consistently, both type I and II IFNs inhibited 
MNV replication in permissive myeloid cells by restricting the translation of MNV proteins [29]. 
Moreover, IFNα and IFNβ were found to prevent systematic spread of MNV, only IFNλ was 
capable of curing persistent MNV infection, suggesting its great therapeutic potential of 
treating norovirus infection [30]. However, the exact mechanism of how IFNs inhibited HuNoV 
RNA replication is unclear. Upon IFN treatment, hundreds of ISGs are induced. However, 
only a subset of them have broad or targeted antiviral effects. Interestingly, a few ISGs are 
even pro-viral for particular viruses, highlighting the complexity of the highly pleiotropic IFN 
system [15]. By profiling the well-known ISGs, we found that IRF-1, RIG-I and MDA5 were 
potent anti-norovirus ISGs. Further studies have showed that type I and III IFNs robustly 
induced a large set of ISGs, especially IRF-1, RIG-I and MDA5 to inhibit HuNoV replication. In 
contrast, IFNγ strongly and predominantly induced IRF-1, which contributed to its anti-
norovirus effects. 
The exact mechanism of how IRF-1, RIG-I and MDA5 counteract HuNoV replication 
requires future research. IRF-1 has been reported to induce the expression of ISGs, similar to 
type I IFNs. IRF-1 specifically binded to the upstream regulatory region of the IFNβ and 
activated IFNβ gene expression in virus-infected fibroblasts [31]. IRF-1 also effectively 
counteracted hepatitis E virus (HEV) replication through the activation of the JAK-STAT 
pathway and the subsequent induction of antiviral ISGs, but independent of IFN production 
[32]. Similarly, it was classically recognized that RIG-I exerted its antiviral activity by inducing 
IFN production upon sensing invading virus infection. However, in HEV study RIG-I 
stimulated the cellular innate immunity against HEV partially through the JAK-STAT pathway, 
regardless of IFN production [33]. Like RIG-I, MDA5 functioned as a sensor to detect many 
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viral infections and was critical for type I IFN induction during virus infections [34]. Notably, 
MDA5 recognized MNV strain MNV-1 infection in vivo and stimulated the production of type 
I IFNs and other cytokines [35]. To further address this issue in our model, we have evaluated 
the effects of these three ISGs on the expression of other ISGs including two known anti-
norovirus ISGs PKR [29] and ISG15 [36]. Overexpression of any of the three ISGs stimulated the 
expression of other ISGs in our HuNoV model (Fig. S7). Nevertheless, the exact antiviral 
mechanism of these ISGs remains to be further investigated. 
Because different types of IFNs activate distinct patterns of ISGs, we hypothesized 
that they may function cooperatively to inhibit HuNV replication. Indeed, we found that IFNγ 
exerted cooperative anti-norovirus activity when combined with type I or III IFNs. Previous 
study has shown that combination of IL29 with IFNα or IFNγ synergistically inhibited HCV 
replication. The combination treatment mechanistically resulted in increased activation of 
the ISRE promoter elements to further enhance ISG expression [37]. Similarly, we have 
demonstrated that the combination of IFNγ with IFNα or IFNλ1 cooperatively induced the 
expression of IRF-1, RIG-I and MDA5, contributing to their augmented anti-norovirus activity. 
These results indicate a cooperation of different types of IFNs in combating norovirus 
replication, but also provide rationale for potential combination therapy.  
High responsiveness of HuNoV to IFN treatment potentiated the application of 
exogenous IFNs as immunotherapy against norovirus gastroenteritis. Conversely, IFN 
antagonism has been employed by some viruses, including zika virus [38] and HEV [39] to 
escape the immune control. By further investigating the JAK-STAT pathway and mRNA levels 
of different ISGs in the presence or absence of HuNoV after IFNα treatment, we found that 
HuNoV showed no major effect on counteracting IFN response (Supplementary Materials 
and Results), which further highlighted the vital role of IFNs on combating norovirus 
infection. 
 
CONCLUSION 
In summary, we have demonstrated the anti-norovirus effects of different types of 
IFNs and identified the key antiviral effectors including IRF-1, RIG-I and MDA5. Furthermore, 
HuNoV displayed no major effect on IFN signaling pathway. Given the fact that both type I 
and II IFNs have been widely used in the clinic and type III IFNs are at the stage of clinical 
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development, our results bear important implications for the future application of IFNs for 
treating norovirus gastroenteritis. 
 
ACKNOWLEDGEMENT 
We gratefully acknowledge Mary K. Estes (Baylor College of Medicine, Houston) for 
providing the pHuNoVU201F and pHuNoVU201F-based constructs. We also thank Charles M. 
Rice (The Rockefeller University, New York) for providing ISG lentiviral vectors. This work was 
supported by Dutch Digestive Foundation (MLDS) for a career development grant (No. CDG 
1304), the Daniel den Hoed Foundation for a Centennial Award fellowship (to Q. Pan), the 
China Scholarship Council for funding PhD fellowship to W. Dang (201406180072), L. Xu 
(201306300027), Y. Yin (201307720045), W. Wang (201303250056) and S. Chen 
(201606760056), and Indonesia Endowment Fund for Education (LPDP) for funding PhD 
fellowship to Mohamad S. Hakim. 
 
AUTHOR CONTRIBUTIONS 
WD, LX, YY, SC and WW performed the experiments; MH and KO contributed to the 
scientific discussion and facilities; WD, MP and QP conceived the project and wrote the 
manuscript. 
  
Chapter 4 
97 | P a g e  
 
REFERENCE 
1. Bartsch SM, Lopman BA, Ozawa S, Hall AJ, Lee BY. 2016. Global Economic Burden of 
Norovirus Gastroenteritis. PLoS One 11:e0151219. 
2. Ye X, Van JN, Munoz FM, Revell PA, Kozinetz CA, Krance RA, Atmar RL, Estes MK, Koo 
HL. 2015. Noroviruses as a Cause of Diarrhea in Immunocompromised Pediatric Hematopoietic Stem 
Cell and Solid Organ Transplant Recipients. Am J Transplant 15:1874-1881. 
3. Bok K, Green KY. 2012. Norovirus gastroenteritis in immunocompromised patients. N 
Engl J Med 367:2126-2132. 
4. Angarone MP, Sheahan A, Kamboj M. 2016. Norovirus in Transplantation. Curr Infect 
Dis Rep 18:17. 
5. Sen GC. 2001. Viruses and interferons. Annu Rev Microbiol 55:255-281. 
6. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen 
F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR. 2008. An important role for type III 
interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180:2474-2485. 
7. de Weerd NA, Nguyen T. 2012. The interferons and their receptors--distribution and 
regulation. Immunol Cell Biol 90:483-491. 
8. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, 
Park Y, Jones EA. 1986. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha 
interferon. A preliminary report. N Engl J Med 315:1575-1578. 
9. Lin FC, Young HA. 2014. Interferons: Success in anti-viral immunotherapy. Cytokine 
Growth Factor Rev 25:369-376. 
10. Razaghi A, Owens L, Heimann K. 2016. Review of the recombinant human interferon 
gamma as an immunotherapeutic: Impacts of production platforms and glycosylation. J Biotechnol 
240:48-60. 
11. Roff SR, Noon-Song EN, Yamamoto JK. 2014. The Significance of Interferon-gamma in 
HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol 4:498. 
12. Couzigou P, Perusat S, Bourliere M, Trimoulet P, Poynard T, Leroy V, Marcellin P, 
Foucher J, Bronowicki JP, Chene G, Group AHGT. 2013. Interferon-gamma with peginterferon alpha-
2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI). J 
Gastroenterol Hepatol 28:329-334. 
13. Chang KO, Sosnovtsev SV, Belliot G, King AD, Green KY. 2006. Stable expression of a 
Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353:463-473. 
14. Dang W, Yin Y, Peppelenbosch MP, Pan Q. 2017. Opposing Effects of Nitazoxanide on 
Murine and Human Norovirus. J Infect Dis 216:780-782. 
15. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A 
diverse range of gene products are effectors of the type I interferon antiviral response. Nature 
472:481-485. 
16. Boor PPC, de Ruiter PE, Asmawidjaja PS, Lubberts E, van der Laan LJW, Kwekkeboom 
J. 2016. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells 
and inhibits arthrogenic and antiviral effects of interferon alfa. Translational Research. 
17. Chang KO, George DW. 2007. Interferons and ribavirin effectively inhibit Norwalk 
virus replication in replicon-bearing cells. J Virol 81:12111-12118. 
18. Woodward JM, Gkrania-Klotsas E, Cordero-Ng AY, Aravinthan A, Bandoh BN, Liu H, 
Davies S, Zhang H, Stevenson P, Curran MD, Kumararatne D. 2015. The role of chronic norovirus 
infection in the enteropathy associated with common variable immunodeficiency. Am J 
Gastroenterol 110:320-327. 
19. Rossignol JF, El-Gohary YM. 2006. Nitazoxanide in the treatment of viral 
gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 
24:1423-1430. 
Chapter 4 
98 | P a g e  
 
20. Siddiq DM, Koo HL, Adachi JA, Viola GM. 2011. Norovirus gastroenteritis successfully 
treated with nitazoxanide. J Infect 63:394-397. 
21. Rossignol JF. 2014. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. 
Antiviral Res 110:94-103. 
22. Kempf B, Edgar JD, Mc Caughey C, Devlin LA. 2017. Nitazoxanide Is an Ineffective 
Treatment of Chronic Norovirus in Patients With X-Linked Agammaglobulinemia and May Yield False-
Negative Polymerase Chain Reaction Findings in Stool Specimens. J Infect Dis 215:486-487. 
23. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. 2004. Laboratory 
efforts to cultivate noroviruses. J Gen Virol 85:79-87. 
24. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, Gonzalez-Hernandez 
MB, Iovine NM, Wobus CE, Vinje J, Tibbetts SA, Wallet SM, Karst SM. 2014. Enteric bacteria promote 
human and mouse norovirus infection of B cells. Science 346:755-759. 
25. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill 
FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin D, Graham DY, Ramani S, Atmar RL, Estes MK. 
2016. Replication of human noroviruses in stem cell-derived human enteroids. Science 353:1387-
1393. 
26. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-lambda) is 
expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 
4:e1000017. 
27. Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, de Ruiter PE, van der Laan LJ, 
Metselaar HJ, Kamar N, Peppelenbosch MP, Pan Q. 2016. Disparity of basal and therapeutically 
activated interferon signalling in constraining hepatitis E virus infection. J Viral Hepat 23:294-304. 
28. Qu L, Murakami K, Broughman JR, Lay MK, Guix S, Tenge VR, Atmar RL, Estes MK. 
2016. Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response. 
J Virol 90:8906-8923. 
29. Changotra H, Jia Y, Moore TN, Liu G, Kahan SM, Sosnovtsev SV, Karst SM. 2009. Type I 
and type II interferons inhibit the translation of murine norovirus proteins. J Virol 83:5683-5692. 
30. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, Diamond 
MS, Virgin HW. 2015. Interferon-lambda cures persistent murine norovirus infection in the absence 
of adaptive immunity. Science 347:269-273. 
31. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi 
T. 1988. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to 
IFN-beta gene regulatory elements. Cell 54:903-913. 
32. Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, Sprengers D, Metselaar HJ, 
Peppelenbosch MP, Pan Q. 2016. IFN regulatory factor 1 restricts hepatitis E virus replication by 
activating STAT1 to induce antiviral IFN-stimulated genes. FASEB J 30:3352-3367. 
33. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, de Man RA, van der Laan LJW, Huang F, 
Kamar N, Peppelenbosch MP, Pan Q. 2017. RIG-I is a key antiviral interferon-stimulated gene against 
hepatitis E virus regardless of interferon production. Hepatology 65:1823-1839. 
34. Siren J, Imaizumi T, Sarkar D, Pietila T, Noah DL, Lin R, Hiscott J, Krug RM, Fisher PB, 
Julkunen I, Matikainen S. 2006. Retinoic acid inducible gene-I and mda-5 are involved in influenza A 
virus-induced expression of antiviral cytokines. Microbes Infect 8:2013-2020. 
35. McCartney SA, Thackray LB, Gitlin L, Gilfillan S, Virgin HW, Colonna M. 2008. MDA-5 
recognition of a murine norovirus. PLoS Pathog 4:e1000108. 
36. Rodriguez MR, Monte K, Thackray LB, Lenschow DJ. 2014. ISG15 functions as an 
interferon-mediated antiviral effector early in the murine norovirus life cycle. J Virol 88:9277-9286. 
37. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. 2008. 
Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit 
hepatitis C virus replication. J Biol Chem 283:30079-30089. 
38. Grant A, Ponia SS, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, Schwarz 
MC, Sanchez-Seco MP, Evans MJ, Best SM, Garcia-Sastre A. 2016. Zika Virus Targets Human STAT2 to 
Inhibit Type I Interferon Signaling. Cell Host Microbe 19:882-890. 
Chapter 4 
99 | P a g e  
 
39. Todt D, Francois C, Anggakusuma, Behrendt P, Engelmann M, Knegendorf L, Vieyres 
G, Wedemeyer H, Hartmann R, Pietschmann T, Duverlie G, Steinmann E. 2016. Antiviral Activities of 
Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrob Agents 
Chemother 60:2132-2139. 
 
  
Chapter 4 
100 | P a g e  
 
Supplementary Information 
SUPPLEMENTARY METHODS 
Antibody 
STAT1 (Rabbit mAb, #9172), phosphor-STAT1(Tyr701) (58D6, Rabbit mAb, #9167), IRF-
1 (D5E4, Rabbit mAb, #8478), MDA5 (D74E4, Rabbit mAb, #5321) antibodies were obtained 
from Cell Signaling Technology (Danvers, MA, USA). RIG-I (H-300, Rabbit polyclonal, #sc-
98911), STAT2 (C-20, Rabbit polyclonal, sc-476) and β-actin (C-4, Mouse mAb, #sc-47778) 
were purchased from Santa Biotechnology (Santa Cruz, CA, USA). Secondary antibodies 
IRDye® 800CW-conjugated goat anti-rabbit and goat anti-mouse IgGs (1:10,000 dilution; Li-
Cor Bioscience, Lincoln, USA) were used, as appropriate.  
Clearance of HuNoV replicons from HG23 cells 
HG23 cells were treated with 0.5 µg/mL of mycophenolic acid (MPA) and harvested 
after 2 days of treatment. Cells were subsequently re-challenged with same concentrations 
of MPA for 4 days. Another round of 4-day treatment was applied with the same 
concentration. After 10 days of treatment the resulting cells were designated HG23DEPL and 
cultured in the absence of G418. 
Colony formation assay 
To detect whether HuNoV replicons were completely cleared from HG23DEPL cells, 
HG23DEPL or HG23 cells were plated into 6-well cell culture plate (1,000 cells per plate) and 
cultured in the medium containing G418 (1 mg/mL). On day 3 and 6, the wells were replaced 
by fresh medium containing the same concentration of G418. After 9 days of treatment, 
colonies were stained with hematoxylin and eosin and visualized.  
Transfection of HuNoV plasmids  
To examine the effects of HuNoV on IFN signaling, a plasmid construct containing the 
full-length HuNoV genome (HuNoVU201F; GII.3 U201 strain) and a construct harboring the 
same genome coupled with a GFP reporter gene were used [1]. Briefly, 293T cells were 
seeded into 6-well cell culture plates at a density of 2 × 105 cells per well. After overnight 
culture, 200 ng of pEGFP-C1 or 2000 ng of HuNoVU201F-ORF1-IRES-GFP or a mixture of HuNoVU201F 
(2000ng) and pEGFP-C1 (200ng) plasmids (a ratio of 10:1) were transfected with FuGene® 
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HD transfection reagent in a total volume of 1 mL Opti-MEM per well. After 6 hours of 
transfection, fresh DMEM medium containing 10% FCS was added into each well. 
Transfected cells were harvested after 2 days of culture and processed for cell sorting using 
FACSAriaTM flow cytometer (BD Bioscience) equipped with a 640-nm laser. GFP-positive cells 
were treated with 1,000 IU/mL of IFNα and analyzed for type I IFN signaling after 24 hours of 
treatment. 
Western blot 
Cell samples were lysed and loaded onto a 10 to 15% sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE). After electrophoresis at 120 V for 100 mins, the proteins 
were electrotransferred to polyvinylidene difluoride (PVDF) membrane (Invitrogen) for 1.5 h 
with an electric current of 250 mA. The membrane was probed with primary antibody plus 
secondary antibody and detected with Odyssey 3.0 Infrared Imaging System (LI-COR 
Biosciences). β-actin was served as standardization of sample loading. 
Reverse transcription PCR (RT-PCR) 
Two primer sets were designed to detect HuNoV replicons in HG23 cells. The primer 
pair designated Neo-F and Neo-R is located in the neomycin resistant gene [2] and is 
predicted to produce a product of 804 bases. Primers NVp36/35 are located in a highly 
conserved RNA polymerase region of HuNoV GI genome and are predicted to give a product 
of 470 bases [3]. For HuNoV reverse genetics system, a primer pair designated NV-4661 [4] 
and NVp110 [5] were used for specific detection of HuNoV GII genome. For RT, cDNA was 
reverse transcribed from extracted cellular RNA by using TakaRa PrimeScriptTM RT reagent 
kit, according to the manufacturer’s instructions. Briefly, 8 µL of total cellular RNA (500 ng) 
was mixed with 2 µL of 5× PrimeScript Buffer on ice. The mixture was incubated at 37℃ for 
15 mins; this was followed by heat inactivation at 85℃ for 5 s. The mixture was 20 times 
diluted and stored at -20℃ for further use. PCR was performed using Q5® High-Fidelity DNA 
polymerase kit (New England Biolabs Inc.) in a 25 µL reaction mixture containing 5 µL of 5× 
Q5 Reaction Buffer, 0.5 µL of a 10 mM dNTPs, 1.25 µL of 10 µM Forward Primer, 1.25 µL of 
10 µM Reverse Primer, 5 µL of template cDNA and 0.25 µL of Q5 High-Fidelity DNA 
Polymerase. Amplification was carried out with initial denaturation at 98℃ [30 s]; 30 cycles 
of 98℃ [10 s], 50-70℃ [30 s], and 72 ℃ [30 s]; and an additional extension step of 72℃ for 2 
min. The GAPDH primer set [6] was used as a reference gene and was amplified in 25 cycles. 
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The products were loaded onto 1 to 2% agarose gel containing SERVA DNA Stain G, and DNA 
electrophoresis at 100 V for 45 min was performed. An 100 base pair (bp) DNA ladder 
(Promega) was also electrophoresed on each gel. Bands were visualized and recorded with 
the Gel.Doc 2000 system (Bio-Rad). All primer combinations were listed in Table S2. 
Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated with a Machery-NucleoSpin RNA II Kit (Bioke, Leiden, The 
Netherlands) and measured with a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was 
reverse transcribed from 500 ng RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The 
cDNA of a targeted gene transcript was amplified for 50 cycles and quantified with a 
SYBRGreen-based real-time PCR (Applied Biosystems), according to the manufacturer’s 
instructions. All the PCR reactions were performed in duplicates and amplification specificity 
was confirmed by melting-curve analysis. Human GAPDH was used as a reference gene. The 
relative expression of targeted gene was calculated as 2-∆∆CT, where ∆∆CT = ∆CTsample - 
∆CTcontrol (∆CT = CT [targeted gene] - CT[GAPDH]). All primer combinations were listed in Table S5. 
MTT assay 
The cytotoxicity of IFNs on host cells was determined by a 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. In brief, cells were seeded into 
96-well cell culture plates containing 0.5% DMSO (control) or increasing concentrations of 
IFNs. After 2 days of treatment, 10 mM MTT (Sigma, Zwijndrecht, The Netherlands) was 
added. With another 3 hours of incubation, the medium was removed and 100 μL of DMSO 
was added to each well. The plate was incubated at 37℃ for 50 min. The absorbance at 490 
nm was recorded on the microplate absorbance reader (Bio-Rad, CA, USA). 
SUPPLEMENTARY RESULTS 
HuNV replication did not interfere with IFNα signaling 
These in vitro data support the potential therapeutic use of IFNs against norovirus 
infection. Conversely, it is important to evaluate whether norovirus interferes with the 
antiviral IFNs response. Previously, we have demonstrated that mycophenolic acid (MPA) 
exerted potent anti-norovirus activity and completely cleared HuNoV replicons from HG23 
cells [7]. Thus, we depleted HuNoV replicons from HG23 cells by MPA and compared the IFNs 
response in HG23 and replicon-depleting HG23 cells (HG23DEPL) after IFNα treatment. We 
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first confirmed the complete depletion of HuNoV replicons from HG23 cells by using RT-PCR 
and colony formation assay. RT-PCR yielded strong bands using neomycin primers and 
NVp36/35 primers in HG23 cells. In the contrast, no bands were observed in HG23DEPL cells 
(Fig. S8A). After 9 days of culture with G418, HG23 cells formed colonies, whereas HG23DEPL 
cells failed to grow any colonies (Fig. S8B), consistently demonstrating the complete 
clearance of HuNoV replicons from HG23 cells. To address the question about the effects of 
HuNoV on IFNs signaling, HG23 and HG23DEPL cells were treated with 1,000 IU/mL of IFNα. At 
the indicated time points induction of JAK-STAT signaling pathway was detected by Western 
blot. As shown in Fig. S8C, phosphorylation of STAT1 was quickly induced, even after 30 mins 
of IFNα treatment in both cells. IFNα stimulated STAT1 phosphorylation in a time-dependent 
manner. There was no significant difference in both cells, indicating that HuNoV protein 
expression and RNA replication had no major effect on JAK-STAT pathway. Furthermore, 
there was no major effect on levels of expression for IFNα-triggered ISGs (Fig. S8D; Fig. S9). 
A plasmid-based HuNoV reverse genetics system (pHuNoVU201F) has been recently 
developed (Fig. S10A). It expressed complete genome of the HuNoV GII.3 U201 strain and 
produced viral particles when transfected into cells [1]. We transfected 293T cells with 
pHuNoVU201F. To monitor transfection efficiency, a plasmid with a GFP expression vector 
pGFP-C1 was co-transfected with pHuNoVU201F to act as a reporter. Cell sorting was 
performed after 2 days of transfection and GFP-positive cells were collected (Fig. S10B). As 
the amount of pGFP-C1 was much higher than pHuNoVU201F (a ratio of 10:1), this indicated 
high transfection efficiency of pHuNoVU201F in GFP-positive cells. In addition, pHuNoVU201F-
ORF1-IRES-GFP was used  as a polymerase KO construct, because it contained a stop codon after 
the GFP. Vector pGFP-C1 alone was used as control. After cell sorting, the expression of 
plasmids was detected. Because of the lack of HuNoV commercial antibodies, we detected 
HuNoV RNA expression using qRT-PCR (Fig. S11A) and RT-PCR (Fig. S11B). qRT-PCR data 
showed the abundant expression of HuNoV RNA in pHuNoVU201F and pHuNoVU201F-ORF1-IRES-GFP 
transfected cells by using self-designed HuNoV GII.3 U201-specific primers and GII-specific 
diagnostic primers. In RT-PCR experiment, we used a GII-specific diagnostic primer set. The 
specificity of the primer set was illustrated in Fig. S12. RT-PCR results showed the same 
results, indicating the successful expression of HuNoV reverse genetics system in 293T cells. 
The cells were subsequently treated with IFNα (1,000 IU/mL) for another 24 hours. HuNoV 
proteins and RNA expression in 293T cells had no major effects on the total levels of STAT1 
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and STAT2 proteins as well as phosphorylated STAT1 protein (Fig. S11C), and did not inhibit 
the induction of ISGs (Fig. S11D). In conclusion, HuNoV proteins and RNA expression did not 
interfere with the IFN signaling pathway. 
 
SUPPLEMENTARY TABLES AND FIGURES 
Table S1 In vitro anti-norovirus activities of IFNs after 2 days of treatment. 
 EC50 EC90 
 IFNα [IU/mL] 59.88 330.70 
IFNβ [IU/mL] 156.20 935.00 
IFNγ [ng/mL] 8.26 11.53 
IFNλ1 [ng/mL] 0.79 1.34 
IFNλ2 [ng/mL] 2.69 8.64 
IFNλ3 [ng/mL] 1.43 10.97 
 
Table S2 Primers used by RT-PCR. 
Target Primer Sense Sequence (5’-3’)
a
 Location Annealing 
HuNoV 
HuNoVGI-
specific 
NVp36 + ATAAAAGTTGGCATGAACA 
4487-
4505
b
 
57℃ 
NVp35 - CTTGTTGGTTTGAGGCCATAT 
4936-
4956
b
 
HuNoV GII-
specific 
NV-4611 + CWGCAGCMCTDGAAATCATGG 
4611-
4631
c
 57℃ 
NVp110 - ACDATYTCATCATCACCATA 
4865-
4884
b
 
Neomycin 
phosphotrans
ferase 
Neo-F + ATGGGATCGGCCATTGAAC  
59℃ 
Neo-R - TCAGAAGAACTCGTCAAG  
GAPDH 
GAPDH-F + TCGTGGAAGGACTCATGACC  
68℃ 
GAPDH-R - TCCACCACCCTGTTGCT  
a
Y = C + T; M = A + C; D = A+T+G; W = A+T 
b
Nucleotide positions are the positions in Hu/NLV/Norwalk/68/US (accession no. M87661). 
c
Nucleotide positions are the positions in Hu/NLV/Lordsdale/93/UK (accession no. X86557). 
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Table S3 Levels of expression for transfected ISGs and their relative anti-norovirus effectiveness. 
Data are presented as the means ± SEM (n = 8 replicates). *P < 0.05, **P < 0.01, ***P < 0.001. 
Gene Gene expression P value 
HuNV replication 
(relative) 
P value 
IRF-1 375,60 ± 91,63 ** 0,05 ± 0.01 *** 
C6orf150 128224,36 ± 12444.49 ** 0,68 ± 0.09 *** 
HPSE 269,30 ± 16,49 ** 0,58 ± 0.06 *** 
RIG-I 1389.00 ± 160.90 ** 0,17 ± 0.02 *** 
MDA5 2389.00 ± 705,00 ** 0,23 ± 0.06 *** 
IFITM3 508,44 ± 5,57 ** 1,04 ± 0.19 NS 
DDX60 83,52 ± 15,91 ** 0,92 ± 0.16 * 
IRF-2 504,50 ± 110,60 ** 1.05 ± 0.15 NS 
RTP4 11382.00 ± 1903.00 ** 0,49 ± 0.07 *** 
UNC84B (SUN2) 8,51 ± 1,10 ** 0,60 ± 0.05 *** 
FAM46C 12,12 ± 1,73 ** 1,04 ± 0.17 NS 
MCOLN2 45,88 ± 8.72 ** 0,82 ± 0.11 NS 
IFI44L 1,10 ± 0,11 NS 0,66 ± 0.06 ** 
IFI6 506,33 ± 104.88 *** 0,87 ± 0.08 NS 
IFITM2 1,29 ± 0,10 NS 0,79 ± 0.16 NS 
MAP3K14 588,44 ± 45.66 *** 0,70 ± 0.13 NS 
MOV10 1,05 ± 0,41 NS 1.02 ± 0.38 NS 
NAMPT (PBEF1) 6,30 ± 1.22 *** 0,73 ± 0.10 * 
OASL 94,27 ± 17,45 *** 1,07 ± 0.12 NS 
IFITM1 118,59 ± 18.11 *** 0,68 ± 0.06 ** 
TREX1 44,38 ± 9,26 *** 0,89 ± 0.23 NS 
ADAR 9,20 ± 2.43 *** 0,80 ± 0.15 * 
LY6E 11306.00 ± 1001.00 *** 0,72 ± 0.04 *** 
IRF-7 1,72 ± 0,20 * 0,72 ± 0.09 ** 
 
Table S4 Levels of expression for IRF-1, RIG-I and MDA5 following IFN treatment. HG23 cells were 
treated with high concentration of IFNs. After 2 days of treatment, the ISG mRNA expression was 
detected by qRT-PCR (n = 3 independent experiments with duplicates each). Data are presented as 
the means ± SEM. 
Gene 
IFNα 
1,000 IU/mL 
IFNβ 
1,000 IU/mL 
IFNγ 
100 ng/mL 
IFNλ1 
100 ng/mL 
IFNλ3 
100 ng/mL 
IRF-1 5.06 ± 0.75 4.48 ± 1.65 20.40 ± 1.54 11.70 ± 0.85 10.47 ± 1.47 
RIG-I 18.45 ± 2.04 11.54 ± 2.32 4.62 ± 0.63 30.67 ± 2.63 22.64 ± 3.15 
MDA5 180.70 ± 70.50 29.38 ± 10.97 36.14 ± 8.10 676.00 ± 218.40 603.50 ± 123.30 
RTP4 65.56 ± 15.23 29.50 ± 3.24 5.84 ± 0.40 564.80 ± 112.10 588.70 ± 78.09 
HPSE 2.98 ± 0.63 3.91 ± 0.32 1.62 ± 0.07 6.33 ± 1.72 6.58 ± 2.01 
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Table S5 Primers used by qRT-PCR. 
Name Sequences
a
 
HuNoV GI-specific primer 
COG1F (+): 5’- CGYTGGATGCGNTTYCATGA-3’ 
COG1R (-): 5’- CTTAGACGCATCATCATTYAC-3’ 
HuNoV GII-specific primer 
QNIF2d (+):5’-ATGTTCAGRTGGATGAGRTTCTCWGA-3’ 
COG2R (-):5’-TCGACGCCATCTTCATTCACA-3’ 
HuNoV GII.3 U201-specific primer 
F: 5’- ACCACCTGCTGCAATAAGTC-3’ 
R: 5’- GTCAAAGGCTGTGTATGGGA -3’ 
Neomycin phosphotransferase 
F: 5’-CCGGCTACCTGCCCATTC-3’ 
R: 5’-CCAGATCATCCTGATCGACAA G-3’ 
CXCL10 
F: 5’- GGTGAGAAGAGATGTCTGAATCC-3’ 
R: 5’- GTCCATCCTTGGAAGCACTGCA-3’ 
DDX60 
F: 5’-GGTGTTTTCACCAGGGAGTATCG-3’ 
R: 5’-CCAGTTTTGGCGATGAGGAGCA-3’ 
GAPDH 
F: 5’-TGTCCCCACCCCCAATGTATC-3’ 
R: 5’-CTCCGATGCCTGCTTCACTACCTT-3’ 
HPSE 
F: 5’-GAATGGACGGACTGCTACCAAG-3’ 
R: 5’-CTCCTAACCAGACCTTCTTGCC-3’ 
IFIT1 
F: 5’-GCCTTGCTGAAGTGTGGAGGAA-3’ 
R: 5’-ATCCAGGCGATAGGCAGAGATC-3’ 
IFIT2 
F: 5’-GGAGCAGATTCTGAGGCTTTGC-3’ 
R: 5’-GGATGAGGCTTCCAGACTCCAA-3’ 
IFIT3 
F: 5’- CCTGGAATGCTTACGGCAAGCT-3’ 
R: 5’- GAGCATCTGAGAGTCTGCCCAA-3’ 
IFITM1 
F: 5’-GGCTTCATAGCATTCGCCTACTC-3’ 
R: 5’-AGATGTTCAGGCACTTGGCGGT-3’ 
IFITM3 
F: 5’-CTGGGCTTCATAGCATTCGCCT-3’ 
R: 5’-AGATGTTCAGGCACTTGGCGGT-3’ 
ISG15 
F: 5’-CTCTGAGCATCCTGGTGAGGAA-3’ 
R: 5’-AAGGTCAGCCAGAACAGGTCGT-3’ 
IRF-1 
F: 5’-GAGGAGGTGAAAGACCAGAGCA-3’ 
R: 5’-TAGCATCTCGGCTGGACTTCGA-3’ 
IFI44L 
F: 5’-TGCACTGAGGCAGATGCTGCG-3’ 
R: 5’-TCATTGCGGCACACCAGTACAG-3’ 
IFI6 
F: 5’-TGATGAGCTGGTCTGCGATCCT-3’ 
R: 5’-GTAGCCCATCAGGGCACCAATA-3’ 
MDA5 (IFIH1) 
F: 5’-GCTGAAGTAGGAGTCAAAGCCC-3’ 
R: 5’-CCACTGTGGTAGCGATAAGCAG-3’ 
MX1 
F: 5’- GGCTGTTTACCAGACTCCGACA-3’ 
R: 5’- CACAAAGCCTGGCAGCTCTCTA-3’ 
OAS3 
F: 5’-CCTGATTCTGCTGGTGAAGCAC-3’ 
R: 5’-TCCCAGGCAAAGATGGTGAGGA-3’ 
PKR 
F: 5’-GAAGTGGACCTCTACGCTTTGG-3’ 
R: 5’-TGATGCCATCCCGTAGGTCTGT-3’ 
RIG-I 
F: 5’-CACCTCAGTTGCTGATGAAGGC-3’ 
R: 5’-GTCAGAAGGAAGCACTTGCTACC-3’ 
RTP4 
F: 5’-GACGCTGAAGTTGGATGGCAAC-3’ 
R: 5’-GTGGCACAGAATCTGCACTTGG-3’ 
a
Y = C + T; R = A + G; W = A+T; N = any 
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Figure S1 The design of long duration experiment. HG23 cells were seeded into 48-well cell 
culture plates (2.5 × 104 cells per well) and treated with IFNs. After 2 days of treatment, cells were 
trypsinized, 2.5 × 104 cells were subcultured into 48-well cell culture plates containing the same 
concentration of IFNs for another 4 days, and 2.5 × 104 cells were collected for qRT-PCR analysis. 
After 6 days of treatment, the same treatment process was performed for the second time. After 10 
days of treatment, 2.5 × 104 cells were subcultured into a 48-well cell culture plate with fresh 
medium containing G418 (1 mg/mL). With another 5 days of culture, the cell layers were stained with 
hematoxylin and eosin and visualized with an inverted light microscopy. 
 
 
Figure S2 Specificity of primer sets used to detect the HuNoV genome in HG23 cells. (A) 
Schematic diagram of the HuNoV subgenomic replicon construct designated pNV-neo. A full-length 
cDNA clone of a HuNoV GI genome was previously engineered into the pSPORT1 plasmid. Meanwhile, 
the neomycin resistance gene was engineered into ORF2 as a selection marker. RNA transcripts were 
synthesized in vitro and were transfected into human Huh7 cells to generate a stably expressed 
Chapter 4 
108 | P a g e  
 
HuNoV replicon model, designated HG23. The location of the two primer sets including HuNoV GI-
specific primers (NVp35 and NVp36) and neomycin primers (Neo-F and Neo-R) were indicated. (B) 
The specificity of primers Neo-F and Neo-R was verified by using purified plasmid pNV-neo as initial 
template. After 30 cycles of amplification a single band at 804 bp was indicative of the specificity of 
the primer pair. (C) Primer pair NVp35 and NVp36 produced a specific and dominant band of 470 bp 
and showed robust specificity. 
 
 
Figure S3 The mRNA expression of 29 ISG genes was assessed by qRT-PCR, normalized to 
GAPDH and shown as fold-change expression compared to the control sample. HG23 cells were 
treated with high concentration of IFNs (1,000 IU/mL IFNα, 1,000 IU/mL IFNβ, 100 ng/mL IFNγ, 100 
ng/mL IFNλ1 and 100 ng/mL IFNλ3) or medium. After 2 days of treatment, the gene expression (nfold) 
was shown as a color scale. 
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Figure S4 Analysis of RFP expression by flow cytometry showed the successful deliver and 
expression of ISG genes in HG23 cells. (A) HG23 cells were transduced with a control vector that 
expressed a Photinus pyralis luciferase (Fluc) gene. At indicated time points of 12, 24 and 48 hours, 
flow cytometry was performed to detect the expression of RFP. The x axis represented fluorescence 
intensity of RFP, while y axis indicated the percentage of the total cell population. (B) HG23 cells 
were transduced with HPSE overexpression lentiviral vector. After 72 hours of transduction, the 
expression level of HPSE was confirmed by detecting RFP. (C) Flow cytometry data demonstrated the 
successful expression of RTP4 after 72 hours of transduction. 
 
 
Figure S5 Flow cytometry data demonstrated the successful overexpression of IRF-1, RIG-I 
and MDA5 in HG23 cells. HG23 cells were transduced with lentiviral vectors IRF-1 (A), RIG-I (B) or 
MDA5 (C). After 12, 24 and 48 hours of transduction, the percentage of RFP-positive cells was 
detected by flow cytometry.  
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Figure S6 Besides IRF-1, RIG-I and MDA5, CP-690550 blocked the induction of other ISGs by 
IFNs. (A) HG23 cells were treated with IFNs, JAK inhibitor CP-690550 (1,000 ng/mL) or in combination. 
After 2 days of treatment, the expression levels for ISGs were quantified by qRT-PCR and compared 
to medium control (n = 3 independent experiments with duplicates each). Data are presented as the 
mean ± SEM (*, P < 0.05; **, P < 0.01). 
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Figure S7 Overexpression of IRF-1, RIG-I and MDA5 activated the expression of other ISGs. 
(A, C and E) qRT-PCR analysis of IRF-1, RIG-I and MDA5 expression in HG23 cells transduced with ISG 
OE vector or Fluc vector or treated with IFNα (1,000 IU/mL) for 48 hours (n = 3 independent 
experiments with duplicates each). (B, D and F) The qRT-PCR analysis of ISG RNA levels in HG23 cells 
transduced with ISG OE vector or Fluc vector or treated with IFNα (1,000 IU/mL) for 48 hours (n = 3 
independent experiments with duplicates each). Data are presented as the mean ± SEM. *P < 0.05, 
**P < 0.05, ***P < 0.05. 
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Figure S8 HuNoV RNA replication did not interfere with IFN signaling. After consecutively 
treating HG23 cells with 0.5 µg/mL MPA for 10 days, the resulting cells were designated HG23DEPL. 
Complete clearance of HuNoV replicons in HG23DEPL was verified by RT-PCR (A) and colony formation 
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assay (B). In the RT-PCR, lane 1 and 2 represented cells from two different passages. M indicated the 
100 bp DNA ladder. In the colony formation assay, 1,000 cells of HG23 or HG23DEPL were plated into 
6-well cell culture plate and maintained in the presence of 1 mg/mL of G418. After 10 days of culture, 
the plates were washed, fixed and stained. Representative data are from independent experiments. 
To compare the JAK/STAT pathway signaling, HG23 or HG23DEPL cells were treated with 1,000 IU/mL 
of IFNα. At indicated time points, the IFNα response was detected. (C) Western blotting of STAT1, p-
STAT1 and STAT2. β-actin was used as a reference. (D) Levels of expression for ISGs in HG23 and 
HG23DEPL cells were determined after the addition of IFNs via qRT-PCR. The y axis represented the 
fold changes in the expression levels normalized to a respective control without IFN treatment (n = 3 
independent experiments with duplicates each). Data are presented as the mean ± SEM (Mann-
Whitney test; *, P < 0.05; **, P < 0.01). 
 
 
Figure S9 HuNoV RNA replication had no effect on ISG induction. (A) qRT-PCR analysis of ISG 
expression in HG23 cells and HG23DEPL cells after IFNα treatment. Data was normalized to GAPDH and 
compared to a respective control without IFN treatment (n = 3 independent experiments with 
duplicates each). Data are presented as the mean ± SEM (*, P < 0.05). 
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Figure S10 Cell sorting of GFP-positive cells after transfection of HuNoV reverse genetics in 
293T cells. (A) Schematic diagrams of pHuNoVU201F- and pHuNoVU201F-based constructs. (Upper) The 
HuNoV GII.3 U201 genome was represented. ORF1 of the HuNoV genome encoded a polyprotein, 
while ORF2 and ORF3 encoded the capsid protein VP1 and VP2, respectively. The whole genome was 
inserted into an expression cassette under the control of the promoter regulating the human EF-1α. 
(Lower) Construct pHuNoVU201F-ORF1-IRES-GFP had an encephalomyocarditis virus, internal ribosomal 
entry site and GFP (EMCV-IRES-GFP) gene with a stop codon that was inserted into the ORF1 region. 
(B) In order to improve the transfection efficiency, we used pGFP-C1, a plasmid expressing green 
fluorescent protein (GFP) as a transfection marker. HEK293T cells were transiently transfected with 
the plasmid pGFP-C1 alone (control) or pHuNoVU201F-ORF1-IRES-GFP alone or pHuNoVU201F combined with 
pGFP-C1. After 48 h of transfection FACS was performed to sort GFP-positive cells. The ration of 
pGFP-C1: pHuNoVU201F was 10:1, so it was convincing that GFP positive cells were successfully 
transfected with pHuNoVU201F. 
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Figure S11 HuNoV protein and RNA expression had no effect on IFN signaling. After 
transfection of HuNoV reverse genetics into 293T cells, the successful expression of HuNoV RNA was 
verified by qRT-PCR and RT-PCR. (A) In the qRT-PCR, two primer sets were used. One was self-
designed HuNoV GII.3 U201-specific primer pair and the other was GII-specific diagnostic primer pair. 
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Human GAPDH was used as a reference gene. (B) Gel-based RT-PCR analysis of HuNoV RNA 
expression by using HuNoV GII-specific primer set. Human GAPDH was used as a reference gene. 
Lane 1 and 2 represented cells from two independent experiments. M indicated the 100 bp DNA 
ladder. HEK293T cells expressing HuNoV reverse genetics were treated with IFNα (1,000 IU/mL) for 
24 hours and used to assess the JAK-STAT pathway. The results were compared to those in pGFP-C1-
transfected control cells. (C) Western blot of STAT1, p-STAT1 and STAT2. β-actin was used as a 
reference. (D) Levels of expression for ISGs in 293T cells with and without transfected HuNoV 
constructs were determined at 24 hours after the addition of IFNα via qRT-PCR. The y axis represents 
the fold changes in the expression levels normalized to a respective control without IFN treatment (n 
= 3 independent experiments with duplicates each). Data presented as mean ± SEM (Mann-Whitney 
test; *, P < 0.05; **, P < 0.01). 
 
 
Figure S12 Specificity of primer sets used to detect the HuNoV reverse genetics. (A) The 
specificity of primers NVp110 and NV-4611 were verified by using purified plasmid pHuNoVU201F and 
pHuNoVU201F-ORF1-IRES-GFP as initial template. After 30 cycles of amplification, a single band at 234 bp 
was indicative of the specificity of the primer pair. 
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TO THE EDITOR 
Norovirus is a major cause of acute gastroenteritis worldwide, and chronic infections 
frequently occur in immunocompromised patients. However, no US Food and Drug 
Administration-approved specific medication is available for treating norovirus infection. 
Interestingly, substantial clinical evidence has suggested that nitazoxanide, originally 
developed as an antiprotozoal agent, is a potential antiviral therapy for norovirus infection [1]. 
Both clinical trials and case studies have reported its effects on reduction of symptom 
duration in immunocompetent patients [2] or clearance of the infection in 
immunocompromised patients [3, 4]. On the contrary, a recent study in the Journal of 
Infectious Diseases by Kempf et al reported that nitazoxanide was not effective for treating 
chronic norovirus gastroenteritis in a patient with X-Linked Agammaglobulinemia [5]. These 
results have sparked concern regarding whether this drug holds promise in treating 
norovirus infection, indicating the need for further assessment of the efficacy and working 
mechanism of nitazoxanide [6]. 
Although the lack of robust cell culture models is a key bottleneck in the norovirus 
research field, there are a few surrogate models currently available, including a human 
subgenomic norovirus replicon (HuNV) [7] and the murine norovirus (MNoV) [8] infectious 
model. Therefore, we have assessed the direct effects of nitazoxanide on norovirus in these 
models to better clarify the current debate.  
We first investigated the effects in the HG23 cell culture model, a Huh-7 cell line-
based HuNV replicon. This subgenomic replicon, derived from a GI genogroup strain, 
encodes the neomycin phosphotransferase gene by replacing part of the viral ORF2 
sequence, thereby conferring resistance of HG23 cells to G418 treatment (Figure 1A). In this 
model, we found that nitazoxanide at 5 μg/mL, a clinically achievable concentration, 
significantly inhibited viral replication by 90% ± 6.4 after 48 hours of treatment without 
toxicity to host cells (P < .001) (Figure 1B). To further evaluate the long-term effects, a 
clearance and rebound assay was performed in this model (Figure 1C). During the clearance 
phase, HG23 cells were constantly treated with nitazoxanide for 10 days, after which the 
cells were cultured in medium containing G418 (1.5 mg/mL) for another 5 days. As shown in 
Figure 1D, nitazoxanide at 5 μg/mL dramatically inhibited HuNV replication and cleared most 
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of the HuNV from host cells, as evidenced by the low confluency of replicon cells after G418 
selection (Figure 1E). 
On the contrary, we found that nitazoxanide significantly increased the RNA 
replication (by 6-fold; P < .01) (Figure 1F) and virus particle production (Figure 1G) of a 
mouse norovirus strain (MNoV-1; GV). We further evaluated this effect on another two 
MNoV strains with distinct biological behaviors, the acutely cleared strain MNoVCW3 and the 
persistent strain MNoVCR6. Notably, nitazoxanide had no effect on MNoVCW3 RNA replication 
and virus production but slightly facilitated the infection of MNoVCR6. 
Our results indicate the complexity of evaluating the effects of nitazoxanide on 
norovirus infection. This is in line with previous findings that nitazoxanide inhibits hepatitis B 
virus, hepatitis C virus, rotavirus, or influenza virus infection through multiple mechanisms [9]. 
Given the opposing effects of nitazoxanide on human and murine norovirus, we postulate 
that the virus genotype and strain are critically important for responsiveness. Currently, 
there are six well-classified norovirus genogroups, with GI, GII and GIV affecting humans. 
Among these genogroups, GII.4 is responsible for most of the pandemics, and GII.17 is an 
emerging pathogenic genotype. Furthermore, chronically infected immunocompromised 
individuals and transplant patients are reservoirs for the emergence of new strains of 
norovirus [10]. Because the diversity of norovirus genotypes circulating in 
immunocompromised patients is much greater than that in healthy populations, larger and 
well-designed clinical studies may help us to understand the distinct responsiveness to 
nitazoxanide among different populations and possibly move us toward more personalized 
treatment. Encouragingly, our results demonstrating a specific antiviral effect in the human 
norovirus replicon system highlight the great potential of nitazoxanide for treating norovirus 
infection, although further research is required to confirm and expand these results. 
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Figure 1. A, Schematic diagram of the human subgenomic norovirus replicon (HuNV) 
construct. RNA transcripts were synthesized in vitro and were transfected into the human Huh-7 cells 
to generate the HG23 model system. After the transfection, the cells were cultured in medium 
complemented with G418 (1.5 mg/mL). B, Nitazoxanide dose-dependently inhibited replication of 
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the HG23 HuNV subgenomic replicon after 48 hours of treatment. The levels of HuNV RNA were 
quantified by quantitative real-time polymerase chain reaction (RT-qPCR) and were compared with 
cells treated with 0.5% dimethyl sulfoxide (DMSO) (control) (n = 3 independent experiments with 2 
replicates each). C, HuNV replicon clearance-rebound assay. During the clearance phase, HG23 
replicon cells were cultured in the presence of nitazoxanide without G418. After 10 days, 
nitazoxanide was removed, and cells were incubated in the presence of G418 (1.5 mg/mL) for 5 days. 
D, Clearance assay with nitazoxanide. Cells were treated with nitazoxanide for 2, 6, or 10 days. At the 
end of each treatment period, the levels of HuNV RNA were determined by RT-qPCR and compared 
with the control cells of the same treatment time (n = 3 independent experiments with 2 replicates 
each). E, Rebound assay with nitazoxanide. After 10 days of treatment, nitazoxanide was omitted, 
and HG23 cells (2.5 × 104 per 48-well) were cultured under the selective pressure of G418 (1.5 
mg/mL). With another 5 days of culture, the cell layers were stained with hematoxylin and eosin. 
Units: μg/mL. F and G, Nitazoxanide exerts differential effects on murine norovirus replication. RAW 
264.7 cells were infected with 3 murine norovirus strains (MNoV-1, MNoVCW3 or MNoVCR6) at a 
multiplicity of infection of 0.1 and were subsequently treated with different concentrations of 
nitazoxanide. After 24 hours of incubation, the relative levels of cellular murine norovirus (MNV) RNA 
and extracellular viral RNA copy numbers were determined by RT-qPCR (n = 3 independent 
experiments with 2 replicates each). Data presented as means ± SEM. *, P < .05; **, P < .01; ***, P 
< .001; ns, not significant; Mann-Whitney test using GraphPad Prism. 
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ABSTRACT 
Norovirus is the main cause of viral gastroenteritis worldwide. Although norovirus 
gastroenteritis is self-limiting in immunocompetent individuals, chronic infections with 
debilitating and life-threatening complications occur in immunocompromised patients. 
Nitazoxanide (NTZ) has been empirically used in the clinic and demonstrated effectiveness 
against norovirus gastroenteritis. In this study we aimed at uncovering the antiviral potential 
and mechanisms of NTZ and its active metabolite, tizoxanide (TIZ) using a human norovirus 
(HuNV) replicon. NTZ and TIZ, collectively referred to as thiazolides (TZD) potently inhibited 
the replication of HuNV and a norovirus surrogate feline calicivirus. Mechanistic studies 
revealed that TZD activated cellular antiviral response and stimulated the expression of a 
subset of interferon-stimulated genes (ISGs), particularly IRF-1 not only in Huh7-based HuNV 
replicon but also in naïve Huh7, Caco-2 and novel human intestinal organoids. 
Overexpression of exogenous IRF-1 inhibited HuNV replication; whereas knockdown of IRF-1 
largely attenuated the anti-norovirus potency of TZD, suggesting that IRF-1 mediated TZD-
induced inhibition of HuNV. By using a JAK inhibitor CP-690550 and STAT1 knockout 
approach, we found that TZD induced antiviral response independent of the classical Janus 
Kinase/signal transducers and activators of transcription (JAK/STAT) pathway. Furthermore, 
TZD and ribavirin synergized to inhibit HuNV replication and completely depleted the 
replicons from host cells after long-term treatment. In summary, our results demonstrated 
that TZD combated HuNV replication through activation of cellular antiviral response, in 
particular inducing a prominent antiviral effector IRF-1. NTZ monotherapy or combination 
with ribavirin represented promising options for treating norovirus gastroenteritis, especially 
in immunocompromised patients. 
Keywords: norovirus, nitazoxanide, cell culture model, IRF-1, ribavirin, synergy 
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INTRODUCTION 
Norovirus is one of the main causative agents for acute viral gastroenteritis in all age 
groups. It is estimated to cause a median number of 699 million illness and 219,000 deaths 
every year, of which more than 90,000 deaths occur in children under five years old [1]. 
Nowadays, norovirus gastroenteritis is also recognized as an emerging burden in 
immunocompromised populations, particularly transplant recipients [2]. Suppression of 
immune system facilitates norovirus infection, resulting in chronic diarrhea and other 
complications [3, 4]. Furthermore, norovirus gastroenteritis has been reported to cause graft-
versus-host disease (GVHD) and sepsis, due to the breakdown of gastrointestinal mucosa in 
those patients [5]. Besides careful fluid replacement and intensive supportive care, no 
specific antivirals are currently available for treating norovirus gastroenteritis. 
Nitazoxanide (NTZ) was developed in the early 1970s and originally commercialized 
as an anti-parasitic drug. Following oral administration, NTZ is absorbed from the 
gastrointestinal (GI) tract and rapidly hydrolyzed by plasma esterase to form its active 
circulating metabolite tizoxanide (TIZ). The concentration of TIZ in serum maximally reaches 
10 µg/mL [6]. Both drugs belong to a class of agents known as thiazolides (TZD). NTZ is 
currently licensed in the United States (Alinia®, Romark Laboratories) for treating diarrhea 
caused by Cryptosporidium parvum and Giardia intestinalis in adults and children above 12 
months age [7]. Interestingly, NTZ has also been reported to exert potent and broad-
spectrum antiviral activities against many viruses including influenza virus, hepatitis B virus 
(HBV), hepatitis C virus (HCV), human immune-deficiency virus (HIV) and rotavirus [7, 8]. 
Mechanistically, it has been demonstrated that NTZ selectively blocks the maturation of the 
viral hemagglutinin of influenza viruses at post-translational level, thus inhibiting the proper 
assembly and release of the virus from the host cells [9]. With regard to HCV, NTZ is involved 
in activation of protein kinase R (PKR), a key kinase that regulates the host innate anti-HCV 
response [10]. For rotavirus, NTZ reduces the size and alters the architecture of rotavirus 
viroplasm, thus decreasing the viral dsRNA formation [8]. NTZ has been recently reported to 
elicit anti-viral innate immunity to combat HIV and other virus infections [11]. However, a 
general consensus regarding the antiviral mechanism-of-action of NTZ is not well established, 
and seemingly depends on the virus itself and host cells. 
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Several clinical studies have recently demonstrated the off-label use of NTZ in 
treating norovirus gastroenteritis. In a randomized double-blind placebo-controlled clinical 
trial, 50 adults and adolescents presenting diarrhea with stool positive for norovirus, 
rotavirus or adenovirus were enrolled. The median resolution time for all subjects as well as 
the ones infected with norovirus was significantly reduced in NTZ-treated group when 
compared to placebo group [12]. Later in a retrospective study comprising 12 patients with 
norovirus gastroenteritis after chemotherapy and hematopoietic stem cell transplantation 
(HSCT), 11 patients clinically responded with improvement in symptoms following NTZ 
administration [5]. Similar results were observed in another study comprising 5 patients with 
norovirus gastroenteritis after HSCT. Oral administration of NTZ resulted in the resolution of 
gastroenteritis and complete viral clearance [13]. These clinical studies have indicated the 
potential of repurposing NTZ as a viable therapeutic option for norovirus gastroenteritis. 
However, further experimental research is required to characterize its bone fide anti-
norovirus activity and mechanistic insight. In a review article based on personal 
communication, It has been mentioned that the 50% inhibitory concentration (IC50) and 90% 
inhibitory concentration (IC90) for TIZ were 0.5 and 1.2 μg/mL respectively using a human 
norovirus (HuNV) replicon [7]. In our previous study, we also found that NTZ displayed potent 
anti-norovirus activity using the same replicon model [14].However, the exact antiviral 
mechanisms of NTZ against norovirus have not been revealed. Thus, we have systematically 
explored the anti-norovirus potential of TZD and studied its potential mechanism-of-action. 
Our results have revealed that TZD triggered cellular innate immune response to combat 
norovirus replication and synergized with ribavirin, a broad-spectrum antiviral drug that 
showed effectiveness against norovirus gastroenteritis in vivo [15]. 
MATERIALS AND METHODS 
Cell lines and virus propagation 
Human Huh7 hepatocellular carcinoma cells expressing HuNV genotype 1 replicons 
(HG23) [16] and human embryonic kidney 293T cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Lonza Verviers, Belgium) supplemented with 10% (vol/vol) heat-
inactivated fetal calf serum (FCS) (Hyclone, Logan, UT, USA). Caco-2 cells (Human Caucasian 
colon adenocarcinoma; ECACC) were cultivated in DMEM supplemented with 20% (vol/vol) 
FCS. Crandell Rees feline kidney cells (CRFK) were maintained in Minimum Essential Medium 
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with Earle’s Salts without glutamine (EME), 1% L-glutamine, 0.05% (w/v) sodium bicarbonate, 
0.02 M Hepes buffer, 0.2% nystatin solution and 10% (vol/vol) fetal bovine serum (FBS). A 
neomycin resistant gene was engineered into open reading frame 2 (ORF2), thereby 
conferring HG23 resistance to gentamicin (G418; Gibco) [16]. G418 was added to HG23 
culture medium at 1.5 mg/mL for selection before experimentation. 
Feline calicivirus (FeCV; kindly gifted from Dr. Erwin Duizer, National Institute for 
Public Health and the Environment, the Netherlands) strain F9 was propagated in 
monolayers of CRFK cells as previously described [17]. Briefly, FeCV was inoculated into CRFK 
monolayers at a multiplicity of infection (MOI) of 0.1. After 3 days of incubation, the FeCV 
cultures were collected by repeated freezing and thawing, and clarified by centrifugation at 
4,000 rpm for 10 min. The supernatant was filtered through a 0.45-μm filter (Waters 
Millipore), titrated three independent times by the 50% tissue culture infectious doses 
(TCID50) and stocked at -80℃ for all subsequent experiments. 
Reagents 
Nitazoxanide (NTZ; Chemical Abstract Service [CAS] no. 55981-09-4; Sigma-Aldrich), 
tizoxanide (TIZ; CAS no. 173903-47-4; Cayman Chemical) and CP-690550 (CAS no. 477600-
75-2; Santa Cruz Biotechnology) were dissolved in dimethyl sulfoxide (DMSO) at 20 mg/mL, 5 
mg/mL and 1 mg/mL, respectively. Ribavirin (CAS no. 36791-04-5; Sigma-Aldrich) was 
stocked in water at 10 mg/mL. Human interferon alpha 2a recombinant protein (IFNα) 
(Catalog no. 111001; Thermo-Fisher Scientific) was stocked in phosphate-buffered saline 
(PBS) containing 0.1% bovine serum albumin (BSA) at 100,000 units/mL based on 
international units. Matched concentration of DMSO (0.05%) were used as vehicle control. 
To avoid repeated freeze-thaws, the compounds were aliquoted and stored at -80℃. During 
experimentation the compounds were stepwise diluted to desired concentration.  
Interferon regulatory factor 1 (IRF-1) (D5E4, Rabbit mAb, #8478) antibody was 
obtained from Cell Signaling Technology and β-actin (C-4, Mouse mAb, #sc-47778) was 
purchased from Santa Biotechnology (Santa Cruz, CA, USA). Secondary antibodies IRDye® 
800CW-conjugated goat anti-rabbit and goat anti-mouse IgGs (1:10,000 dilution; Li-Cor 
Bioscience, Lincoln, USA) were used, as appropriate. 
Culturing and passaging human primary intestinal organoids 
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Culture of human primary intestinal organoids was performed as described before [18]. 
Intestinal biopsies were dissected, cut longitudinally and completely washed with pre-cold 
PBS. After removing villus and fat, small intestine was minced into small pieces (~ 1 mm3) in 
a 10 cm culture dish using a scalpel and washed with complete chelating solution (CCS) (1.0 
g/L Na2HPO4.2H2O, 1.08 g/L KH2PO4, 5.6 g/L NaCl, 0.12 g/L KCl, 15 g/L sucrose, 10 g/L D-
Sorbitol and 80 μg/L DL-dithiothreitol dissolved in MilliQ H2O) for 3 times by pipetting up and 
down 15 times, followed by further incubation with 8 mM EDTA on a shaking platform for 15 
min at 4℃. Supernatant was discarded and biopsies were gently rinsed with PBS to 
completely get rid of EDTA. It was thoroughly suspended in CCS solution by pipetting up and 
down 10 times with a 10-mL pipet to loosen crypts, and 2 mL of FCS was added. The 
supernatant contained crypts and was collected in a 50 mL tube; whereas the remaining 
biopsies were further digested with EDTA for 2 to 3 times and supernatant with crypts was 
pooled. Crypt suspension was first centrifuged at 300 g for 5 min. Supernatant was gently 
removed and the pellet was resuspended in 2 mL complete medium growth factor (GF)- 
(CMGF-, advanced DMEM/F12 supplemented with 1% [vol/vol] of GlutaMAXTM Supplement 
[Gibco, Grand island, USA], 10 mM of Hepes and 100 U/mL of Penicillin-Streptomycin]. 
Second round of centrifugation at 130g for 5 min was performed to harvest crypt. The crypt 
pellet was finally suspended in ice-cold growth factor reduced phenol-red free Matrigel 
(Corning, Bedford, USA) and dropped into the center of a pre-warmed (37℃) 24-well tissue 
culture plate at 100 to 500 crypts per well. The plate was incubated at 37℃, 15 min for 
Matrigel solidification. Crypts were finally cultured in culture medium (Table S1) and 
passaged every 6 days.  
After approximately 6 days, organoids were passaged. Briefly, organoids were 
collected to a 15 mL falcon tube and dissociated mechanically by pipetting up and down 15 
to 20 times by passing through a 5-mL pipet inserting a 200 μL tip. The resulting suspension 
was centrifuged at 150 g for 5 min at 4℃ and pellet was cultured in fresh Matrigel with a 1:3 
split ratio. 
HuNV antiviral assay 
Twenty-four hours before experimentation, HG23 cells were cultured in the medium 
without G418. HG23 cells were seeded into 48-well tissue culture plates (2.5 × 104 cells per 
well), treated with compounds alone or in combination, and quantified for HuNV RNA levels 
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after 2 days of treatment by qRT-PCR using a primer pair targeting the RNA-dependent RNA 
polymerase (RdRP) of HuNV. To further evaluate the long-term effects of compounds on 
HuNV replication, long-term treatment and rebound assay was designed, as described 
previously [14, 19, 20]. During long-term treatment HG23 cells were treated with compounds for 
2, 6 or 10 days. Cells were passaged to avoid overgrowth and drugs were replenished at 
times in between. At the end of each treatment period, HuNV RNA levels were determined 
by qRT-PCR. After 10 days of treatment, compounds were omitted. HG23 cells were plated 
into 48-well tissue culture plate (2.5 × 104 per well) and cultured under the selective 
pressure of G418 (1 mg/mL). Following 5 days of culture, cell colonies were stained with 
hematoxylin and eosin, and visualized by an inverted Zeiss Axiovert 200 microscope 
equipped with Zeiss AxioCam MRm camera (LLC, Thornwood, NY, USA). 
FeCV TCID50 and antiviral assay 
FeCV stock was quantified by TCID50 assay. In briefly, 50 μL of 10-fold dilutions of 
FeCV were inoculated into 100 μL of CRFK cells in 96-well tissue culture plates at 1,000 cells 
per well. After 5 days of incubation at 37℃, each well was scored under a light scope for the 
cytopathic effect (CPE). A TCID50 was calculated from 6 replicates by using the Reed-
Muench method. 
The antiviral activities of TZD against FeCV were detected by qRT-PCR and CPE 
reduction assay. The antiviral assay with FeCV was initiated by inoculated virus into CRFK 
monolayers at an MOI of 0.1 (2.5 × 104 cells per well of 48-well tissue culture plate). 
Following 90 min incubation at 37℃, cells were washed with PBS for 3 times to remove free 
virus and increasing concentrations of TZD were added. After 24 hours of treatment, 
extracellular RNA and intracellular RNA were extracted from the supernatant (virus particles, 
100 μL) and cell monolayers respectively. The relative intracellular FeCV RNA levels were 
normalized to feline glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and calculated 
with the 2-ΔΔCT method. To further quantify the absolute numbers of virus genomes in the 
supernatant, FeCV genome copy number was detected using qRT-PCR using a primer pair of 
forward primer (5’-GAACTACCCGCCAATCAACAT-3’; corresponding to nucleotide [nt] 2420-
2440) and reverse primer (5’-CGGCTCTGATGGCTTGAAACTG-3’; corresponding to nt 2507-
2528). Briefly, a cDNA-containing target sequence in FeCV was amplified using Q5® High-
Fidelity DNA polymerase kit (New England Biolabs Inc.) in a 25 µL reaction mixture 
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containing 5 µL of 5× Q5 Reaction Buffer, 0.5 µL of a 10 mM dNTPs, 1.25 µL of 10 µM 
forward primer (5’-GAACTACCCGCCAATCAACAT-3’; corresponding to nt 2420-2440), 1.25 µL 
of 10 µM reverse primer (5’-CGGCTCTGATGGCTTGAAACTG-3’; corresponding to nt 2507-
2528), 5 µL of template cDNA and 0.25 µL of Q5 High-Fidelity DNA Polymerase. Amplification 
was carried out with initial denaturation at 98℃ [30 s]; 35 cycles of 98℃ [10 s], 66℃ [30 s], 
and 72 ℃ [30 s]; and an additional extension step of 72℃ for 2 min. The product was 
subjected to agarose gel electrophoresis, purified using the ChargeSwitch-Pro PCR clean-up 
kit (Invitrogen) and 10-time serially diluted. The dilutions were quantified by qRT-PCR to 
generate a standard curve, which was expressed by plotting the log copy numbers against 
the cycle threshold (CT) values (Fig. S1). The FeCV genome copy numbers in the medium 
were calculated by comparing the CT with that of the standard curve. 
FeCV could induce significant CPE in CRFK cell line [21]. The antiviral activities of TZD 
against FeCV were further confirmed by using an MTT-based CPE induction assay. Briefly, 10 
μL of FeCV was inoculated into 80 μL of CRFK cells (1 × 104 cells per well of 96-well tissue 
culture plate) at an MOI of 0.5, followed by addition of 10 μL of increasing concentrations of 
TZD. After 2 days of incubation, a clear CPE was observed characterized by complete 
destruction of the cell monolayers in the control well. Then, an MTT assay was performed 
and the absorbance (optical density [OD]) at 490 nm was recorded. CPE reduction was 
calculated as [(ODtreated)FeCV-ODVC]/[ODCC-ODVC], where (ODtreated)FeCV represented the OD of 
virus-infected cells treated with drugs, while ODCC and ODVC represented the OD of the cell 
control and virus control, respectively. The protective effect of TZD on FeCV-infected CRFK 
cells could also be directly visualized by observing the survival of cells. In brief, each well was 
stained with hematoxylin and eosin, and visualized with an inverted light microscope. 
Drug treatment on Caco-2 and organoids 
Caco-2 cells were plated into 48-well tissue culture plate (2 × 104 cells per well) and 
incubated with 10 μg/mL TZD. After 2 days of treatment, the medium was discarded and cell 
monolayers were washed 3 times with PBS. Cells were subsequently lysed for RNA 
extraction. 
The organoid experiment was performed on monolayer cultures of organoids, as 
described [22]. A 24-well tissue culture plate was pre-covered with 50% Collagen R and 
incubated at 37℃ for 30 mins. Organoids were harvested, transferred to 24-well tissue 
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culture plate (100 to 200 organoids per well) and centrifuged at 1500 rpm for 10 min. The 
drug was added and the cultures were further incubated for 48 hours. After treatment the 
supernatant was aspirated and the monolayers were washed with PBS for 3 times and lysed 
for qRT-PCR. 
Generation of IRF-1-expressing lentiviral pseudoparticles and lentiviral 
transduction 
HEK293T cells were used to generate IRF-1-expressing lentivirus vectors. Briefly, 293T 
cells were co-transfected with IRF-1-expressing plasmid pTRIP.CMV.IVSb.IRF-1.ires.TagRFP, 
HIV-1 gag-pol and VSV-G (a ratio of 1:0.8:0.2) in Opti-MEM using polyethyleneimine (PEI). 
After 6 hours of transfection, cells were gently washed once with PBS and refreshed with 
growth medium. After 48 and 72 hours of transfection, lentivirus-containing supernatants 
were pooled and filtered through a 0.45-μm pore size filter. Two hours of ultracentrifugation 
(22,000 rpm) was used to concentrate lentiviral particles. The pellet was subsequently re-
suspended and stored at -80℃ with the dilution of 7 log viral RNA copies per mL. 
For transduction assay, HG23 cells were seeded into 48-well tissue culture plate (5 × 
104 cells per well) and transduced with lentiviral pseudoparticles encoding IRF-1. After 2 
days of culture cells were collected for detecting IRF-1 by qRT-PCR and Western blot. 
STAT1 knockout in Huh7 using the CRISPR/Cas9 system 
STAT1 knockout (KO) Huh7 clone was established by Lenti-CRISPR/Cas9 system 
(STAT1 sgRNA: TCCCATTACAGGCTCAGTCG). In brief, HEK293T cells were co-transfected with 
lentiCRISPRv2-STAT1, pVSVg  and psPAX2 (a ratio of 1:0.5:0.75) using FUGEN HD 
Transfection Reagent (Qiagen), according to the manufacturer’s instructions. After 24 hours 
of incubation, medium was replaced with fresh medium supplemented with 1% FCS. 
Lentivirus-containing supernatants were pooled at 24 and 48 hours, and subsequently 
filtered through a 0.45-µm pore size filter. Huh7 cells were infected with lentiviral 
supernatant for 2 days and further incubated with selection medium containing 4 µg/mL 
puromycin for 7 days. To obtain knockout clones, single cells were sorted into 96-well tissue 
culture plates and cultured with puromycin (4 µg/mL). Medium were refreshed every 4 days 
during selection. Cell colonies were collected and identified by Western blot and genome 
sequence. 
Western blot 
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Cell samples were lysed and loaded onto a 10 to 15% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel. After electrophoresis at 120 V for 100 
mins, the proteins were electrotransferred to a polyvinylidene difluoride (PVDF) membrane 
(pore size, 0.45 μm; Invitrogen) for 1.5 h, with an electric current of 250 mA. The membrane 
was probed with primary antibody plus secondary antibody and detected with Odyssey 3.0 
infrared imaging system (LI-COR Biosciences). β-actin was served as standardization of 
sample loading. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total RNA was isolated with a Machery NucleoSpin RNA II kit (Bioke, Leiden, The 
Netherlands) and measured with a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was 
reverse transcribed from 500 ng of RNA using a cDNA synthesis kit (TaKaRa Bio, Inc.). The 
cDNA of a targeted gene transcript was amplified for 50 cycles and quantified with a SYBR 
Green-based real-time PCR (Applied Biosystems), according to the manufacturer’s 
instructions. All the PCRs were performed in duplicates and amplification specificity was 
confirmed by melting-curve analysis. Human and feline GAPDH were used as reference 
genes. The relative expression of targeted gene was calculated as 2-∆∆CT, where ∆∆CT = 
∆CTsample - ∆CTcontrol (∆CT = CT[targeted gene] - CT[GAPDH]). All primer combinations were listed in 
Table S2. 
Statistics 
Data are presented as mean ± standard error of the mean (SEM). Comparisons 
between groups were performed with Mann-Whitney test using GraphPad Prism 5.0 
(GraphPad Software Inc., La Jolla, CA, USA). Differences were considered significant at a P 
value less than 0.05. 
RESULTS 
TZD exhibited potent antiviral activities toward HuNV and FeCV replication 
without significant cytotoxicity 
A Huh7-based HuNV replicon model (HG23) representing one of very few options in 
modeling HuNV replication in cell culture has been widely used for studying anti-norovirus 
agents. After 2 days of treatment, NTZ and TIZ dose-dependently inhibited HuNV replication 
(Fig. 1A). The toxicities of TZD toward HG23 cells were determined by a 3-(4,5-dimethyl-2-
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thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (supplementary material). TZD 
showed no major toxicities toward HG23 cells at the clinically relevant concentration of 10 
μg/mL (Fig. 1A). These results have demonstrated the potent anti-norovirus effects of TZD 
without triggering major cytotoxicities. 
Consistently, TZD dose-dependently reduced a norovirus surrogate FeCV cellular viral 
RNA and viral genomes in the supernatant after 24 hours of treatment without significant 
cytotoxicities (Fig. 1B and C). The inhibitory effect was also confirmed in a CPE reduction 
assay, demonstrating that TZD at 5 and 10 μg/mL protected CRFK cells from FeCV-induced 
CPE formation (Fig. 1D). Meanwhile, TZD at 5 and 10 μg/mL could significantly increase the 
survival of FeCV-infected CRFK cells (Fig. 1E). Collectively, our results demonstrated that TZD 
potently inhibited HuNV and its surrogate FeCV replication. 
TZD activated the expression of interferon-stimulated genes (ISGs), especially 
IRF-1 
TZD have been recently reported to stimulate innate antiviral immunity in peripheral 
blood mononuclear cells in vitro potentially accounting for its anti-HIV activity [11]. IFN 
signaling is a vital component of the innate immunity against viral pathogens. It signals 
through the Janus Kinase/signal transducers and activators of transcription (JAK-STAT) 
pathway and transcriptionally induces hundreds of ISGs as ultimate antiviral effectors [23, 24]. 
We thus investigated the antiviral state in HG23 cells after TZD treatment. Treatment with 
10 µg/mL NTZ or TIZ for 2 days induced the expression of a panel of important ISGs, 
including IRF-1, interferon regulatory factor (IRF) 9, retinoic acid-inducible gene I (RIG-I), 
IFI27 (also known as ISG12 or p27), RNA-dependent protein kinase PKR, ISG15, Mx1 and 
melanoma differentiation-associated protein (MDA) 5 (Fig. 2A). Some of those ISGs exerted 
broad activities against many virus [25]. Interestingly, compared with exogenous IFNα (1,000 
IU/mL) serving as a positive control, TZD were more potent at inducing IRF-1 mRNA 
expression (NTZ [11.26 ± 1.94] vs TIZ [8.26 ± 1.70] vs IFNα [4.89 ± 0.75]; Fig. 2A). Western 
blot analysis confirmed the potent induction of IRF-1 in response to TZD treatment at 
protein level (Fig. 2B; Fig. S2). We next excluded the implication of HuNV replicon in TZD-
mediated stimulation of ISGs, as TZD treatment also induced ISGs in naïve Huh7 cells. 
Consistent with HG23, IRF-1 mRNA was stimulated by TZD more effectively than 1,000 IU/mL 
of IFNα in Huh7 cells (NTZ [17.31 ± 2.94] vs TIZ [14.86 ± 3.49] vs IFN [2.57 ± 0.17]; Fig. 2C). 
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Figure 1 TZD potently inhibited HuNV and its surrogate FeCV replication without significant 
cytotoxicities. (A) Nitazoxanide and its active metabolite tizoxanide dose-dependently inhibited 
HuNV replication without clear toxicities to host cells after 2 days of treatment. The level of HuNV 
replicon RNA was quantified using qRT-PCR and compared to vehicle control (0.05% DMSO, set as 1) 
(n = 3 independent experiments with duplicates each). (B) TZD elicited potent antiviral potential 
against FeCV. CRFK cells were first infected with FeCV (an MOI of 0.1) and incubated with vehicle 
control or increasing concentrations of TZD. After 24 hours of treatment, cellular FeCV RNA level was 
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quantified by qRT-PCR, normalized to feline GAPDH and compared to vehicle control (set as 1). (C) 
Same as (B) for detecting the cellular FeCV RNA, viral RNA copy numbers in the supernatant 
(secreted viruses) were also detected after 24 hours of treatment with vehicle control or TZD. TZD 
significantly reduced extracellular FeCV viral genomes (n = 3 independent experiments with 
duplicates each). (D and E) The anti-FeCV activities of TZD were further validated by an MTT-based 
and hematoxylin and eosin staining-based CPE reduction assay. CRFK cells were first infected with 
FeCV (an MOI of 0.5) and incubated with vehicle control or TZD. After 2 days of treatment, CPE was 
quantified by the MTT assay, and residual cells were observed after fixation and staining with 
hematoxylin and eosin. In Figure E, CC and VC represented cell control and virus control respectively. 
Images are representative of three independent experiments. Data are presented as the means ± 
SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).  
 
Figure 2 TZD robustly stimulated the expression of IRF-1 and several other ISGs in HuNV 
replicon model and intestinal models of Caco-2 and primary organoids. (A) Fold changes of ISGs 
induced by NTZ (10 µg/mL), TIZ (10 µg/mL) or IFNα (1,000 IU/mL) in HG23 cells. After 2 days of 
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treatment, levels of ISG mRNA were quantified by qRT-PCR and normalized to human GAPDH. Results 
were expressed as fold changes compared to the vehicle control (DMSO; n = 3 independent 
experiments with duplicates each). (B) Western blot analysis of IRF-1 protein expression in response 
to NTZ (10 µg/mL), TIZ (10 µg/mL) or IFNα (1,000 IU/mL). Data are representative of three 
independent experiments. (C) Naïve Huh7 cells were treated with NTZ (10 µg/mL), TIZ (10 µg/mL), 
IFNα (1,000 IU/mL) or vehicle control. After 2 days of treatment, relative levels of ISG mRNA were 
quantified by qRT-PCR (n = 3 independent experiments with duplicates each). (D) Morphology of 3-D 
human primary intestinal organoids in Matrigel. (E) Relative levels of ISG RNA were quantified by 
qRT-PCR after 2 days of treatment with NTZ (10 µg/mL) or IFNα (1,000 IU/mL) in Caco-2 cells (n = 3 
independent experiments with duplicates each). (C) Relative levels of ISG RNA in human intestinal 
organoids after treatment with NTZ (10 µg/mL) or IFNα (1,000 IU/mL) for 2 days (n = 3 independent 
experiments with duplicates each). Data are presented as the means ± SEM (*, P < 0.05; **, P < 0.01). 
TZD robustly induced ISGs in human intestinal cell line and primary organoids 
Though the cellular tropism of HuNV is not completely understood, gastrointestinal 
(GI) tract is believed to be the reservoir for HuNV replication. We further extended TZD 
treatment to human intestinal epithelial cells (Caco-2) and primary human intestinal 
organoids that recapitulated the nature of intestinal epithelium (Fig. 2D). Consistently, TZD 
triggered antiviral response in those two models, even though to a lesser extent when 
compared to HG23 cells and Huh7 cells (Fig. 2E and F). TZD stimulated higher or comparable 
levels of IRF-1 mRNA compared to 1,000 IU/mL IFNα in two models. 
Although the expression levels and patterns of ISGs differed among different cell 
models after TZD treatment, IRF-1 was consistently highly induced. IRF-1 has been reported 
to be one of the most important ISGs exerting antiviral activities against 14 different viruses 
within 7 families [26]. Thus, we further specifically investigated the role of IRF-1 on TZD-
mediated inhibition of HuNV replication. 
IRF-1 inhibited HuNV replication and contributed to TZD-mediated anti-
norovirus effects 
To dissect the role of IRF-1 on HuNV replication, we first overexpressed IRF-1 in HG23 
cells. A bicistronic lentiviral vector co-expressing an IRF-1 and the red fluorescent protein 
TagRFP as well as a control virus containing a luciferase gene from Photinus pyralis (Fluc) 
were used in the study [25]. IRF-1 mRNA and protein levels were significantly increased in 
overexpressing cells after 2 days of transduction (Fig. 3A). Exogenous IRF-1 overexpression 
resulted in a robust inhibition of HuNV RNA replication by 94.4 ± 2.9% (Fig. 3B). To further 
explore the role of basal IRF-1, a loss-of-function assay was performed to silence IRF-1 by 
transducing a lentiviral-based hairpin RNA (shRNA) construct targeting IRF-1. A nontargeting 
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scrambled vector was used as a control. Successful knockdown of endogenous IRF-1 was 
confirmed by qRT-PCR (by 52.4 ± 9.1%) and Western blot analysis (by 72%) (Fig. 3C). In the 
absence of TZD, IRF-1 knockdown had minor effect on HuNV RNA replication (Fig. 3D). 
However, anti-norovirus effects of TZD were largely attenuated in IRF-1 knockdown cells 
when compared to control cells. This attenuated effect in TZD treatment was greater than 
that in TIZ treatment (Fig. 3E). These results indicated that IRF-1 exerted antiviral activity and 
contributed to TZD-mediated inhibition of HuNV replication. 
Triggering antiviral response by TZD was independent of JAK-STAT pathway 
To elucidate the mechanisms by which TZD stimulated cellular antiviral immunity, we 
first examined whether TZD induced the production and secretion of interferons (IFNs). IFN 
genes including IFNα, IFNβ and IL28A/B were detected in HG23 and intestinal organoids 
following NTZ treatment. NTZ unexpectedly showed minor effects on IFN mRNA expression 
(Fig. S3).  
The JAK/STAT pathway is the principal cascade for IFN signaling. Upon binding to the 
two IFN receptor subunits (IFNAR1 and IFNAR2), type I IFNs activate the Janus kinases (Jak1 
and Tyk2) and signal transducers of transcription (STAT1 and STAT2), resulting in the 
elevation of hundreds of ISGs. To examine whether TZD stimulated ISGs through the JAK-
STAT pathway, TZD were combined with CP-690550 (Tofacitinib), a potent and selective JAK 
inhibitor. An 100 IU/mL IFNα was used as a control. The antiviral activity of IFNα was 
partially abolished and HuNV RNA levels were restored from 4.5 ± 1.7% to 28.9 ± 14.6% 
when combined with CP-690550 (Fig. 4A). In contrast, CP-690550 did not interfere with the 
anti-norovirus effects of TZD. Correspondingly, CP-690550 significantly suppressed IFNα but 
not TZD-mediated induction of ISGs including IRF-1 (Fig. 4B), PKR, ISG15 and MDA5 (Fig. 4C).  
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Figure 3 IRF-1 mediated TZD-triggered inhibition of HuNV replication. (A) To overexpress 
IRF-1, HG23 cells were transduced with lentiviral IRF-1-expressing vector or Fluc-expressing vector 
(control). After 2 days of transduction, the level of IRF-1 expression was detected by qRT-PCR (n = 3 
independent experiments with duplicates each) and Western blot (n = 3 independent experiments). 
INFα (1,000 IU/mL) was used as a positive control. (B) Overexpression of IRF-1 potently inhibited 
HuNV replication (n = 3 independent experiments with duplicates each). (C) To further evaluate the 
role of basal IRF-1 on HuNV replication, HG23 cells were transduced with lentiviral shRNA vector 
targeting IRF-1. A scrambled vector was used as a nontargeting control. Successful knockdown of IRF-
1 was confirmed by qRT-PCR (n = 3 independent experiments with duplicates each) and Western blot 
(n = 3 independent experiments). (D) Knockdown of IRF-1 had minor effects on HuNV replication (n = 
3 independent experiments with duplicates each). (E) IRF-1 shRNA and nontargeting control cells 
were mock-treated or treated with indicated concentration of TZD. After 2 days of treatment, the 
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levels of HuNV RNA were quantified by qRT-PCR and compared to a respective control (n = 3 
independent experiments with duplicates each). Data are presented as the means ± SEM (*, P < 0.05; 
**, P < 0.01; ***, P < 0.001). 
STAT1 is a key component of the JAK-STAT pathway. CRISPR/Cas9 mediated approach 
was used to efficiently knockout STAT1 in Huh7 cells. The successful knockout was confirmed 
by Western blot. Compared to Huh7 control cells, STAT1 protein was undetectable in Huh7 
KO cells (Fig. 4D). To further confirm the complete knockout of STAT1, Huh7 control and KO 
cells were treated with IFNα. As expected, IFNα treatment (1,000 IU/mL) significantly 
induced STAT1 expression in Huh7 control cells but not in KO cells, while no major difference 
was observed in STAT2 mRNA in both cells (Fig. 4E). These data indicated the successful 
knockout of STAT1. Next, Huh7 control and KO cells were treated with TZD or 1,000 IU/mL 
IFNα for 2 days and the expression of ISGs was measured by qRT-PCR. We first observed that 
STAT1 KO slightly decreased the basal levels of a subset of ISGs including MDA5, Mx1 and 
DDX60. This was probably due to the fact that STAT1 was critical to maintain cellular innate 
immune homeostasis. As expected, the induction levels of ISGs in KO cells were significantly 
diminished in response to IFNα treatment when compared to control cells. However, TZD 
induced similar levels of ISGs in both control cells and KO cells including IRF-1 (Fig. 4F), 
MDA5, Mx1, DDX60, ISG15 and IFIT1 (Fig. 4G), suggesting that TZD induced antiviral 
response and ISG expression independent of the JAK-STAT pathway. 
Nuclear factor-kappa B (NFκB) signaling participates in modulating the activation of 
various proinflammatory cytokine genes and ISGs [27], contributing to a vital role on 
combating pathogen invasion. By using Huh7- and Caco-2-based NFκB luciferase reporter 
cells, we further excluded the activation of the NFκB pathway by TZD (Fig. S4). Thus, a novel 
mechanism is likely involved in TZD-induced cellular antiviral response. 
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Figure 4 Stimulation of antiviral response by TZD was independent of JAK-STAT pathway. (A) 
HG23 cells were treated with vehicle only (DMSO; control), NTZ (10 µg/mL), TIZ (10 µg/mL), IFNα 
(100 IU/mL) alone or in combination with CP-690550 (1,000 ng/mL). After 2 days of treatment, the 
HuNV replication was quantified by qRT-PCR (n = 3 independent experiments with duplicates each). 
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(B and C) The expression of IRF-1 and other ISGs including PKR, ISG15 and MDA5 was quantified by 
qRT-PCR (n = 3 independent experiments with duplicates each). (D) STAT1 knockout (KO) clone was 
established from Huh7 cells expressing STAT1 sgRNAs. Successful KO of STAT1 was confirmed by 
Western blot. (E) To further confirm successful KO of STAT1, Huh7 control and STAT1 KO cells were 
treated with IFNα (1,000 IU/mL) for 2 days. Levels of STAT1 and STAT2 RNA were evaluated by qRT-
PCR (n = 3 independent experiments with duplicates each). Knockout of STAT1 abolished the 
induction of STAT1 but not STAT2 after IFNα treatment. (F and G) Huh7 control and STAT1 KO cells 
were mock-treated (DMSO; control) or treated with NTZ (10 µg/mL), TIZ (10 µg/mL), or IFNα (1,000 
IU/mL). After 2 days of treatment, the expression levels of IRF-1, MDA5, Mx1, DDX60, ISG15 and IFIT1 
were detected by qRT-PCR. The results were first normalized to human GAPDH and then compared 
to control cells (n = 3 independent experiments with duplicates each). Data are presented as the 
means ± SEM (*, P < 0.05; **, P < 0.01). 
Synergistic anti-norovirus activity and augmented ISG induction by TZD and 
ribavirin combination 
To achieve better antiviral efficacy, we have evaluated the combination effect of TZD 
and ribavirin against HuNV replication. In short-term (2 days) treatment, combination of NTZ 
and ribavirin did not achieve significantly enhanced inhibition of HuNV replication and 
showed additive effect as calculated by the Mac Synergy II software (Fig. 5A). Similar results 
were observed in TIZ and ribavirin combination (Fig. 5B). 
We next prolonged treatment time in a long-term assay (10-day), and HuNV RNA was 
quantified after 2, 6 and 10 days of treatment. Importantly, NTZ combining with ribavirin 
resulted in an enhanced inhibition of HuNV replication after prolonged treatment (Fig. 6A). 
Antiviral data at 10 day suggested potent synergistic effect in combination as shown in the 3-
D MacSynergy II plot (Fig. 6B). To further detect the residual HuNV replicons in host cells 
after prolonged combination treatment, a rebound assay was designed by culturing HG23 
cells with selection marker G418. If HuNV replicons were completely deleted from host cells, 
HG23 could not proliferate to form colonies. As shown In Fig. 6C, no colonies were found in 
the combination of 2.5 µg/mL NTZ and 5 µg/mL ribavirin, indicating the complete clearance 
of HuNV replicons from host cells. To gain more evidence to support this finding, gel-based 
RT-PCR assay was performed to specifically detect HuNV replicons in the cell culture RNA. No 
bands were detectable after high concentration of combination treatment, confirming the 
depletion of HuNV replicons from host cells (Fig. S5). Similar results were obtained with TIZ 
and ribavirin combination (Fig. 7; Fig. S5). Concurrently, we have observed synergistic 
induction of ISGs in combination treatment including IRF-1, MDA5, PKR and Mx1 (Fig. 8). Of 
note, this synergistic induction of ISGs was modest on day 2, but more robust on day 6 and 
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10 (Fig. 8). This may support the combined anti-norovirus effects of TZD and ribavirin that 
were additive in short-term treatment but synergistic after long-term treatment. 
 
Figure 5 TZD worked addtively with ribavirin to inhibit HuNV replication after short-term 
treatment. (A) HG23 cells were treated with various concentrations of NTZ alone, ribavirin alone or 
the two in combination for 2 days. Antiviral activities were determined by qRT-PCR (n = 3 
independent experiments with duplicates each; Left). To further explore the drug-drug interaction, 
antiviral results were analyzed with a mathematical model (Right). The 3-D surface plot shown 
represented the difference (within 95% confidence interval [CI]) between the actual experimental 
effects and theoretical additive effect of the combination at various concentrations of the two 
compounds. (B) The combination of TIZ with ribavirin. 
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Figure 6 Long-term combination of NTZ with ribavirin synergistically inhibited HuNV 
replication and completely depleted HuNV replicons from host cells. (A) HG23 cells were incubated 
with NTZ alone, ribavirin alone or two drugs in combination. After 2 days of culture, cells were 
passaged to fresh drug-containing medium for another 4 days of incubation. After 6 days, cells were 
passaged with another round of 4 days of treatment. At the end of each treatment, HG23 cells were 
harvested and analyzed for the levels of HuNV RNA (n = 3 independent experiments with duplicates 
each). (B) Synergy analysis. The antiviral results after 10 days of treatment were analyzed with 
MacSynergy. (C) Rebound assay. After 10 days of treatment, HG23 cells were plated into 48-well 
tissue culture plates (2 × 104 cells per well) containing 250 µL of medium with 1 mg/mL G418. After 5 
days of culture, cell colonies were stained and visualized using an inverted light microscope. Data 
presented are presentative of 3 independent experiments. Data are presented as the means ± SEM 
(*, P < 0.05; **, P < 0.01). 
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Figure 7 Combining TIZ with ribavirin synergistically inhibited HuNV replication. (A) 
Combination of TIZ with ribavirin showed greater efficacy against HuNV replication compared to 
individual drug (n = 3 independent experiments with duplicates each). (B) Synergy analysis. (C) 
Rebound assay after long-term treatment. Data are presented as the means ± SEM (*, P < 0.05; **, P 
< 0.01). 
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Figure 8 Augmented induction of ISGs after combination treatment of TZD and ribavirin. 
The qRT-PCR analysis of the expression levels of IRF-1, MDA5 and PKR after treatment with TZD (2.5 
µg/mL NTZ and 2.5 µg/mL TIZ) and ribavirin (0, 2.5 and 5 µg/mL) in HG23 cells for 2, 6 and 10 days (n 
= 3 independent experiments with duplicates each). Data are presented as the means ± SEM (*, P < 
0.05; **, P < 0.01). 
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DISCUSSION 
With the accessibility of rotavirus vaccine [28], norovirus contributes substantially to 
the main cause of acute viral gastroenteritis across all settings and all age groups. In healthy 
general populations, norovirus normally causes self-limiting gastroenteritis. However, it 
often results in prolonged symptoms and virus shedding in immunocompromised patients. 
In a retrospective study comprising 2183 sold organ transplant (SOT) recipients, 4.6% 
recipients were diagnosed norovirus-positive and 22.8% of these patients developed chronic 
norovirus gastroenteritis [29]. Meanwhile, norovirus gastroenteritis is a great global economic 
burden due to the resulting huge health system costs and productivity losses [1]. Some 
clinical studies have reported the successful use of human immunoglobulin (HIG) [30] and 
ribavirin [31] for empirical treatment. Due to inadequate clinical data and experimental 
studies, both drugs require further evaluation as potential therapies. NTZ was recently 
demonstrated to be effective therapy for norovirus gastroenteritis in immunocompromised 
patients [7]. It showed high tolerance and minor adverse effects even after several weeks of 
administration in those patients [5]. Herein we documented that TZD exerted potent anti-
norovirus efficacy through inducing innate antiviral response, in particular IRF-1 in a HuNV 
replicon (HG23). It exhibited synergistic anti-norovirus activity with ribavirin, which 
supported the potential of the combination treatment. 
The HuNV replicon represents one of the few options for anti-HuNV drug evaluation. 
However, it dose not fully recapitulate the HuNV life cycle with deficiency of viral 
attachment, entry, assembly and release. Meanwhile, the relatively low replication level 
(ranging from 1,000 to 3,000 copies per cell) [16] may not fully resemble the fact that the 
peak amount of virus shedding reached 95 × 109 genomic copies/g feces in patients upon 
HuNV infection [32]. The shortage of HuNV infectious model prompted us to exploit HuNV 
surrogates to further confirm the anti-norovirus properties of TZD. Murine norovirus (MNV) 
is a good model system to study norovirus biology and pathogenesis as well as antiviral 
therapies [33]. Surprisingly, NTZ exerted opposing effects on human and murine norovirus 
replication. High concentration of NTZ (10 μg/mL) increased MNV strain MNV-1 replication 
and elicited no effects on the replication of another two strains MNVCW3 and MNVCR6 [14]. 
FeCV belongs to the family Caliciviridea and possesses many biochemical characteristics, 
similar genomic organization and primary RNA sequence compared to norovirus. Thus, FeCV 
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has been used as a surrogate model to study norovirus, especially in the aspects of antiviral 
development, inactivation methods and effective intervention in transmission [34-36]. 
Moreover, FeCV could be persistently cultivated in CRFK cells. We have demonstrated 
similar anti-calicivirus effects elicited by TZD against FeCV. Those results collectively suggest 
that TZD possessed potent antiviral potential against HuNV. 
NTZ was originally developed as an antiprotozoal agent and was later reported to be 
a broad-spectrum antiviral drug toward many virus including influenza, rotavirus, HBV, HCV, 
HIV, yellow fever virus and Japanese encephalitis viruses [7]. It has been repurposed for the 
treatment of influenza in a phase 2b/3 clinical trial [7]. However, the exact mechanism-of-
action remained largely elusive. NTZ was previously reported to stimulate anti-viral innate 
immunity, which contributed to its anti-HIV activity [11]. In our study we have demonstrated 
that TZD inhibited HuNV replication by inducing a panel of ISGs. Amongst the induced ISGs 
with generic antiviral effects, some were previously noted to have anti-norovirus activity. 
ISG15 mitigated murine norovirus 1 (MNV1) replication in vitro and in vivo by targeting an 
early step in the viral life cycle [37]. MDA5, a cellular sensor recognized MNV-1 and further 
triggered host immune response to MNV-1 [38]. PKR mediated type II IFN inhibition of MNV-1 
translation [39]. 
Intriguingly, IRF-1, a broad antiviral ISG was potently induced by TZD at comparable 
or even higher levels when compared to 1,000 IU/mL IFNα treatment. This was observed in 
multiple cell types including HG23, naïve Huh7, Caco-2 and primary intestinal organoids. 
Importantly, we demonstrated that IRF-1 possessed potent anti-norovirus effect and 
mediated the antiviral effects of TZD. Interesting, IRF-1 by itself was able to induce the 
expression of many ISGs, resulting in an ampler magnitude of antiviral immunity by inducing 
IFN production [40, 41] or by directing activating the JAK-STAT pathway [42]. Classically, 
transcription of ISGs is via the JAK-STAT pathway. By pharmacological and genetic 
approaches, we found that the induction of ISGs by TZD was independent of this cascade. 
Further studies also excluded the activation of NFκB pathway and the production of IFNs in 
the action of TZD. One possible mechanism-of-action in the up-regulation of ISGs by TZD 
may be due to the inhibition of a transcriptional repressor. Accumulating evidence suggests 
that many DNA-binding proteins act as a transcriptional repressor for the induction of ISGs 
[43]. NTZ is involved in multiple biological roles including interfering with crucial metabolic 
and pro-death signaling [44]. Thus, NTZ may inhibit those transcriptional repressors, resulting 
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in the induction of ISG expression. Further research is called to reveal the exact mechanism-
of-action. 
Although NTZ has been empirically used in several cases for treating norovirus 
gastroenteritis [45-47], the efficacy remained controversial. NTZ was reported to be ineffective 
in a patient with X-Linked Agammaglobulinemia [48]. Ribavirin, a broad-spectrum antiviral 
agent has been reported to inhibit norovirus in vitro [19]. Clinical studies demonstrated that 
ribavirin treatment resulted in complete viral clearance in a subset of patients, but failed in 
others [31]. In this study, the combination of these two regimens resulted in synergistic anti-
norovirus effects and could completely clear the virus replicons from host cells, even below 
or at clinically achievable concentrations. One potential antiviral mechanism of ribavirin was 
through modulating the cellular immunity and inducing ISGs [49]. Consistently, we observed 
augmented induction of ISGs by combination of TZD and ribavirin. 
In summary, we have demonstrated the bone fide anti-norovirus effects of TZD 
through induction of cellular antiviral response. They further synergized with ribavirin in 
antiviral activities and ISG induction. These knowledge bear important implications of 
repurposing NTZ or in combination with ribavirin for treating norovirus gastroenteritis.   
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Supplementary Information 
SUPPLEMENTARY METHODS 
Reverse transcription PCR (RT-PCR) 
Two primer sets were designed to detect HuNV replicons in HG23 cells. Primers Neo-F/Neo-
R are located in the neomycin resistant gene [1] and predicted to produce a 804 bp product. 
Primers NVp36/35 are located in a highly conserved RNA polymerase region of HuNV GI 
genome and predicted to give a 470 bp product [2]. For RT, cDNA was reverse transcribed 
from extracted cellular RNA by using TakaRa PrimeScriptTM RT reagent kit. Briefly, 8 µL of 
total cellular RNA (500 ng) was mixed with 2 µL of 5× PrimeScript Buffer on ice. The mixture 
was incubated at 37℃ for 15 mins; this was followed by heat inactivation at 85℃ for 5 s. The 
mixture was 20 times diluted and stored at -20℃ for further use. PCR was performed using 
Q5® High-Fidelity DNA polymerase kit (New England Biolabs Inc.) in a 25 µL reaction mixture 
containing 5 µL of 5× Q5 Reaction Buffer, 0.5 µL of a 10 mM dNTPs, 1.25 µL of 10 µM 
Forward Primer, 1.25 µL of 10 µM Reverse Primer, 5 µL of template cDNA and 0.25 µL of Q5 
High-Fidelity DNA Polymerase. Amplification was carried out with initial denaturation at 98℃ 
[30 s]; 30 cycles of 98℃ [10 s], 50-70℃ [30 s] and 72 ℃ [30 s], and an additional extension 
step of 72℃ for 2 min. The GAPDH primer set was used as a reference gene and was 
amplified in 25 cycles [3]. The products were loaded onto 1 to 2% agarose gel containing 
SERVA DNA Stain G. DNA electrophoresis at 100 V for 45 min was performed. An 100 bp DNA 
ladder (Promega) was also electrophoresed on each gel. Bands were visualized and recorded 
with the Gel.Doc 2000 system (Bio-Rad). All primer combinations were listed in Table S2. 
MTT assay 
Cytotoxicities of the compounds against host cells were determined by a 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. In brief, cells were 
seeded into 96-well tissue culture plates containing 0.05% DMSO (control) or increasing 
concentrations of drugs. After the time indicated, 10 mM MTT (Sigma, Zwijndrecht, 
Netherlands) was added. With another 3 hours of incubation, the medium was removed and 
100 μL of DMSO was added to each well. The plate was incubated at 37℃ for 50 min. The 
absorbance at 490 nm was recorded on the microplate absorbance reader (Bio-Rad, CA, 
USA). 
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SUPPLEMENTARY TABLES AND FIGURES 
Table S1 Overview of culture medium components for human intestinal organoids. 
Components Storage (℃) Stocks Final Company 
Wnt 3a 4 Conditioned medium 50% Self-produced 
R-Spondin 1 -20 Conditioned medium 20% Self-produced 
Noggin -20 Conditioned medium 10% Self-produced 
B27 -20 50× 1 Gibco 
N2 -20 100× 1 Gibco 
N-Acetylcysteine (mol/L) -20 0.5 1 × 10
-3
 Invitrogen 
Nicotinamide (mol/L) -20 1 1 × 10
-2
 Sigma-Aldrich 
A83-01(TGF-beta inhibitor) 
(mol/L) 
-20 5 × 10
-4
 5 × 10
-7
 Tocris 
SB202190 (p38 inhibitor) 
(mol/L) 
-20 3 × 10
-2
 3 × 10
-6
 Sigma-Aldrich 
Human EGF (g/L) -20 5 × 10
-2
 5 × 10
-5
 Sigma-Aldrich 
Prostaglandin E2 (mol/L) -20 1 × 10
-4
 1 × 10
-8
 PeproTech 
Gastrin (mol/L) -20 1 × 10
-4
 1 × 10
-8
 PeproTech 
Y-27632 (Rho kinase inhibitor) 
(mol/L) 
-20 1 × 10
-2
 1 × 10
-5
 Bio-Connect BV 
 
Table S2 Primers used by qRT-PCR. 
Name Sequences
a
 Location 
HuNoV GI-specific 
primer 
COG1F (+): 5’- CGYTGGATGCGNTTYCATGA-3’
b
 
COG1R (-): 5’- CTTAGACGCATCATCATTYAC-3’
b
 
5291
b
 
5375
b
 
FeCV 
F: 5’- GAACTACCCGCCAATCAACAT -3’ 
R: 5’- CGGCTCTGATGGCTTGAAACTG-3’ 
2420-2440 
2507-2528 
DDX60 
F: 5’-GGTGTTTTCACCAGGGAGTATCG-3’ 
R: 5’-CCAGTTTTGGCGATGAGGAGCA-3’ 
 
Human GAPDH 
F: 5’-TGTCCCCACCCCCAATGTATC-3’ 
R: 5’-CTCCGATGCCTGCTTCACTACCTT-3’ 
 
Feline GAPDH 
GAPDH.57f: 5’- GCCGTGGAATTTGCCGT-3’ 
GAPDH.138r: 5’- GCCATCAATGACCCCTTCAT-3’ 
 
IFIT1 
F: 5’-GCCTTGCTGAAGTGTGGAGGAA-3’ 
R: 5’-ATCCAGGCGATAGGCAGAGATC-3’ 
 
IRF9 
F: 5’- CCACCGAAGTTCCAGGTAACAC-3’ 
R: 5’- AGTCTGCTCCAGCAAGTATCGG-3’ 
 
IFI27 
F: 5’- CGTCCTCCATAGCAGCCAAGAT-3’ 
R: 5’- ACCCAATGGAGCCCAGGATGAA-3’ 
 
IFITM3 
F: 5’-CTGGGCTTCATAGCATTCGCCT-3’ 
R: 5’-AGATGTTCAGGCACTTGGCGGT-3’ 
 
ISG15 
F: 5’-CTCTGAGCATCCTGGTGAGGAA-3’ 
R: 5’-AAGGTCAGCCAGAACAGGTCGT-3’ 
 
IRF-1 
F: 5’-GAGGAGGTGAAAGACCAGAGCA-3’ 
R: 5’-TAGCATCTCGGCTGGACTTCGA-3’ 
 
IFI6 
F: 5’-TGATGAGCTGGTCTGCGATCCT-3’ 
R: 5’-GTAGCCCATCAGGGCACCAATA-3’ 
 
MDA5 (IFIH1) 
F: 5’-GCTGAAGTAGGAGTCAAAGCCC-3’ 
R: 5’-CCACTGTGGTAGCGATAAGCAG-3’ 
 
Mx1 
F: 5’- GGCTGTTTACCAGACTCCGACA-3’ 
R: 5’- CACAAAGCCTGGCAGCTCTCTA-3’ 
 
OAS3 
F: 5’-CCTGATTCTGCTGGTGAAGCAC-3’ 
R: 5’-TCCCAGGCAAAGATGGTGAGGA-3’ 
 
OASL 
F: 5’-GTGCCTGAAACAGGACTGTTGC-3’ 
R: 5’-CCTCTGCTCCACTGTCAAGTGG-3’ 
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PKR 
F: 5’-GAAGTGGACCTCTACGCTTTGG-3’ 
R: 5’-TGATGCCATCCCGTAGGTCTGT-3’ 
 
RIG-I 
F: 5’-CACCTCAGTTGCTGATGAAGGC-3’ 
R: 5’-GTCAGAAGGAAGCACTTGCTACC-3’ 
 
RSDA2 
F: 5’-CCAGTGCAACTACAAATGCGGC-3’ 
R: 5’-CGGTCTTGAAGAAATGGCTCTCC-3’ 
 
a
Y = C + T; R = A + G; W = A+T; N = any 
b
Corresponding nucleotide position of Norwalk/68 virus (accession no. M87661) of the 5’end. 
 
Table S3 Primers used by RT-PCR. 
Target Primer Sense Sequence (5’-3’)
a
 
Locatio
n 
Anneali
ng 
HuNV 
HuNV GI-
specific 
NVp36 + ATAAAAGTTGGCATGAACA 
4487-
4505
b
 
70℃ 
NVp35 - CTTGTTGGTTTGAGGCCATAT 
4936-
4956
b
 
Neomycin 
phosphotran
sferase 
Neo-F + ATGGGATCGGCCATTGAAC  
59℃ 
Neo-R - TCAGAAGAACTCGTCAAG  
GAPDH 
GAPDH-F + TCGTGGAAGGACTCATGACC  
68℃ 
GAPDH-R - TCCACCACCCTGTTGCT  
a
Y = C + T; M = A + C; D = A+T+G; W = A+T 
b
Nucleotide positions are the positions in Hu/NLV/Norwalk/68/US (accession no. M87661). 
 
 
 
Fig. S1 Standard curve for quantifying FeCV genome copy numbers. 
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Fig. S2 Densitometric analysis of 
Western blot of IRF-1 protein 
expression after treatment with 
NTZ (10 μg/mL), TIZ (10 μg/mL), 
IFNα (1,000 IU/mL) or matched 
concentration of DMSO as vehicle 
control (CTR). The data are plotted 
as the means ± SEM and statistical 
comparisons were analyzed by t test 
(n = 5). **P < 0.01. 
Fig. S3 NTZ had no major 
effects on the induction of IFN 
genes. The qRT-PCR analysis of IFN 
genes including IFNα, IFNβ and 
IL28A/B after NTZ treatment (10 
µg/mL for 2 days) in HG23 (A) and 
human intestinal organoids (B). Data 
are representative of 3 independent 
experiments. 
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Fig. S4 Stimulation of ISGs by TZD was independent of NFκB pathway. Huh7 and Caco-2-
based NFκB luciferase reporter cells were mock-treated (DMSO) or stimulated for 24 and 48 hours 
with tumor necrosis factor-alpha (TNFα) (10, 100 and 1,000 ng/mL), NTZ (1 µg/mL) or TIZ (1 µg/mL). 
Luciferase activities were determined and normalized to the DMSO control (n = 3 independent 
experiments with duplicates each). TZD treatment failed to induce NFκB-dependent reporter gene 
activity. 
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Fig. S5 Combination of TZD with ribavirin completely depleted HuNV replicons from HG23 
cells after prolonged treatment. After 10 days of treatment, total cellular RNA was isolated from 
HG23 cells and gel-based reverse transcription polymerase chain reaction (RT-PCR) was performed to 
detect HuNV replicons with two primer pairs. The Neo-F/R pair was designed to amplify the full 
length neomycin phosphotransferase (804 base pair [bp]); while the NVp35/36 pair specifically detected 
genogroup I (GI) norovirus and yielded a 470 bp DNA amplicons. Human GAPDH primer set was used 
as a reference gene. A total of 6 samples were detected and indicated by numbers.  
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Despite being the responsible etiological agent for approximately one fifth of all 
cases of acute diarrhea, norovirus receives less attention when compared to other infectious 
pathogens [1]. The inability to cultivate human norovirus (HuNV) largely impedes the growth 
of our understanding and further study of the biology and pathogenesis of norovirus and the 
associated diseases. Moreover, a lack of accurate and cheap detection methodology further 
thwarts diagnosis, leading to lag behind in raising the awareness of the importance and 
significance of norovirus. The introduction of PCR technology has significantly improved and 
simplified the detection of norovirus RNA, and this technology is currently considered the 
‘golden-standard’ for norovirus diagnosis [2]. Accumulating evidence has confirmed norovirus 
as the etiological agent for chronic and severe gastroenteritis in immunocompromised 
populations. However, regarding the clinical manifestations, epidemiology and potential 
treatment of norovirus infection in hematopoietic stem cell transplant (HSCT) and solid 
organ transplant (SOT) recipients, no generally accepted consensus has been reached. In 
order to address this issue, in Chapter 2, I systematically reviewed the burden provoked by 
and potential therapy for norovirus infection in the transplantation setting. I focused on five 
aspects, including prevalence and clinical characteristics, diagnosis, risk factors, transmission 
and evolution, and potential therapies. I hope my review will foster reaching a consensus 
and raising the awareness of the problem in the field. Furthermore, I hope it shall help 
expanding our understanding of the burden of norovirus diarrhea in immunocompromised 
populations and provide some clues for the development of novel antiviral strategies. Finally, 
it sets the stage for the remainder of this thesis. 
The immune system is highly suppressed in transplant recipients due to the intake of 
immunosuppressants. Thus, these individuals are susceptible to a variety of infections. 
Recent studies have demonstrated that immunosuppressants can directly affect viral 
replication [3]. The calcineurin inhibitors cyclosporine A (CSA) and tacrolimus (FK506) 
stimulated hepatitis E virus (HEV) replication [4], whereas rapamycin and everolimus 
unexpectedly facilitated HEV replication [5]. With respect to rotavirus, CsA and FK506 did not 
affect its replication [6]. In contrast, mycophenolic acid (MPA) potently inhibited a variety of 
virus replication including HEV [4], rotavirus [6], dengue virus [7],  hepatitis C virus (HCV) [8] and 
hepatitis B virus (HBV) [9]. In Chapter 3, I screened a subset of immunosuppressants for their 
potential as anti-noroviral agents and found that MPA exerted strong inhibition of norovirus 
replication, whereas the calcineurin inhibitors CsA and FK506 moderately decreased HuNV 
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replication. I further established that ribavirin, a broad-spectrum antiviral agent inhibited 
norovirus replication and resulted in an additive effect when combined with these norovirus 
counteracting immunosuppressants. These observations bear important implications for the 
optimization and management of immunosuppressants in transplant recipients. Meanwhile, 
ribavirin holds promise for combating norovirus infection, though further in vivo mechanistic 
studies are needed. 
Treatment of norovirus infection is still a challenge. Immunocompromised patients 
with norovirus gastroenteritis are in greatest need of an effective and specific treatment. 
Several chemicals have been reported to display in vitro activities against norovirus 
replication [10], however the potential drug efficacies have not been clearly defined in vivo. 
Thus, I tried to develop new tricks for old drugs and reincarnate them as anti-norovirus 
drugs. In Chapter 4, I profiled interferons (IFNs) for their anti-norovirus potential. The results 
demonstrated that HuNV RNA replication was largely inhibited by the application of all types 
of IFNs, including IFN-αβ (type I), IFNγ (type II), IL-29 and IL28B (type III), but to a lesser 
extent when compared to the effects these cytokines have on HCV replication. Interferon-
stimulated genes (ISGs) are the ultimate antiviral effectors of the IFN-induced signal 
transduction cascade. By using an overexpression approach, I profiled a subset of important 
human ISGs for their action and function as anti-norovirus proteins. Among all the ISGs I 
investigated, interferon regulatory factor 1 (IRF-1), retinoic acid-inducible gene I (RIG-I) and 
melanoma differentiation-associated gene 5 (MDA5) were identified as being the most 
potent anti-norovirus effectors of the IFN signal transduction cascade. Interestingly, type I 
and III IFNs coordinately and cooperatively induced these three ISGs, whereas type II IFN 
predominantly induced IRF-1 to accomplish their antiviral activities. Those findings have 
great clinical importance, as it provides a rational foundation for developing IFN-based 
therapies to combat norovirus-associated diseases. Furthermore, exploiting the actions of 
IRF-1, RIG-I and MDA5 on HuNV may allow future development of ISG-mediated therapeutic 
strategies that potentially have less side effects as compared to IFN-based therapy. Acitretin, 
a retinoic acid derivative approved by the United States Food and Drug Administration (FDA) 
was shown to enhance RIG-I signaling ex vivo of HIV-infected cells, contributing to 
controlling HIV infection [11]. The natural ligand of RIG-I, 5’-triphosphate RNA (5’-pppRNA) 
was reported to activate RIG-I to stimulate an antiviral response that inhibited HEV 
replication [12]. Further insight into the biochemical mechanisms of these ISGs may provide a 
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platform for the development of antivirals acting against norovirus –associated 
gastroenteritis. 
Nitazoxanide is recently discovered to be potentially useful against norovirus 
diarrhea and has been used in several empirical studies that demonstrates effectiveness 
toward norovirus gastroenteritis [13, 14]. However, a recent Letter to the Editor described the 
failure of nitazoxanide treatment in clearing norovirus chronic infection in a patient with X-
linked agammaglobulinemia (XLA) [15]. To uncover the reason behind this apparent 
inconsistency, I explored the in vitro effects of nitazoxanide on HuNV and MNV replication (I 
did this in Chapter 5) and I was the first to discover the opposing effects of nitazoxanide on 
these viruses. I attributed this inconsistency to the genetic differences in the norovirus 
strains, as HuNV belongs to genogroup II and MNV belongs to genogroup V. Meanwhile, 
different host cell cultures may alternatively respond to nitazoxanide treatment, which 
potentially contributed to the opposing activity of nitazoxanide observed. In Chapter 6, I 
continued to investigate the antiviral mechanism of nitazoxanide. I established that 
nitazoxanide profoundly and robustly triggered a host immune response and induced the 
production of a subset of ISGs, particularly IRF-1. I further established that nitazoxanide 
acted in synergy with ribavirin, which thus potentiated nitazoxanide monotherapy as well as 
combination therapy with ribavirin as promising strategies for combating norovirus 
infections in immunocompromised patients as well as in the setting of acute outbreaks. Thus, 
in conjunction I hope my studies open new rational avenues for combating norovirus-
associated disease. 
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Norovirus is de verzamelnaam van een groep van virussen welke een belangrijke 
oorzaak vormen van diarree. Er wordt aangenomen dat mondiaal de helft van alle acute 
buikgriepepisoden (acute gastro-enteritis) door norovirussen worden veroorzaakt. Het virus 
veroorzaakt regelmatig epidemieën van een relatief kleine schaal voor. Het norovirus is 
uiterst besmettelijk en kan mensen treffen van eigenlijk iedere leeftijd. Norovirus wordt 
overgedragen via water en voedsel dat met ontlasting besmet is, maar ook via een direct 
contact met besmette personen. Tenslotte verspreidt het virus zich ook door 
aerosolvorming waarna het virus verschillende oppervlakten kan besmetten (bijvoorbeeld 
de deurkruk of het lichtknopje van het toilet zijn berucht in dit opzicht). In dit proefschrift wil 
ik een bijdrage leveren aan de strijd van de mensheid tegen het norovirus. 
Probleem bij onderzoek naar norovirus is dat het niet gekweekt kan worden in 
cellijnen en dat er eigenlijk geen goede/doelmatige proefdiermodellen zijn. Recentelijk is de 
situatie wat verbetert door het beschikbaar komen van zogenaamde repliconmodellen die in 
ieder geval een gedeelte van de levenscyclus van norovirus kunnen ondersteunen alsook 
door de beschikbaar komen van organoïden. Deze nieuwe modellen openen een venster op 
beter onderzoek waarvan ik in dit proefschrift gebruik heb gemaakt. In hoofdstuk 1 geef in 
een uitgebreide rechtvaardiging van mijn onderzoek en leg ik aan de lezer uit waarom ik 
voor de uitgevoerde strategie met betrekking tot deze dissertatie gekozen heb. 
Maar in eerste instantie begon ik met een onderzoek om uit te zoeken hoe groot het 
probleem van norovirus infectie is en dan met name in de transplantatiegeneeeskunde. Dit 
doe ik in hoofdstuk 2. Hierin verzamel ik op systematische wijze alle primaire studies die in 
de literatuur verschenen zijn en ik stel vast dat transplantatiepatiënten uiterst gevoelig zijn 
voor norovirus, dat als zij besmet zijn ernstig ziek worden en ook heel lang ziek zijn omdat ze 
het virus niet klaren. Ook zijn ze dat zeer besmettelijk en zowel medepatiënten alsook de 
medische staf kunnen gemakkelijk besmet worden. Er zijn dan ook zeer uitgebreide 
hygiënische voorzorgsmaatregelen nodig. Ook stel ik vast dat er nog geen goede medicatie is 
om deze patiënten te behandelen. Verminderen van de immunosuppressie (riskant vanwege 
orgaanafstoting) en intraveneus immunoglobuline kunnen wat helpen. Interessant is dat 
nitazoxadine (een antiparasitair middel) lijkt helpen. Echter data is beperkt en in de 
afwezigheid van een rationele verklaring hoe dit middel zou kunnen helpen bij norovirus-
geïnfecteerde patiënten moet men voorzichtig blijven. 
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Het zou echter ook kunnen dat de juiste keuze van immunosuppressie al veel kan 
betekenen met betrekking tot preventie van norovirusinfectie. Patiënten met 
orgaantransplantatie moeten sowieso middelen krijgen die afstoting van het 
getransplanteerde orgaan verkomen. Dergelijke middelen grijpen vaak diep in op de 
cellulaire fysiologie. Omdat de virale levenscyclus van het norovirus complex is (zie ook 
hoofdstuk 1) is het wel mogelijk dat sommige afstotingvoorkomende medicatie ook 
interfereert met de levenscyclus van het norovirus. Ik onderzoek deze mogelijkheid in 
hoofdstuk 3. In dit hoofdstuk onderzoek de invloed van een aantal immunosuppressiva die 
gebruikt worden om afstoting te voorkomen in een repliconmodel. Inderdaad bleken 
sommige medicijnen interactie te vertonen met de levenscyclus van het norovirus. Het 
meest interessant was wellicht Mycofenolzuur, de werkzame stof van de geneesmiddelen 
Mycofenolaatmofetil (MMF, CellCept van Roche) en Mycofenolzuur natrium (EC-MPS, entric 
coated mycophenolic acid sodium, Myfortic van Novartis.  Deze stof remt het enzym IMPDH, 
waardoor het afweersysteem verzwakt en in de combinatie met andere immunosuppresiva 
is het profylactisch met betrekking tot de afstoting van transplantie-organen. Gebruik van dit 
middel lijkt dan ook aangewezen voor patiënten die een hoog risico lopen op besmetting 
met norovirus of reeds een infectie hebben opgelopen. Ik heb deze resultaten gepubliceerd: 
Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, van der Laan LJW, Felczak K, Pankiewicz 
KW, Chang KO, Koopmans MPG, Metselaar HJ, Peppelenbosch MP, Pan Q. Inhibition of 
Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against 
Norovirus Replication. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01095-17. 
doi: 10.1128/AAC.01095-17. Antimicrobial Agents and Chemotherapy is een vooraanstaand 
tijdschrift uitgegeven door de  American Society for Microbiology en ik heb dus goede hoop 
dat ik met deze publicatie de relevante doelgroep kan bereiken. 
In een volgend hoofdstuk 4 onderzoek ik de interactie van norovirus met 
interferonen. Interferonen zijn glycoproteïnen die de cellen van het immuunsysteem 
afscheiden na contact met virussen. De naam interferon komt van de observatie dat 
interferonen interfereren met de virale replicatie. Interferonen zijn onder andere werkzaam 
bij chronische hepatitis B en hepatitis C, maar de werking van interferonen op de afweer 
tegen norovirus was nog niet onderzocht. Ik stel vast in dit hoofdstuk dat alle geteste 
interferonen norovirusreplicatie kunnen onderdrukken en ik karakteriseer de betrokken 
moleculaire mechanismen in enig detail. Ik heb deze resultaten gepubliceerd: Dang W, Xu L, 
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Yin Y, Chen S, Wang W, Hakim MS, Chang KO, Peppelenbosch MP, Pan Q. IRF-1, RIG-I and 
MDA5 display potent antiviral activities against norovirus coordinately induced by different 
types of interferons. Antiviral Res. 2018 May 10;155:48-59. doi: 
10.1016/j.antiviral.2018.05.004. Antiviral Research is een vooraanstaand tijdschrift en het 
officiële tijdschrift van de International Society for Antiviral Research en ik heb dus goede 
hoop dat ik met deze publicatie de relevante doelgroep kan bereiken. 
Zoals gezegd zijn er aanwijzingen dat nitazoxadine een goede optie is bij de 
behandeling van norovirus infectie, maar is het bewijs anekdotisch van aard. In hoofdstuk 5 
probeer ik het gebruik van deze medicatie voor dit doel te rationaliseren. Ik laat zien dat het 
middel direct aangrijpt op de levenscyclus van het humaan norovirus maar niet op het muis 
norovirus, waar het zelfs virusreplicatie lijkt te stimuleren (het muis norovirus is vroeger veel 
gebruikt voor preklinisch onderzoek in proefdieren, maar mijn resultaten laten zien dat dit 
wellicht een ongelukkige keuze is geweest). Deze bevindingen dragen bij aan het groeiende 
momentum dat gebruik van nitazoxadine voor de behandeling van norovirusinfectie nu 
ondergaat. Ik heb deze resultaten gepubliceerd: Dang W, Yin Y, Peppelenbosch MP, Pan Q. 
Opposing Effects of Nitazoxanide on Murine and Human Norovirus. J Infect Dis. 2017 Sep 
15;216(6):780-782. The Journal of Infectious Diseases is een vooraanstaand tijdschrift en het 
officiële tijdschrift van de Infectious Diseases Society of America en ik heb dus goede hoop 
dat ik met deze publicatie de relevante doelgroep kan bereiken. 
In Hoofdstuk 6 bouw ik deze bevindingen verder uit en karakteriseer ik het 
mechanisme van werking van nitazoxadine in detail, waarmee ik de geschiktheid van deze 
medicatie voor de behandeling van transplantatiepatiënten die lijden aan een 
nororvirusinfectie verder objectiveer. Een belangrijk punt is dat de potentie van dit middel 
nog beter wordt als het gecombineerd wordt met ribavirine. Ribavirine is een antiviraal 
geneesmiddel dat de werking van alpha-interferon versterkt en al gebruikt wordt voor de 
behandeling van hepatitis C. Ik laat nu zien dat het middel ook effectief is tegen norovirus en 
met de nu ontdekte synergie met nitazoxadine lijkt een geheel nieuw venster of effectieve 
behandeling van norovirusinfectie bij transplantatiepatiënten te zijn geopend. Deze 
resultaten zijn buiten het bestek van dit proefschrift nog niet gepubliceerd maar wel goed 
ontvangen door Antimicrobial Agents and Chemotherapy waar ik snel een versie naar toe wil 
sturen die acceptabel voor dit vooraanstaande tijdschrift zou moeten zijn. 
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In hoofdstuk 7, tenslotte vat ik de resultaten uit dit proefschrift nog eens samen en 
bediscussieer ik hun samenhang, ook in de contekst van de contemporaine biomedische 
literatuur. In haar totaliteit hoop ik met dit proefschrift een wezenlijke bijdrage te hebben 
geleverd in het gevecht der mensheid met de gesel die het  norovirus op de mensheid doet 
nederdalen. 
 177 | P a g e  
 
Appendix 
 
 
 
 
 
 
Acknowledgements 
Publications 
PhD Portfolio 
Curriculum Vitae 
 
 
 
 
 
 
 
 
 
Appendix 
179 | P a g e  
 
 
Appendix 
180 | P a g e  
 
 
Appendix 
181 | P a g e  
 
 
Appendix 
182 | P a g e  
 
 
Appendix 
183 | P a g e  
 
 
Appendix 
184 | P a g e  
 
 
Appendix 
185 | P a g e  
 
 
Appendix 
186 | P a g e  
 
 
Appendix 
187 | P a g e  
 
Publication list 
1. Dang W, Yin Y, Peppelenbosch MP et al. Opposing Effects of Nitazoxanide on 
Murine and Human Norovirus. J Infect Dis 2017; 216: 780-2. 
2. Dang W, Yin Y, Wang Y et al. Inhibition of Calcineurin or IMP Dehydrogenase 
Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrob 
Agents Chemother 2017; 61. 
3. Dang W, Xu L, Ma B et al. Nitazoxanide Inhibits Human Norovirus Replication 
and Synergizes with Ribavirin by Activation of Cellular Antiviral Response. Antimicrob Agents 
Chemother (in press). 
4. Dang W, Xu L, Yin Y et al. IRF-1, RIG-I and MDA5 display potent antiviral 
activities against norovirus coordinately induced by different types of interferons. Antiviral 
Res 2018; 155: 48-59. 
5. Dang W, Yu P, Mohamad H et al. Norovirus Infection in Hematopoietic Stem 
Cell and Solid Organ Transplant Recipients: a Systematic Review. Under submission. 
6. Yin Y, Dang W, Zhou X et al. PI3K-Akt-mTOR axis sustains rotavirus infection 
via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. Virulence 
2018; 9: 83-98. 
7. Yin Y, Bijvelds M, Dang W et al. Modeling rotavirus infection and antiviral 
therapy using primary intestinal organoids. Antiviral Res 2015; 123: 120-31. 
8. Yin Y, Wang Y, Dang W et al. Mycophenolic acid potently inhibits rotavirus 
infection with a high barrier to resistance development. Antiviral Res 2016; 133: 41-9. 
9. Wang K, Dang W, Yan J et al. Membrane perturbation action mode and 
structure-activity relationships of Protonectin, a novel antimicrobial peptide from the venom 
of the neotropical social wasp Agelaia pallipes pallipes. Antimicrob Agents Chemother 2013; 
57: 4632-9. 
10. Yan J, Wang K, Dang W et al. Two hits are better than one: membrane-active 
and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide 
derived from mammalian NK-lysin. Antimicrob Agents Chemother 2013; 57: 220-8. 
11. Wang K, Yan J, Dang W et al. Dual antifungal properties of cationic 
antimicrobial peptides polybia-MPI: membrane integrity disruption and inhibition of biofilm 
formation. Peptides 2014; 56: 22-9. 
Appendix 
188 | P a g e  
 
12. Wang K, Yan J, Dang W et al. Membrane active antimicrobial activity and 
molecular dynamics study of a novel cationic antimicrobial peptide polybia-MPI, from the 
venom of Polybia paulista. Peptides 2013; 39: 80-8. 
13. Wang K, Dang W, Xie J et al. Antimicrobial peptide protonectin disturbs the 
membrane integrity and induces ROS production in yeast cells. Biochim Biophys Acta 2015; 
1848: 2365-73. 
14. Wang K, Jia F, Dang W et al. Antifungal effect and action mechanism of 
antimicrobial peptide polybia-CP. J Pept Sci 2016; 22: 28-35. 
 
Appendix 
189 | P a g e  
 
 
PhD Portfolio 
Name of PhD student                          Wen Dang 
Department                                           Gastroenterology and Hepatology, Erasmus MC- 
                                                                 University Medical Center, Rotterdam 
PhD Period                                             September 2014 – September 2018 
Promotor                                                Prof. dr. Maikel P. Peppelenbosch 
Copromotor                                           Dr. Qiuwei Pan 
 
PhD training  
Seminars 
• 2014-2018, Weekly MDL seminar program in experimental gastroenterology and 
hepatology (attending); (42 weeks/year; @1.5 h) (ECTS, 9.0). 
• 2014-2018, Weekly MDL seminar program in experimental gastroenterology and 
hepatology (presenting); (preparation time 16 h; 2 times/year) (ECTS, 4.6). 
• 2014-2018, Biweekly research group education (attending); (20 times/year; @1.5 h) 
(ECTS, 4.3). 
• 2014-2018, Biweekly research group education (presenting); (preparation time 8 h; 4 
times/year) (ECTS, 4.6). 
General Courses and Workshops 
• 2015, Course in Virology 2015 (ECTS, 1.8). 
• 2018, Biomedical English Writing Course for MSc and PhD-students (ECTS, 2.0). 
• 2018, The annual Course on Molecular Medicine (ECTS, 0.6). 
• 2018, the Workshop on Microsoft Excel 2010: Basic/Advanced (ECTS, 0.6). 
• 2018, The Erasmus MC Cancer Institute Research Day (ECTS, 0.3). 
• 2018, The Course Scientific Integrity. 
 
 
Appendix 
190 | P a g e  
 
National and International Conferences 
• 2016, Annual Day of the Molecular Medicine, Postgraduate School Molecular 
Medicine, Rotterdam, the Netherlands (Poster presentation). 
• 2016, 9th Dutch Experimental Gastroenterology and Hepatology (DEGH) meeting, 
Veldhoven, The Netherlands (Poster presentation). 
• 2018, Virus 2018-Breakthrough in Viral Replication, Barcelona, Spain (Poster 
presentation). 
• 2018, 31st International Conference on Antiviral Research (ISAR, International Society 
For Antiviral Research), Porto, Portugal (Poster presentation). 
 
Academic Awards 
 
• 2018, 31st International Conference on Antiviral Research (ISAR, International Society 
For Antiviral Research), Porto, Portugal ($ 400,00). 
• 2014, China Scholarship Council (CSC) Scholarship (File No. 201406180072) 
• 2014, National Scholarship for Graduate Students (¥ 20,000). 
 
Appendix 
191 | P a g e  
 
Curriculum Vitae 
Wen Dang was born on February 8th 1989 in Shandan, Zhangye, Gansu province, China. He 
was raised by his beloved parents Zhenguo Dang and Meiying Sun and finished his primary, 
secondary and high school in his hometown. 
In 2007, he started his undergraduate study of life sciences and technology at the 
School of Life Sciences in Lanzhou University, Lanzhou, China (4 years). In 2011, he initiated 
his master research in the same university at the School of Basic Medical Sciences under the 
supervision of Prof. Rui Wang. His main focus was to discovery and synthesize novel 
antimicrobial peptides (AMPs) as novel agents to combat emerging resistant bacterial and 
fungal infections. 
In 2014, with the support of China Scholarship Council (CSC) scholarship, he started 
his PhD research at the Department of Gastroenterology and Hepatology, Erasmus 
University Medical Center, Rotterdam, the Netherlands. Under the supervision of Prof. 
Maikel P. Peppelenbosch and Dr. Qiuwei Pan, his main research was to study norovirus-host 
interactions and to develop antivirals against norovirus infection. 
